

Summary Tables by Market Group, Health Area, Country and Product

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Market Group
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Acceleration Market Group	41,942	-	-	3,129	3,382,778	4,670	1,501,143	1,085	564	123	3	26,663
Anglophone Africa Market Group	95,551	23	-	5	4,012,517	4,161	1,661,065	803	144	-	55	40,258
Franco/Lusophone Africa Market Gro	10,209	4	-	-	1,811,247	2,577	726,890	8,990	456	-	-	27,282
Latin America & Asia Market Group	4,244	-	48	2,195	4,186,405	1,947	1,591,750	3	78	-	-	14,232
Foundation Market Group	3,394	2	-	677	1,600,475	1,878	625,204	61,220	239	881	2	77,362
Social Enterprise	18,683	-	-	-	1,233,886	1,234	431,636	-	313	-	-	3,788
Total	174,022	30	48	6,006	16,227,308	16,468	6,537,688	72,101	1,795	1,004	60	189,585

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	4,188,251	26,150,430	21,995,933	(16%)		24,036,878	92%
Acceleration Market Group	361,126	4,677,485	3,642,740	(22%)	100%	4,096,068	89%
Modern Contraception	147,656	1,354,750	1,601,669	18%	44%	1,305,027	123%
HIV & STIs	189,765	2,922,876	1,720,293	(41)%	47%	2,388,411	72%
Malaria	6,406	130,182	76,803	(41)%	2%	116,230	66%
Maternal, Newborn, and Child H	8,885	40,594	54,374	34%	1%	62,513	87%
Non-communicable diseases	2	70	73	3%	0%	73	100%
Nutrition	-	249	-	(100)%	0%	-	0%
Safe Abortion	1,918	131,766	93,163	(29)%	3%	119,871	78%
Tuberculosis	6,292	88,122	84,817	(4)%	2%	94,197	90%
WASH	202	8,877	11,548	30%	0%	9,747	118%
Anglophone Africa Market Group	508,500	8,737,057	7,098,951	(19%)	100%	6,838,586	104%
Modern Contraception	298,541	3,574,876	3,190,057	(11)%	45%	3,168,819	101%
HIV & STIs	206,969	4,895,700	3,817,645	(22)%	54%	3,592,960	106%
Malaria	-	228,768	56,590	(75)%	1%	35,727	158%
Maternal, Newborn, and Child H	116	6,418	2,171	(66)%	0%	4,132	53%
Non-communicable diseases	7	306	1,457	376%	0%	264	552%
Safe Abortion	2,326	22,753	23,148	2%	0%	25,618	90%
Tuberculosis	24	300	284	(5)%	0%	626	45%
WASH	516	7,937	7,599	(4)%	0%	10,440	73%
Franco/Lusophone Africa Market Group	715,759	2,498,201	2,625,497	5%	100%	2,722,253	96%
Modern Contraception	136,838	1,231,563	1,411,435	15%	54%	1,242,892	114%
HIV & STIs	56,098	461,736	413,494	(10)%	16%	543,046	76%
Malaria	519,356	719,056	741,889	3%	28%	868,795	85%
Maternal, Newborn, and Child H	178	58,996	19,576	(67)%	1%	37,043	53%
Non-communicable diseases	-	6	2	(67)%	0%	-	0%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	2,137	18,987	24,828	31%	1%	18,447	135%
WASH	1,152	7,857	14,274	82%	1%	12,029	119%
Latin America & Asia Market Group	92,055	1,215,801	1,278,619	5%	100%	1,133,232	113%
Modern Contraception	65,432	803,569	906,992	13%	71%	873,063	104%
HIV & STIs	11,285	232,104	195,435	(16)%	15%	214,953	91%
Malaria	20	2,386	243	(90)%	0%	424	57%
Maternal, Newborn, and Child H	176	5,860	6,929	18%	1%	1,827	379%
Non-communicable diseases	-	-	-	0%	0%	-	0%
Nutrition	6	-	25	0%	0%	-	0%
Safe Abortion	4,660	52,617	51,016	(3)%	4%	42,896	119%
Tuberculosis	10,475	119,106	117,936	(1)%	9%	38	310,703%
WASH	-	160	43	(73)%	0%	30	142%
Foundation Market Group	2,386,388	7,586,885	6,338,408	(16%)	100%	7,584,880	84%
Modern Contraception	101,601	863,324	1,033,128	20%	16%	949,254	109%
HIV & STIs	36,955	212,797	175,730	(17)%	3%	146,629	120%
Malaria	2,229,425	5,638,477	4,864,942	(14)%	77%	6,242,139	78%
Maternal, Newborn, and Child H	13,876	673,037	123,714	(82)%	2%	92,588	134%
Non-communicable diseases	4	61	48	(21)%	0%	210	23%
Nutrition	3,085	104,340	86,897	(17)%	1%	103,209	84%
Safe Abortion	1,438	11,120	13,857	25%	0%	14,822	93%
Tuberculosis	-	76,671	38,021	(50)%	1%	34,091	112%
WASH	4	7,057	2,072	(71)%	0%	1,936	107%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Social Enterprise	124,424	1,433,239	1,011,719	(29%)	100%	1,661,860	61%
Modern Contraception	17,849	340,352	208,723	(39)%	21%	376,521	55%
HIV & STIs	103,293	963,709	722,562	(25)%	71%	1,103,405	65%
Maternal, Newborn, and Child H	(76)	22,965	27,074	18%	3%	26,486	102%
Nutrition	21	337	241	(29)%	0%	381	63%
Safe Abortion	3,337	105,875	53,118	(50)%	5%	155,067	34%
Other	-	-	-	0%	0%	-	0%
Inactive	-	1,762	0	(100%)	-%	-	-%
Modern Contraception	-	1,520	-	(100)%	0%	-	0%
HIV & STIs	-	242	-	(100)%	0%	-	0%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	4,188,251	26,150,430	21,995,933	(16)%		24,036,878	92%
Modern Contraception	767,916	8,169,954	8,352,003	2%	100%	7,915,576	106 %
Acceleration Market Group	147,656	1,354,750	1,601,669	18%	19 %	1,305,027	123%
Anglophone Africa Market Group	298,541	3,574,876	3,190,057	(11)%	38 %	3,168,819	101%
Franco/Lusophone Africa Market Group	136,838	1,231,563	1,411,435	15%	17 %	1,242,892	114%
Latin America & Asia Market Group	65,432	803,569	906,992	13%	11 %	873,063	104%
Foundation Market Group	101,601	863,324	1,033,128	20%	12 %	949,254	109%
Social Enterprise	17,849	340,352	208,723	(39)%	2 %	376,521	55%
Inactive	-	1,520	-	(100)%	0 %	-	0%
HIV & STIs	604,365	9,689,164	7,045,159	(27)%	100%	7,989,404	88 %
Acceleration Market Group	189,765	2,922,876	1,720,293	(41)%	24 %	2,388,411	72%
Anglophone Africa Market Group	206,969	4,895,700	3,817,645	(22)%	54 %	3,592,960	106%
Franco/Lusophone Africa Market Group	56,098	461,736	413,494	(10)%	6 %	543,046	76%
Latin America & Asia Market Group	11,285	232,104	195,435	(16)%	3 %	214,953	91%
Foundation Market Group	36,955	212,797	175,730	(17)%	2 %	146,629	120%
Social Enterprise	103,293	963,709	722,562	(25)%	10 %	1,103,405	65%
Inactive	-	242	-	(100)%	0 %	-	0%
Malaria	2,755,208	6,718,869	5,740,466	(15)%	100%	7,263,315	79 %
Acceleration Market Group	6,406	130,182	76,803	(41)%	1 %	116,230	66%
Anglophone Africa Market Group	-	228,768	56,590	(75)%	1 %	35,727	158%
Franco/Lusophone Africa Market Group	519,356	719,056	741,889	3%	13 %	868,795	85%
Latin America & Asia Market Group	20	2,386	243	(90)%	0 %	424	57%
Foundation Market Group	2,229,425	5,638,477	4,864,942	(14)%	85 %	6,242,139	78%
Maternal, Newborn, and Child Health	23,156	807,869	233,837	(71)%	100%	224,590	104 %
Acceleration Market Group	8,885	40,594	54,374	34%	23 %	62,513	87%
Anglophone Africa Market Group	116	6,418	2,171	(66)%	1 %	4,132	53%
Franco/Lusophone Africa Market Group	178	58,996	19,576	(67)%	8 %	37,043	53%
Latin America & Asia Market Group	176	5,860	6,929	18%	3 %	1,827	379%
Foundation Market Group	13,876	673,037	123,714	(82)%	53 %	92,588	134%
Social Enterprise	(76)	22,965	27,074	18%	12 %	26,486	102%
Non-communicable diseases	14	443	1,579	257%	100%	547	289 %
Acceleration Market Group	2	70	73	3%	5 %	73	100%
Anglophone Africa Market Group	7	306	1,457	376%	92 %	264	552%
Franco/Lusophone Africa Market Group	-	6	2	(67)%	0 %	-	0%
Latin America & Asia Market Group	-	-	-	0%	0 %	-	0%
Foundation Market Group	4	61	48	(21)%	3 %	210	23%
Nutrition	3,111	104,927	87,163	(17)%	100%	103,591	84 %
Acceleration Market Group	-	249	-	(100)%	0 %	-	0%
Franco/Lusophone Africa Market Group	-	-	-	0%	0 %	-	0%
Latin America & Asia Market Group	6	-	25	0%	0 %	-	0%
Foundation Market Group	3,085	104,340	86,897	(17)%	100 %	103,209	84%
Social Enterprise	21	337	241	(29)%	0 %	381	63%
Safe Abortion	15,816	343,119	259,132	(24)%	100%	376,721	69 %
Acceleration Market Group	1,918	131,766	93,163	(29)%	36 %	119,871	78%
Anglophone Africa Market Group	2,326	22,753	23,148	2%	9 %	25,618	90%
Franco/Lusophone Africa Market Group	2,137	18,987	24,828	31%	10 %	18,447	135%
Latin America & Asia Market Group	4,660	52,617	51,016	(3)%	20 %	42,896	119%
Foundation Market Group	1,438	11,120	13,857	25%	5 %	14,822	93%
Social Enterprise	3,337	105,875	53,118	(50)%	20 %	155,067	34%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tuberculosis	16,792	284,198	241,059	(15)%	100%	128,952	187 %
Acceleration Market Group	6,292	88,122	84,817	(4)%	35 %	94,197	90%
Anglophone Africa Market Group	24	300	284	(5)%	0 %	626	45%
Latin America & Asia Market Group	10,475	119,106	117,936	(1)%	49 %	38	310,703%
Foundation Market Group	-	76,671	38,021	(50)%	16 %	34,091	112%
WASH	1,874	31,888	35,536	11%	100%	34,182	104 %
Acceleration Market Group	202	8,877	11,548	30%	32 %	9,747	118%
Anglophone Africa Market Group	516	7,937	7,599	(4)%	21 %	10,440	73%
Franco/Lusophone Africa Market Group	1,152	7,857	14,274	82%	40 %	12,029	119%
Latin America & Asia Market Group	-	160	43	(73)%	0 %	30	142%
Foundation Market Group	4	7,057	2,072	(71)%	6 %	1,936	107%
Other	-	-	-	0%	0%	-	0 %
Social Enterprise	-	-	-	0%	0 %	-	0%

POPULATION SERVICES INTERNATIONAL
 Monthly DALY Report by Country
 Period: 12
 Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	4,188,251	26,150,430	21,995,933	(16%)		24,036,878	92%
Acceleration Market Group	361,126	4,677,485	3,642,740	(22%)	100%	4,096,068	89%
India	50,798	181,428	299,908	65 %	8%	151,017	199%
Modern Contraception	50,798	175,412	291,926	66%	8%	142,343	205 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	1,677	0 %
WASH	-	6,017	7,982	33%	0%	6,997	114 %
Kenya	129,685	2,114,656	1,610,141	(24)%	44%	2,352,036	68%
Modern Contraception	46,810	536,784	634,129	18%	17%	579,992	109 %
HIV & STIs	69,247	1,454,845	900,739	(38)%	25%	1,646,645	55 %
Malaria	5,538	93,015	39,504	(58)%	1%	75,807	52 %
Maternal, Newborn, and Child Health	7,888	27,111	32,163	19%	1%	46,781	69 %
Non-communicable diseases	-	56	40	(29)%	0%	63	63 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	202	2,845	3,566	25%	0%	2,750	130 %
Myanmar	21,002	282,568	301,075	7 %	8%	317,773	95%
Modern Contraception	7,378	70,471	74,428	6%	2%	81,594	91 %
HIV & STIs	5,465	73,048	82,287	13%	2%	87,494	94 %
Malaria	868	37,167	37,299	0%	1%	40,423	92 %
Maternal, Newborn, and Child Health	997	13,483	22,210	65%	1%	15,733	141 %
Non-communicable diseases	2	15	33	125%	0%	10	333 %
Nutrition	-	249	-	(100)%	0%	-	0 %
Tuberculosis	6,292	88,122	84,817	(4)%	2%	92,520	92 %
WASH	-	15	-	(100)%	0%	-	0 %
Nigeria	10,312	40,908	112,654	175 %	3%	-	-%
Modern Contraception	10,312	32,064	112,654	251%	3%	-	0 %
HIV & STIs	-	8,844	-	(100)%	0%	-	0 %
PSI Nigeria	34,276	620,137	581,695	(6)%	16%	620,328	94%
Modern Contraception	32,359	488,371	488,531	0%	13%	500,457	98 %
Safe Abortion	1,918	131,766	93,163	(29)%	3%	119,871	78 %
South Africa	115,053	1,437,788	737,267	(49)%	20%	654,913	113%
Modern Contraception	-	51,649	-	(100)%	0%	641	0 %
HIV & STIs	115,053	1,386,139	737,267	(47)%	20%	654,272	113 %
Anglophone Africa Market Group	508,500	8,737,057	7,098,951	(19)%	100%	6,838,586	104%
Ethiopia	26,391	270,640	165,192	(39)%	2%	144,850	114%
Modern Contraception	8,820	90,177	53,642	(41)%	1%	47,793	112 %
HIV & STIs	17,090	176,544	105,510	(40)%	1%	89,820	117 %
Malaria	-	-	1	0%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	481	3,919	6,039	54%	0%	7,237	83 %
Ghana	-	170,301	69,948	(59)%	1%	97,820	72%
Modern Contraception	-	170,186	69,858	(59)%	1%	95,927	73 %
HIV & STIs	-	64	-	(100)%	0%	1,792	0 %
WASH	-	51	90	76%	0%	101	89 %
Lesotho	3,807	469,110	59,567	(87)%	1%	34,799	171%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	286	40,199	5,791	(86)%	0%	3,516	165 %
HIV & STIs	3,497	428,660	53,492	(88)%	1%	30,657	174 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	24	252	284	13%	0%	626	45 %
Malawi	43,825	1,186,609	1,161,833	(2)%	16%	1,170,485	99%
Modern Contraception	20,276	527,237	521,296	(1)%	7%	578,870	90 %
HIV & STIs	23,549	656,727	635,862	(3)%	9%	588,683	108 %
Malaria	-	2,142	4,503	110%	0%	2,818	160 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
WASH	-	502	172	(66)%	0%	113	152 %
Namibia	-	-	2,252	- %	-%	-	-%
Modern Contraception	-	-	242	0%	0%	-	0 %
HIV & STIs	-	-	2,011	0%	0%	-	0 %
PSI Uganda	223,703	1,524,598	1,675,134	10 %	24%	1,617,541	104%
Modern Contraception	215,931	1,472,215	1,625,215	10%	23%	1,561,294	104 %
HIV & STIs	5,806	32,612	31,763	(3)%	0%	34,195	93 %
Maternal, Newborn, and Child Health	116	6,240	2,171	(65)%	0%	4,132	53 %
Non-communicable diseases	-	57	28	(51)%	0%	-	0 %
Safe Abortion	1,840	13,263	15,847	19%	0%	17,809	89 %
WASH	9	210	111	(47)%	0%	111	100 %
Rwanda	12,118	233,817	253,361	8 %	4%	272,046	93%
Modern Contraception	3,192	66,221	69,310	5%	1%	70,959	98 %
HIV & STIs	8,902	167,159	183,843	10%	3%	200,615	92 %
WASH	24	437	208	(52)%	0%	472	44 %
Swaziland	22,236	793,184	564,666	(29)%	8%	330,572	171%
Modern Contraception	1,417	51,387	35,519	(31)%	1%	18,016	197 %
HIV & STIs	20,819	741,797	529,147	(29)%	7%	312,556	169 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Tanzania	16,199	1,061,037	470,523	(56)%	7%	506,709	93%
Modern Contraception	15,712	749,549	410,668	(45)%	6%	463,818	89 %
HIV & STIs	-	74,658	80	(100)%	0%	1,690	5 %
Malaria	-	226,626	52,086	(77)%	1%	32,909	158 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	487	9,787	7,302	(25)%	0%	7,808	94 %
WASH	1	418	387	(7)%	0%	484	80 %
Uganda	48,906	399,586	419,148	5 %	6%	285,612	147%
Modern Contraception	10,627	176,878	86,295	(51)%	1%	69,347	124 %
HIV & STIs	38,279	222,799	332,853	49%	5%	216,265	154 %
Malaria	-	-	-	0%	0%	-	0 %
Maternal, Newborn, and Child Health	-	178	-	(100)%	0%	-	0 %
Non-communicable diseases	-	28	-	(100)%	0%	-	0 %
Safe Abortion	-	(297)	-	(100)%	0%	-	0 %
WASH	-	-	-	(100)%	0%	-	0 %
Zambia	52,109	480,639	489,201	2 %	7%	510,034	96%
Modern Contraception	15,363	154,316	218,533	42%	3%	172,215	127 %
HIV & STIs	36,746	324,338	270,075	(17)%	4%	335,898	80 %
WASH	-	1,986	592	(70)%	0%	1,922	31 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Zimbabwe	59,207	2,147,537	1,768,125	(18)%	25%	1,868,119	95%
Modern Contraception	6,918	76,512	93,687	22%	1%	87,065	108 %
HIV & STIs	52,282	2,070,343	1,673,010	(19)%	24%	1,780,790	94 %
Non-communicable diseases	7	220	1,428	548%	0%	264	541 %
Tuberculosis	-	48	-	(100)%	0%	-	0 %
WASH	-	414	-	(100)%	0%	-	0 %
Franco/Lusophone Africa Market Group	715,759	2,498,201	2,625,497	5%	100%	2,722,253	96%
Angola	6,184	698,314	296,140	(58)%	11%	276,666	107%
Modern Contraception	2,738	126,838	124,450	(2)%	5%	142,140	88 %
HIV & STIs	2,047	15,712	12,097	(23)%	0%	23,605	51 %
Malaria	261	549,478	147,306	(73)%	6%	106,722	138 %
Safe Abortion	977	4,992	10,834	117%	0%	2,557	424 %
WASH	162	1,294	1,454	12%	0%	1,641	89 %
Benin	37,285	303,564	286,737	(6)%	11%	306,792	93%
Modern Contraception	35,865	250,634	226,398	(10)%	9%	245,407	92 %
HIV & STIs	767	13,101	40,358	208%	2%	24,948	162 %
Malaria	3	686	8	(99)%	0%	-	0 %
Maternal, Newborn, and Child Health	177	36,620	14,653	(60)%	1%	33,329	44 %
Non-communicable diseases	-	6	2	(67)%	0%	-	0 %
Safe Abortion	60	492	970	97%	0%	-	0 %
WASH	412	2,024	4,349	115%	0%	3,108	140 %
Burundi	66,675	172,616	210,992	22 %	8%	151,589	139%
Modern Contraception	12,119	45,527	48,423	6%	2%	42,894	113 %
HIV & STIs	7,910	47,419	45,371	(4)%	2%	37,486	121 %
Malaria	46,620	79,470	116,894	47%	4%	70,791	165 %
Safe Abortion	25	200	305	52%	0%	418	73 %
Cameroon	232,586	529,278	691,231	31 %	26%	900,441	77%
Modern Contraception	17,186	348,630	348,511	0%	13%	272,311	128 %
HIV & STIs	11,945	140,955	128,782	(9)%	5%	152,624	84 %
Malaria	202,537	11,135	204,354	1,735%	8%	461,281	44 %
Maternal, Newborn, and Child Health	2	22,376	4,923	(78)%	0%	3,715	133 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	916	5,968	4,617	(23)%	0%	10,508	44 %
WASH	1	214	44	(80)%	0%	2	2,120 %
Cote d'Ivoire	7,173	23,105	139,081	502 %	5%	81,095	172%
Modern Contraception	5,964	18,920	133,056	603%	5%	78,028	171 %
HIV & STIs	1,147	3,805	4,815	27%	0%	2,387	202 %
WASH	62	380	1,211	219%	0%	679	178 %
Mozambique	69,969	513,571	506,589	(1)%	19%	588,280	86%
Modern Contraception	42,624	304,610	339,629	11%	13%	317,733	107 %
HIV & STIs	26,890	205,130	160,174	(22)%	6%	264,540	61 %
Malaria	-	95	-	(100)%	0%	-	0 %
WASH	455	3,736	6,786	82%	0%	6,006	113 %
Niger	279,793	132,613	402,999	204 %	15%	292,956	138%
Modern Contraception	10,714	58,092	126,545	118%	5%	65,342	194 %
HIV & STIs	-	239	5,596	2,246%	0%	1,328	421 %
Malaria	268,989	70,640	268,989	281%	10%	225,393	119 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Safe Abortion	91	3,642	1,868	(49)%	0%	893	209 %
PSI Benin	1,283	45,270	38,235	(16)%	1%	50,634	76%
Modern Contraception	1,216	41,578	32,001	(23)%	1%	46,563	69 %
Safe Abortion	67	3,692	6,234	69%	0%	4,071	153 %
Senegal	14,811	79,870	53,493	(33)%	2%	73,800	72%
Modern Contraception	8,412	36,734	32,422	(12)%	1%	32,473	100 %
HIV & STIs	5,393	35,375	16,302	(54)%	1%	36,127	45 %
Malaria	947	7,552	4,338	(43)%	0%	4,608	94 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	60	209	431	106%	0%	593	73 %
Latin America & Asia Market Group	92,055	1,215,801	1,278,619	5%	100%	1,133,232	113%
Cambodia	10,361	232,921	213,730	(8)%	17%	250,805	85%
Modern Contraception	6,331	131,480	122,502	(7)%	10%	142,792	86 %
HIV & STIs	2,749	67,870	63,185	(7)%	5%	77,713	81 %
Malaria	-	395	8	(98)%	0%	160	5 %
Maternal, Newborn, and Child Health	176	5,849	6,902	18%	1%	1,752	394 %
Safe Abortion	1,105	27,327	21,133	(23)%	2%	28,390	74 %
Caribbean	-	-	-	- %	-%	-	-%
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Costa Rica	271	2,369	2,194	(7)%	-%	2,522	87%
Modern Contraception	34	301	279	(7)%	0%	320	87 %
HIV & STIs	236	2,068	1,915	(7)%	0%	2,201	87 %
Dominican Republic	383	18,652	26,603	43 %	2%	15,540	171%
Modern Contraception	115	5,499	7,636	39%	1%	4,631	165 %
HIV & STIs	268	13,153	18,966	44%	1%	10,909	174 %
El Salvador	10	6,512	8,720	34 %	1%	7,134	122%
Modern Contraception	5	1,756	2,254	28%	0%	1,794	126 %
HIV & STIs	5	4,744	6,466	36%	1%	5,340	121 %
Maternal, Newborn, and Child Health	-	11	-	(100)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	-	2	-	(100)%	0%	-	0 %
El Salvador SA	427	2,578	5,987	132 %	-%	1,910	314%
Modern Contraception	261	2,507	4,104	64%	0%	1,851	222 %
HIV & STIs	164	44	1,842	4,070%	0%	-	0 %
Safe Abortion	2	27	41	52%	0%	59	70 %
Guatemala	4	38,762	14,268	(63)%	1%	29,609	48%
Modern Contraception	3	23,967	6,359	(73)%	0%	13,146	48 %
HIV & STIs	1	14,686	7,909	(46)%	1%	16,463	48 %
Safe Abortion	-	109	-	(100)%	0%	-	0 %
Guatemala SA	983	64,123	66,414	4 %	5%	10,527	631%
Modern Contraception	(341)	63,646	59,902	(6)%	5%	10,203	587 %
HIV & STIs	1,308	124	6,027	4,771%	0%	-	0 %
Safe Abortion	16	353	485	37%	0%	324	150 %
Honduras	38	18,932	9,298	(51)%	1%	19,810	47%
Modern Contraception	37	3,000	1,911	(36)%	0%	2,693	71 %
HIV & STIs	2	15,932	7,387	(54)%	1%	17,117	43 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Honduras SA	285	-	8,133	- %	1%	-	-%
Modern Contraception	38	-	1,097	0%	0%	-	0 %
HIV & STIs	247	-	7,036	0%	1%	-	0 %
Kazakhstan	91	965	1,068	11 %	-%	562	190%
Modern Contraception	1	10	17	75%	0%	4	408 %
HIV & STIs	90	955	1,051	10%	0%	558	188 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Kyrgyzstan	59	602	729	21 %	-%	457	160%
Modern Contraception	-	13	12	(12)%	0%	22	52 %
HIV & STIs	59	589	717	22%	0%	435	165 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Laos	714	29,900	22,541	(25)%	2%	27,508	82%
Modern Contraception	699	24,777	17,657	(29)%	1%	22,913	77 %
HIV & STIs	-	3,829	3,522	(8)%	0%	3,564	99 %
Malaria	14	250	174	(30)%	0%	156	112 %
Safe Abortion	-	982	1,159	18%	0%	837	138 %
Tuberculosis	-	64	29	(54)%	0%	38	77 %
Nepal	6,019	35,896	30,254	(16)%	2%	30,224	100%
Modern Contraception	3,967	20,428	16,464	(19)%	1%	17,110	96 %
HIV & STIs	-	5	-	(100)%	0%	-	0 %
Safe Abortion	2,052	15,463	13,791	(11)%	1%	13,114	105 %
Nicaragua	932	14,253	17,728	24 %	1%	-	3,693,519%
Modern Contraception	406	8,610	11,074	29%	1%	-	0 %
HIV & STIs	525	5,542	6,538	18%	1%	-	1,362,213 %
Safe Abortion	1	102	116	14%	0%	-	0 %
Nicaragua SA	-	-	-	- %	-%	16,895	-%
Modern Contraception	-	-	-	0%	0%	10,574	0 %
HIV & STIs	-	-	-	0%	0%	6,148	0 %
Safe Abortion	-	-	-	0%	0%	173	0 %
Pakistan	47,824	568,435	580,103	2 %	45%	383,003	151%
Modern Contraception	31,010	398,022	415,951	5%	33%	348,668	119 %
HIV & STIs	4,849	43,119	31,928	(26)%	2%	34,336	93 %
Nutrition	6	-	25	0%	0%	-	0 %
Safe Abortion	1,484	8,252	14,292	73%	1%	-	0 %
Tuberculosis	10,475	119,042	117,907	(1)%	9%	-	0 %
Panama	284	6,551	4,472	(32)%	-%	7,260	62%
Modern Contraception	67	1,538	1,038	(33)%	0%	1,719	60 %
HIV & STIs	217	5,013	3,434	(31)%	0%	5,542	62 %
Papua New Guinea	195	2,041	1,152	(44)%	-%	3,278	35%
Modern Contraception	102	169	584	246%	0%	1,889	31 %
HIV & STIs	93	154	537	249%	0%	1,309	41 %
Malaria	-	1,714	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	-	27	0%	0%	76	36 %
WASH	-	4	3	(19)%	0%	4	93 %
PSI Pakistan	23,022	118,333	248,606	110 %	19%	304,660	82%
Modern Contraception	22,685	117,247	237,845	103%	19%	292,577	81 %
HIV & STIs	337	1,086	10,760	891%	1%	12,083	89 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tajikistan	140	17,530	14,367	(18)%	1%	19,404	74%
Modern Contraception	5	415	65	(84)%	0%	80	81 %
HIV & STIs	135	17,115	14,302	(16)%	1%	19,324	74 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Viet Nam	13	36,446	2,252	(94)%	-%	2,123	106%
Modern Contraception	7	184	240	30%	0%	76	314 %
HIV & STIs	-	36,079	1,912	(95)%	0%	1,912	100 %
Malaria	6	27	60	127%	0%	108	56 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	-	156	39	(75)%	0%	26	148 %
Foundation Market Group	2,386,388	7,586,885	6,338,408	(16)%	100%	7,584,880	84%
Haiti	9,720	169,008	126,628	(25)%	2%	87,193	145%
Modern Contraception	419	24,275	9,015	(63)%	0%	9,184	98 %
HIV & STIs	6,575	66,067	35,918	(46)%	1%	12,871	279 %
Malaria	759	1,995	36,309	1,720%	1%	23,585	154 %
Maternal, Newborn, and Child Health	1,967	-	7,366	0%	0%	7,462	99 %
Non-communicable diseases	-	1	-	(80)%	0%	-	0 %
Tuberculosis	-	76,671	38,021	(50)%	1%	34,091	112 %
Liberia	10	12,039	7,836	(35)%	-%	27,447	29%
Modern Contraception	-	5,528	3,547	(36)%	0%	12,602	28 %
HIV & STIs	10	6,378	4,198	(34)%	0%	14,733	28 %
WASH	-	133	91	(32)%	0%	112	81 %
Madagascar	106,245	2,112,645	1,093,857	(48)%	17%	1,094,187	100%
Modern Contraception	58,062	452,712	514,782	14%	8%	476,130	108 %
HIV & STIs	30,336	140,232	134,843	(4)%	2%	117,859	114 %
Malaria	12,375	1,443,630	378,404	(74)%	6%	459,706	82 %
Maternal, Newborn, and Child Health	4,835	65,741	58,077	(12)%	1%	36,677	158 %
Non-communicable diseases	1	23	9	(62)%	0%	-	0 %
Nutrition	-	119	-	(100)%	0%	-	0 %
Safe Abortion	634	4,684	6,217	33%	0%	3,618	172 %
WASH	2	5,504	1,525	(72)%	0%	197	773 %
Mali	1,285,020	3,372,072	3,231,077	(4)%	51%	3,114,047	104%
Modern Contraception	42,485	376,214	500,260	33%	8%	446,445	112 %
HIV & STIs	-	1	578	55,700%	0%	1,036	56 %
Malaria	,241,725	2,989,340	2,722,429	(9)%	43%	2,654,094	103 %
Non-communicable diseases	3	36	39	7%	0%	210	18 %
Safe Abortion	805	6,437	7,640	19%	0%	11,204	68 %
WASH	1	43	131	206%	0%	1,059	12 %
Somaliland	10,870	174,375	152,264	(13)%	2%	158,117	96%
Modern Contraception	634	4,596	5,524	20%	0%	4,893	113 %
HIV & STIs	35	119	193	62%	0%	131	147 %
Malaria	43	841	1,055	25%	0%	866	122 %
Maternal, Newborn, and Child Health	7,074	67,253	58,271	(13)%	1%	48,449	120 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Nutrition	3,085	100,190	86,897	(13)%	1%	103,209	84 %
WASH	-	1,377	325	(76)%	0%	568	57 %

POPULATION SERVICES INTERNATIONAL
 Monthly DALY Report by Country
 Period: 12
 Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
South Sudan	974,523	1,746,746	1,726,746	(1)%	27%	3,103,888	56%
Malaria	974,523	1,202,671	1,726,746	44%	27%	3,103,888	56 %
Maternal, Newborn, and Child Health	-	540,043	-	(100)%	0%	-	0 %
Nutrition	-	4,031	-	(100)%	0%	-	0 %
Social Enterprise	124,424	1,433,239	1,011,719	(29)%	100%	1,661,860	61%
India LLC	34,339	649,269	372,241	(43)%	37%	805,943	46%
Modern Contraception	11,860	285,814	163,821	(43)%	16%	312,748	52 %
HIV & STIs	19,217	234,615	128,227	(45)%	13%	311,642	41 %
Maternal, Newborn, and Child Health	(76)	22,965	27,074	18%	3%	26,486	102 %
Safe Abortion	3,337	105,875	53,118	(50)%	5%	155,067	34 %
Other	-	-	-	0%	0%	-	0 %
Paraguay	3,048	25,359	24,842	(2)%	2%	24,784	100%
Modern Contraception	718	7,129	6,925	(3)%	1%	7,205	96 %
HIV & STIs	2,309	17,892	17,676	(1)%	2%	17,198	103 %
Nutrition	21	337	241	(29)%	0%	381	63 %
PSI South Africa	87,037	758,612	614,636	(19)%	61%	831,133	74%
Modern Contraception	5,270	47,409	37,977	(20)%	4%	56,569	67 %
HIV & STIs	81,767	711,203	576,659	(19)%	57%	774,565	74 %
Inactive	-	1,762	-	(100)%	-%	-	-%
Guinea	-	1,762	-	(100)%	-%	-	-%
Modern Contraception	-	1,520	-	(100)%	0%	-	0 %
HIV & STIs	-	242	-	(100)%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acute Malnutrition Screening_CU5	21	-	410	312	619,573	(100)%	619,573	621,360	410	-	-
Franco/Lusophone Africa Market Group	-	-	-	312	518	(100)%	518	1,895	-	-	-
Foundation Market Group	21	-	410	-	619,055	(100)%	619,055	619,465	410	-	-
Antiretroviral Treatment	-	-	-	-	-	-%	-	18,119	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	18,119	-	-	-
Antiretroviral Treatment (Currently Enrolled)	70,958	71,395	545,956	313,246	535,855	2%	535,855	1,554,153	45,496	-	98,464
Acceleration Market Group	15,532	15,167	174,024	170,176	152,003	14%	152,003	402,508	14,502	-	34,444
Anglophone Africa Market Group	14,751	14,210	163,277	105,390	148,026	10%	148,026	430,536	13,606	-	29,008
Franco/Lusophone Africa Market Group	6,113	6,367	62,079	7,723	19,016	226%	19,016	87,725	5,173	-	10,345
Latin America & Asia Market Group	-	827	7,541	-	233	3,136%	233	7,774	628	-	1,049
Foundation Market Group	34,562	34,824	139,035	29,957	216,577	(36)%	216,577	625,610	11,586	-	23,619
Antiretroviral Treatment (Newly Enrolled)	1,275	3,314	19,554	13,389	15,865	23%	15,865	62,517	19,554	-	-
Acceleration Market Group	263	309	3,744	3,981	3,434	9%	3,434	13,330	3,744	-	-
Anglophone Africa Market Group	607	685	7,255	4,695	6,634	9%	6,634	30,120	7,255	-	-
Franco/Lusophone Africa Market Group	139	159	1,404	1,396	1,807	(22)%	1,807	3,625	1,404	-	-
Latin America & Asia Market Group	-	47	449	-	92	388%	92	541	449	-	-
Foundation Market Group	266	2,114	6,702	3,317	3,898	72%	3,898	14,901	6,702	-	-
Antiretroviral Treatment (Tablet)	-	-	-	-	-	-%	-	97,980	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	97,980	-	-	-
ARV Prophylaxis 28 wks (Mother and Baby)	-	-	-	-	-	-%	-	382	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	382	-	-	-
ARV Prophylaxis 28 wks (Mother Only)	-	-	-	-	-	-%	-	359	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	359	-	-	-
Basic Care Package	-	-	-	-	1	(100)%	1	176,452,482	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,064,698	-	-	-
Anglophone Africa Market Group	-	-	-	-	1	(100)%	1	174,969,459	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	418,325	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
CD4 Tests Provided to HIV+ Clients	-	-	-	-	666	(100)%	666	16,834	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	4,995	-	-	-
Anglophone Africa Market Group	-	-	-	-	544	(100)%	544	9,416	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	122	(100)%	122	1,919	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	504	-	-	-
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-	-%	-	10	10	-	4
Anglophone Africa Market Group	3	2	10	-	-	-%	-	10	10	-	4
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3	167%	3	11	8	-	3
Anglophone Africa Market Group	2	1	8	-	3	167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Refer to any Treatment	1	-	2	-	-	-%	-	13	2	-	-
Anglophone Africa Market Group	1	-	2	-	-	-%	-	13	2	-	-
Cervical Cancer-HPV DNA and Refer to Conization	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
Cervical Cancer-HPV DNA Screening	333	728	4,123	-	-	-%	-	4,123	4,123	-	-
Anglophone Africa Market Group	333	582	3,346	-	-	-%	-	3,346	3,346	-	-
Latin America & Asia Market Group	-	146	777	-	-	-%	-	777	777	-	-
Cervical Cancer-Pap and Conization	-	-	1,753	-	-	-%	-	1,753	1,753	-	778
Anglophone Africa Market Group	-	-	1,753	-	-	-%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	4	(100)%	4	39	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	25	-	-	-
Foundation Market Group	-	-	-	-	4	(100)%	4	4	-	-	-
Inactive	-	-	-	-	-	-%	-	10	-	-	-
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-	-%	-	11	9	-	2
Anglophone Africa Market Group	-	-	9	-	-	-%	-	11	9	-	2
Cervical Cancer-Pap and Refer to Conization	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
Cervical Cancer-Pap Smear Screening	30	58	438	-	92	376%	92	7,795	438	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	6,497	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	291	-	-	-
Latin America & Asia Market Group	30	58	438	-	92	376%	92	918	438	-	-
Inactive	-	-	-	-	-	-%	-	89	-	-	-
Cervical Cancer-VIA and Conization	11	18	245	290	126	94%	126	549	245	-	88
Anglophone Africa Market Group	11	18	245	290	126	94%	126	549	245	-	88
Cervical Cancer-VIA and Cryotherapy	25	59	2,077	1,247	1,162	79%	1,162	23,516	2,077	-	684
Acceleration Market Group	7	22	307	240	286	7%	286	11,553	307	-	73
Anglophone Africa Market Group	2	18	1,598	307	639	150%	639	10,047	1,598	-	561
Franco/Lusophone Africa Market Group	3	2	16	-	48	(67)%	48	390	16	-	2
Latin America & Asia Market Group	-	-	-	-	-	-%	-	8	-	-	-
Foundation Market Group	13	16	156	700	189	(17)%	189	1,498	156	-	48
Inactive	-	-	-	-	-	-%	-	20	-	-	-
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25	240%	25	523	85	-	15
Acceleration Market Group	-	-	-	-	-	-%	-	127	-	-	-
Anglophone Africa Market Group	1	6	85	-	25	240%	25	396	85	-	15
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	102	(77)%	102	2,083	23	-	4
Acceleration Market Group	-	-	-	-	4	(100)%	4	4	-	-	-
Anglophone Africa Market Group	1	3	23	290	98	(77)%	98	2,079	23	-	4
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	39	(100)%	39	2,084	-	-	-
Acceleration Market Group	-	-	-	150	29	(100)%	29	913	-	-	-
Anglophone Africa Market Group	-	-	-	-	10	(100)%	10	625	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	536	-	-	-
Cervical Cancer-VIA/VILI Screening	8,014	13,178	137,560	145,293	194,523	(29)%	194,523	1,178,264	137,560	-	-
Acceleration Market Group	288	1,514	37,955	21,500	34,714	9%	34,714	502,387	37,955	-	-
Anglophone Africa Market Group	1,325	4,178	45,450	88,793	95,922	(53)%	95,922	386,536	45,450	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	3,329	3,156	28,676	-	50,592	(43)%	50,592	189,505	28,676	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	387	-	-	-
Foundation Market Group	3,072	4,329	25,479	35,000	13,295	92%	13,295	99,179	25,479	-	-
Inactive	-	-	-	-	-	-%	-	270	-	-	-
Chlorhexidine	563	5,793	38,321	25,755	130,742	(71)%	130,742	656,236	34,489	-	2,315
Acceleration Market Group	-	-	-	-	-	-%	-	148,406	-	-	-
Anglophone Africa Market Group	263	777	6,590	16,755	23,622	(72)%	23,622	43,255	5,931	-	458
Foundation Market Group	300	5,015	31,731	9,000	107,120	(70)%	107,120	464,575	28,558	-	1,857
Clean Delivery Kit	-	-	-	-	3,449	(100)%	3,449	1,708,471	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	346,994	-	-	-
Anglophone Africa Market Group	-	-	-	-	3,449	(100)%	3,449	470,003	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	710,114	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	180,586	-	-	-
Inactive	-	-	-	-	-	-%	-	774	-	-	-
Condom	44,472,930	37,377,252	417,858,083	553,397,069	504,429,167	(17)%	504,429,167	21,864,868,151	3,133,921	3,133,921	3,694,143
Acceleration Market Group	3,408,750	4,118,821	45,303,579	41,769,999	38,017,548	19%	38,017,548	9,799,101,930	339,777	339,777	1,000,040
Anglophone Africa Market Group	2,463,283	3,785,709	46,603,378	49,703,561	65,266,786	(29)%	65,266,786	3,193,512,061	349,525	349,525	932,948
Franco/Lusophone Africa Market Group	5,460,296	4,224,472	41,173,232	59,938,298	51,015,576	(19)%	51,015,576	1,670,441,894	308,799	308,799	522,101
Latin America & Asia Market Group	18,641,510	20,299,308	184,767,633	196,479,173	187,072,729	(1)%	187,072,729	4,038,875,034	1,385,757	1,385,757	394,062
Foundation Market Group	79,536	292,240	1,828,764	2,920,716	3,347,338	(45)%	3,347,338	954,325,997	13,716	13,716	16,365
Social Enterprise	14,419,555	4,656,703	98,181,497	202,585,322	159,709,190	(39)%	159,709,190	810,700,372	736,347	736,347	828,627
USA	-	-	-	-	-	-%	-	289,819	-	-	-
Inactive	-	-	-	-	-	-%	-	1,397,621,044	-	-	-
Condom Provided	-	-	-	-	-	-%	-	18,930,351	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	50,644	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	17,527,104	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	673,774	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	-	-%	-	651,148	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	27,681	-	-	-
Counseling & Tx for Moderate Acute MalnutritionCU5	545	2,096	19,252	20,946	20,332	(5)%	20,332	194,739	19,252	-	60,218
Franco/Lusophone Africa Market Group	-	-	-	4	-	-%	-	8	-	-	-
Foundation Market Group	545	2,096	19,252	20,942	20,332	(5)%	20,332	194,731	19,252	-	60,218
Deworming Tablets	-	-	-	-	-	-%	-	1,095,308	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,095,308	-	-	-
Diarrhea Treatment Kit	12,890	22,424	432,701	780,367	666,448	(35)%	666,448	20,170,174	389,431	-	26,500
Acceleration Market Group	-	-	-	-	-	-%	-	6,854,139	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	24,379	-	-	-
Franco/Lusophone Africa Market Group	1,010	21,316	300,418	424,000	431,332	(30)%	431,332	4,433,547	270,376	-	17,600
Latin America & Asia Market Group	2,820	1,107	40,570	91,951	57,190	(29)%	57,190	989,246	36,513	-	798
Foundation Market Group	9,060	1	91,713	264,416	177,926	(48)%	177,926	5,121,917	82,542	-	8,103
Inactive	-	-	-	-	-	-%	-	2,746,946	-	-	-
Diarrhea Treatment Kit Provided	635	-	15,782	29,000	20,038	(21)%	20,038	84,713	15,782	-	572
Acceleration Market Group	-	-	15,147	29,000	18,226	(17)%	18,226	69,404	15,147	-	503
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,400	-	-	-
Foundation Market Group	635	-	635	-	1,812	(65)%	1,812	12,909	635	-	69
Early Infant Male Circumcision	-	-	-	-	-	-%	-	4,886	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,886	-	-	-
Emergency Contraception	323,667	350,839	3,186,854	2,499,767	3,049,904	4%	3,049,904	47,776,015	143,408	143,408	25,903
Acceleration Market Group	-	333	1,000	-	(121)	-%	(121)	16,367,341	45	45	4
Anglophone Africa Market Group	19,641	11,004	123,300	7,000	180,947	(32)%	180,947	1,771,057	5,549	5,549	2,145
Franco/Lusophone Africa Market Group	12,358	2,421	51,168	255,200	135,874	(62)%	135,874	727,474	2,303	2,303	1,389
Latin America & Asia Market Group	256,540	299,816	2,547,734	981,837	2,139,235	19%	2,139,235	23,609,520	114,648	114,648	19,909
Foundation Market Group	(4)	(6)	44,760	15,700	40,018	12%	40,018	165,291	2,014	2,014	547
Social Enterprise	35,132	37,270	418,892	1,240,030	553,951	(24)%	553,951	3,484,995	18,850	18,850	1,909

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	1,650,337	-	-	-
Emergency Contraception Provided	25,844	13,809	201,747	1,199,860	29,591	582%	29,591	266,696	10,087	10,087	3,283
Acceleration Market Group	20,252	9,473	75,323	19,800	4,173	1,705%	4,173	80,924	3,766	3,766	561
Anglophone Africa Market Group	1,578	1,144	91,980	30,493	6,887	1,236%	6,887	100,086	4,599	4,599	2,329
Franco/Lusophone Africa Market Group	307	295	4,060	3,000	2,877	41%	2,877	8,547	203	203	127
Latin America & Asia Market Group	3,703	2,891	30,261	1,146,567	15,372	97%	15,372	75,034	1,513	1,513	263
Foundation Market Group	4	6	123	-	282	(56)%	282	2,104	6	6	2
Inactive	-	-	-	-	-	-%	-	1	-	-	-
Expanded Clean Delivery Kit	-	-	-	-	13,160	(100)%	13,160	25,000	-	-	-
Anglophone Africa Market Group	-	-	-	-	13,160	(100)%	13,160	25,000	-	-	-
Expanded Clean Delivery Kit (+CHX)	669	973	11,709	20,285	14,531	(19)%	14,531	26,857	10,538	-	1,713
Anglophone Africa Market Group	669	973	11,709	20,285	14,531	(19)%	14,531	26,857	10,538	-	1,713
Family Planning Counseling	-	-	-	-	-	-%	-	42,190	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,882	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	21,833	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	3,787	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	688	-	-	-
Fecal Sludge Management (Households)	-	40	3,800	750	2,071	83%	2,071	7,453	18,942	-	-
Acceleration Market Group	-	6	489	400	697	(30)%	697	2,768	2,347	-	-
Franco/Lusophone Africa Market Group	-	34	3,311	350	1,374	141%	1,374	4,685	16,595	-	-
Fecal Sludge Management (Liters)	-	523,667	13,055,000	15,559,190	9,121,000	43%	9,121,000	29,322,200	-	-	1,443
Acceleration Market Group	-	30,000	1,914,000	2,000,000	4,011,000	(52)%	4,011,000	13,071,200	-	-	118
Franco/Lusophone Africa Market Group	-	493,667	11,141,000	13,559,190	5,110,000	118%	5,110,000	16,251,000	-	-	1,325
Female Condom	24,404	182,394	1,721,664	1,763,132	1,709,647	1%	1,709,647	87,884,528	12,912	12,912	21,698
Acceleration Market Group	-	-	85,553	70,000	79,641	7%	79,641	10,481,146	642	642	461
Anglophone Africa Market Group	1,124	13,751	174,851	533,000	469,229	(63)%	469,229	48,744,678	1,311	1,311	5,678
Franco/Lusophone Africa Market Group	23,280	168,643	1,461,260	1,160,132	1,160,677	26%	1,160,677	13,213,905	10,959	10,959	15,559

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	100	(100)%	100	660,929	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	9,300,709	-	-	-
Social Enterprise	-	-	-	-	-	-%	-	985,104	-	-	-
Inactive	-	-	-	-	-	-%	-	4,498,057	-	-	-
Female Condom Provided	-	-	-	-	-	-%	-	112,394	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	87,306	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	22,060	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,027	-	-	-
Fever Cases Attended	178,135	101,571	1,051,956	286,938	916,338	15%	916,338	7,198,191	1,051,956	-	-
Acceleration Market Group	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,978,275	520,128	-	-
Anglophone Africa Market Group	67,555	25,845	238,868	-	-	-%	-	238,868	238,868	-	-
Franco/Lusophone Africa Market Group	-	-	-	8,385	14,143	(100)%	14,143	26,907	-	-	-
Latin America & Asia Market Group	8,568	8,834	88,447	75,685	118,263	(25)%	118,263	368,372	88,447	-	-
Foundation Market Group	28,033	18,106	204,513	202,868	86,150	137%	86,150	3,585,769	204,513	-	-
Fever Cases Tested with Microscopy	4,030	5,064	44,156	30,340	56,797	(22)%	56,797	483,644	44,156	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	7,474	-	-	-
Latin America & Asia Market Group	-	2,246	6,737	-	-	-%	-	6,737	6,737	-	-
Foundation Market Group	4,030	2,818	37,419	30,340	56,797	(34)%	56,797	469,433	37,419	-	-
Fever Cases Tested with RDTs	182,893	111,364	1,162,076	276,374	1,120,815	4%	1,120,815	7,707,972	1,162,076	-	-
Acceleration Market Group	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,970,447	520,128	-	-
Anglophone Africa Market Group	64,534	24,741	227,984	-	-	-%	-	227,984	227,984	-	-
Franco/Lusophone Africa Market Group	-	-	-	8,385	14,143	(100)%	14,143	42,041	-	-	-
Latin America & Asia Market Group	11,112	13,038	116,202	95,551	134,061	(13)%	134,061	411,889	116,202	-	-
Foundation Market Group	33,268	24,799	297,762	172,438	274,829	8%	274,829	4,055,611	297,762	-	-
Free Condom	11,706,959	9,588,115	105,689,754	109,721,482	180,808,636	(42)%	180,808,636	2,728,777,592	792,673	792,673	1,716,161
Acceleration Market Group	-	2,400	1,920,960	35,500,000	68,170,320	(97)%	68,170,320	1,487,878,858	14,407	14,407	56,881

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	5,912,539	4,297,117	61,742,141	44,434,784	77,319,731	(20)%	77,319,731	791,688,792	463,066	463,066	1,352,880
Franco/Lusophone Africa Market Group	924,524	354,673	14,956,285	5,193,631	3,201,731	367%	3,201,731	84,946,478	112,172	112,172	98,975
Latin America & Asia Market Group	56,590	472,857	3,741,906	3,124,160	3,430,359	9%	3,430,359	61,743,271	28,064	28,064	8,033
Foundation Market Group	4,813,306	4,461,068	23,328,462	21,468,907	28,342,179	(18)%	28,342,179	183,879,714	174,963	174,963	199,393
Inactive	-	-	-	-	344,316	(100)%	344,316	118,640,479	-	-	-
Free Female Condom	62,429	385,890	1,563,995	333,000	1,803,686	(13)%	1,803,686	19,216,179	11,730	11,730	32,473
Acceleration Market Group	11,695	9,857	49,875	-	1,108,500	(96)%	1,108,500	6,617,636	374	374	269
Anglophone Africa Market Group	47,550	367,230	1,398,332	251,000	623,007	124%	623,007	7,487,195	10,487	10,487	31,104
Franco/Lusophone Africa Market Group	2,184	3,700	99,284	52,000	49,536	100%	49,536	1,153,978	745	745	1,021
Latin America & Asia Market Group	1,000	5,103	16,504	30,000	21,200	(22)%	21,200	370,278	124	124	80
Foundation Market Group	-	-	-	-	253	(100)%	253	3,329,424	-	-	-
Inactive	-	-	-	-	1,190	(100)%	1,190	257,668	-	-	-
HAART (Mother and Baby)	-	-	-	-	-	-%	-	256	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	256	-	-	-
HAART (Mother Only)	-	-	-	-	-	-%	-	239	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	239	-	-	-
HIV Self-Testing Kit	246,375	182,667	1,405,373	1,716,537	2,354,376	(40)%	2,354,376	4,129,296	1,264,836	-	-
Acceleration Market Group	5,390	155,147	647,230	1,066,643	1,357,422	(52)%	1,357,422	2,004,652	582,507	-	-
Anglophone Africa Market Group	240,457	27,198	756,647	641,306	996,954	(24)%	996,954	2,123,148	680,982	-	-
Franco/Lusophone Africa Market Group	-	-	-	1,388	-	-%	-	-	-	-	-
Latin America & Asia Market Group	528	323	1,496	7,200	-	-%	-	1,496	1,346	-	-
HIV Testing Services	122,645	158,837	1,375,018	1,174,518	2,232,177	(38)%	2,232,177	24,694,556	1,375,018	-	39,836
Acceleration Market Group	14,865	18,072	318,640	293,418	1,091,132	(71)%	1,091,132	7,344,676	318,640	-	12,203
Anglophone Africa Market Group	18,061	24,893	315,263	518,172	541,424	(42)%	541,424	10,763,361	315,263	-	23,436
Franco/Lusophone Africa Market Group	6,415	5,876	87,835	93,415	106,415	(17)%	106,415	3,088,407	87,835	-	663
Latin America & Asia Market Group	2,048	4,812	69,479	78,439	98,169	(29)%	98,169	441,260	69,479	-	154
Foundation Market Group	81,256	105,183	583,801	191,074	395,037	48%	395,037	2,282,402	583,801	-	3,380

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	774,450	-	-	-
Hypertension Diagnosis	21,912	3,203	80,787	34,572	100,760	(20)%	100,760	281,443	80,787	-	-
Acceleration Market Group	19,902	1,061	51,351	20,000	57,768	(11)%	57,768	162,354	51,351	-	-
Anglophone Africa Market Group	1,951	2,141	21,416	-	16,890	27%	16,890	58,632	21,416	-	-
Latin America & Asia Market Group	-	-	7,961	14,572	26,102	(70)%	26,102	60,398	7,961	-	-
Foundation Market Group	59	-	59	-	-	-%	-	59	59	-	-
Hypertension Screening	102,381	94,526	1,218,119	236,477	1,403,815	(13)%	1,403,815	3,884,487	1,218,119	-	-
Acceleration Market Group	27,633	1,934	108,524	50,000	176,640	(39)%	176,640	506,763	108,524	-	-
Anglophone Africa Market Group	74,748	92,591	917,675	36,477	813,698	13%	813,698	2,570,110	917,675	-	-
Latin America & Asia Market Group	-	-	191,920	150,000	413,477	(54)%	413,477	807,614	191,920	-	-
Hypertension_C Controlled Condition	16,782	833	51,877	13,009	74,033	(30)%	74,033	187,733	20,751	-	-
Acceleration Market Group	16,777	824	39,737	-	43,499	(9)%	43,499	124,883	15,895	-	-
Anglophone Africa Market Group	5	9	105	-	91	15%	91	262	42	-	-
Latin America & Asia Market Group	-	-	12,035	13,009	30,443	(60)%	30,443	62,588	4,814	-	-
Implant 3	23,954	18,098	110,512	87,804	35,182	214%	35,182	1,137,885	99,461	248,652	229,039
Acceleration Market Group	363	1,401	10,355	12,600	1,528	578%	1,528	828,901	9,320	23,299	15,549
Anglophone Africa Market Group	20,120	11,143	74,741	73,620	16,575	351%	16,575	226,811	67,267	168,167	171,357
Franco/Lusophone Africa Market Group	(582)	2,740	7,068	(4,896)	7,323	(3)%	7,323	30,592	6,361	15,903	11,843
Latin America & Asia Market Group	191	305	2,894	4,920	1,681	72%	1,681	26,738	2,605	6,512	886
Foundation Market Group	3,862	2,509	15,454	1,560	8,075	91%	8,075	27,108	13,909	34,772	29,405
Inactive	-	-	-	-	-	-%	-	(2,265)	-	-	-
Implant 3 Insertion	31,460	42,393	408,136	341,797	334,633	22%	334,633	1,351,860	408,136	1,020,340	893,288
Acceleration Market Group	8,449	10,592	51,603	38,123	8,884	481%	8,884	64,098	51,603	129,008	98,957
Anglophone Africa Market Group	12,604	19,783	217,237	201,554	240,316	(10)%	240,316	927,744	217,237	543,093	515,191
Franco/Lusophone Africa Market Group	4,819	5,839	69,284	27,532	24,546	182%	24,546	115,987	69,284	173,210	164,406
Latin America & Asia Market Group	745	900	12,010	12,195	12,809	(6)%	12,809	46,262	12,010	30,025	6,874
Foundation Market Group	4,843	5,278	58,002	62,393	48,078	21%	48,078	193,062	58,002	145,005	107,860

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	4,707	-	-	-
Implant 4	(437)	80	18,362	-	(3,897)	-%	(3,897)	39,389	16,526	52,883	47,402
Anglophone Africa Market Group	(436)	81	18,459	-	(3,883)	-%	(3,883)	26,452	16,613	53,162	47,669
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,200	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	(700)	-	-	-
Foundation Market Group	(1)	(1)	(97)	-	(14)	-%	(14)	7,437	(87)	(279)	(267)
Implant 4 Insertion	836	1,645	11,032	-	34,188	(68)%	34,188	55,405	11,032	35,302	31,682
Acceleration Market Group	-	-	-	-	288	(100)%	288	288	-	-	-
Anglophone Africa Market Group	835	1,644	10,829	-	33,884	(68)%	33,884	46,313	10,829	34,653	31,072
Franco/Lusophone Africa Market Group	-	-	21	-	2	950%	2	752	21	67	40
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,342	-	-	-
Foundation Market Group	1	1	182	-	14	1,200%	14	2,710	182	582	569
Implant 5	8,835	13,865	116,919	50,794	85,932	36%	85,932	877,382	105,227	399,863	353,093
Acceleration Market Group	(4,760)	(13)	(4,707)	(7,600)	2,423	(294)%	2,423	270,291	(4,236)	(16,098)	(11,752)
Anglophone Africa Market Group	4,956	5,823	54,899	26,000	29,617	85%	29,617	251,433	49,409	187,755	180,053
Franco/Lusophone Africa Market Group	6,194	4,497	31,813	29,052	27,720	15%	27,720	153,538	28,632	108,800	94,482
Latin America & Asia Market Group	2,446	1,958	14,480	3,342	20,838	(31)%	20,838	100,033	13,032	49,522	10,876
Foundation Market Group	(1)	1,600	20,434	-	5,334	283%	5,334	90,452	18,391	69,884	79,433
Inactive	-	-	-	-	-	-%	-	11,635	-	-	-
Implant 5 Insertion	34,099	40,627	449,186	372,974	373,214	20%	373,214	2,436,147	449,186	1,706,907	1,513,222
Acceleration Market Group	8,863	10,126	117,879	62,915	82,547	43%	82,547	552,515	117,879	447,940	394,964
Anglophone Africa Market Group	8,796	15,523	175,768	175,505	154,215	14%	154,215	948,502	175,768	667,918	601,310
Franco/Lusophone Africa Market Group	9,861	8,565	89,663	71,842	76,301	18%	76,301	391,935	89,663	340,719	304,059
Latin America & Asia Market Group	288	1,620	20,152	12,712	21,679	(7)%	21,679	107,932	20,152	76,578	15,843
Foundation Market Group	6,291	4,793	45,724	50,000	38,472	19%	38,472	371,665	45,724	173,751	197,046
Inactive	-	-	-	-	-	-%	-	63,598	-	-	-
Infant Fortified Food	-	-	-	-	-	-%	-	91,859	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	-	-%	-	91,859	-	-	-
Injectable 1	15,091	18,068	203,675	150,016	130,168	56%	130,168	3,863,133	14,101	14,101	3,266
Acceleration Market Group	-	-	-	-	-	-%	-	1,546,164	-	-	-
Latin America & Asia Market Group	15,091	18,068	203,675	150,016	130,168	56%	130,168	2,316,960	14,101	14,101	3,266
Inactive	-	-	-	-	-	-%	-	9	-	-	-
Injectable 1 Provided	4,928	9,654	103,353	44,561	89,057	16%	89,057	330,980	7,950	7,950	1,621
Acceleration Market Group	6	5	44	-	37	19%	37	81	3	3	3
Anglophone Africa Market Group	-	2	42	36	537	(92)%	537	1,809	3	3	2
Latin America & Asia Market Group	4,922	9,648	102,997	44,525	88,483	16%	88,483	328,820	7,923	7,923	1,599
Foundation Market Group	-	-	270	-	-	-%	-	270	21	21	17
Injectable 2	(391)	1,854	146,097	39,747	188,630	(23)%	188,630	23,434,053	21,915	21,915	5,997
Acceleration Market Group	-	-	-	-	-	-%	-	15,907,000	-	-	-
Franco/Lusophone Africa Market Group	(391)	2,348	21,203	20,016	54,602	(61)%	54,602	315,547	3,180	3,180	1,697
Latin America & Asia Market Group	-	(494)	124,894	19,731	134,028	(7)%	134,028	7,211,502	18,734	18,734	4,300
Inactive	-	-	-	-	-	-%	-	4	-	-	-
Injectable 2 Provided	5,500	7,855	86,435	211,422	102,606	(16)%	102,606	313,335	14,406	14,406	6,494
Acceleration Market Group	1,175	1,296	13,459	-	5,875	129%	5,875	19,334	2,243	2,243	1,891
Anglophone Africa Market Group	2,923	2,009	21,725	29,000	22,699	(4)%	22,699	56,072	3,621	3,621	2,453
Franco/Lusophone Africa Market Group	1,399	941	12,209	50,000	15,848	(23)%	15,848	50,959	2,035	2,035	1,094
Latin America & Asia Market Group	3	3,609	39,042	132,422	58,184	(33)%	58,184	186,969	6,507	6,507	1,056
Inactive	-	-	-	-	-	-%	-	1	-	-	-
Injectable 3-IM	349,659	342,840	3,929,254	3,760,923	5,050,702	(22)%	5,050,702	95,873,439	884,082	884,082	367,013
Acceleration Market Group	58,149	43,750	514,301	480,600	493,679	4%	493,679	32,556,262	115,718	115,718	25,256
Anglophone Africa Market Group	16,948	35,134	721,284	605,251	1,797,775	(60)%	1,797,775	14,806,282	162,289	162,289	82,874
Franco/Lusophone Africa Market Group	10,421	21,826	180,120	105,000	272,940	(34)%	272,940	1,424,760	40,527	40,527	27,622
Latin America & Asia Market Group	13,221	15,108	323,866	560,836	687,092	(53)%	687,092	12,072,225	72,870	72,870	13,349
Foundation Market Group	241,325	228,903	2,150,139	1,988,500	1,669,487	29%	1,669,487	31,296,675	483,781	483,781	216,424

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	9,595	(1,882)	39,544	20,736	129,729	(70)%	129,729	238,354	8,897	8,897	1,489
Inactive	-	-	-	-	-	-%	-	3,478,881	-	-	-
Injectable 3-IM Provided	140,430	174,912	1,716,865	1,613,683	1,573,348	9%	1,573,348	4,855,256	429,216	429,216	214,181
Acceleration Market Group	47,032	59,148	385,457	204,422	175,770	119%	175,770	756,511	96,364	96,364	44,273
Anglophone Africa Market Group	21,679	32,953	416,171	357,197	342,639	21%	342,639	1,124,919	104,043	104,043	68,817
Franco/Lusophone Africa Market Group	28,879	27,482	317,069	255,395	272,082	17%	272,082	945,303	79,267	79,267	61,541
Latin America & Asia Market Group	32,026	47,770	517,607	761,629	705,711	(27)%	705,711	1,675,614	129,402	129,402	25,493
Foundation Market Group	10,814	7,559	80,561	35,040	77,146	4%	77,146	352,909	20,140	20,140	14,057
Injectable 3-SC	20,079	31,722	843,570	857,082	617,820	37%	617,820	2,514,134	189,803	189,803	102,517
Acceleration Market Group	3,278	2,602	31,405	32,150	-	-%	-	31,405	7,066	7,066	884
Anglophone Africa Market Group	1,959	12,052	91,046	53,892	55,900	63%	55,900	146,946	20,485	20,485	15,188
Franco/Lusophone Africa Market Group	14,448	10,433	211,263	151,480	26,328	702%	26,328	240,206	47,534	47,534	35,169
Latin America & Asia Market Group	-	(34)	(102)	1,400	-	-%	-	(102)	(23)	(23)	(1)
Foundation Market Group	394	6,669	509,958	618,160	535,592	(5)%	535,592	2,095,679	114,741	114,741	51,277
Injectable 3-SC Provided	18,471	13,222	108,959	44,763	5,904	1,746%	5,904	114,863	27,240	27,240	21,069
Acceleration Market Group	897	1,258	9,727	-	-	-%	-	9,727	2,432	2,432	2,050
Anglophone Africa Market Group	11,900	6,214	33,304	-	-	-%	-	33,304	8,326	8,326	6,144
Franco/Lusophone Africa Market Group	5,345	5,310	63,385	39,163	5,729	1,006%	5,729	69,114	15,846	15,846	12,592
Latin America & Asia Market Group	-	256	769	5,600	-	-%	-	769	192	192	5
Foundation Market Group	329	184	1,774	-	175	914%	175	1,949	444	444	277
IPTp2	2,066	881	12,028	291,388	85,804	(86)%	85,804	356,479	12,028	-	890
Acceleration Market Group	1,860	287	6,109	-	3,893	57%	3,893	20,406	6,109	-	228
Anglophone Africa Market Group	-	-	-	-	-	-%	-	44,748	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	54	-	-	-
Foundation Market Group	206	595	5,919	291,388	81,911	(93)%	81,911	291,271	5,919	-	662
Iron Folic Acid Tablet	-	-	-	19,843	-	-%	-	48,283,018	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	48,283,018	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	19,843	-	-%	-	-	-	-	-
ITN	-	421,834	1,265,503	-	-	-%	-	20,663,108	2,050,115	-	45,033
Acceleration Market Group	-	-	-	-	-	-%	-	5,306,807	-	-	-
Anglophone Africa Market Group	-	421,834	1,265,503	-	-	-%	-	13,342,614	2,050,115	-	45,033
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,983,399	-	-	-
Inactive	-	-	-	-	-	-%	-	30,288	-	-	-
IUD 10	34,551	22,360	223,988	227,046	263,103	(15)%	263,103	3,174,241	201,589	927,310	665,817
Acceleration Market Group	(198)	3	(331)	(4,600)	684	(148)%	684	1,449,927	(298)	(1,370)	(1,500)
Anglophone Africa Market Group	26,966	17,835	118,862	93,709	94,747	25%	94,747	511,378	106,976	492,089	468,770
Franco/Lusophone Africa Market Group	3,322	1,641	15,548	28,463	29,804	(48)%	29,804	222,893	13,993	64,369	51,793
Latin America & Asia Market Group	3,085	833	77,261	102,474	64,790	19%	64,790	715,576	69,535	319,861	87,016
Foundation Market Group	1,381	2,055	12,638	7,000	7,568	67%	7,568	92,641	11,374	52,321	59,730
Social Enterprise	(5)	(7)	10	-	65,510	(100)%	65,510	65,520	9	41	9
Inactive	-	-	-	-	-	-%	-	116,306	-	-	-
IUD 10 Insertion	35,458	46,250	463,563	539,581	572,847	(19)%	572,847	3,670,801	463,563	2,132,390	1,503,202
Acceleration Market Group	8,223	10,578	101,968	103,790	90,084	13%	90,084	727,339	101,968	469,053	450,542
Anglophone Africa Market Group	4,852	10,992	107,088	188,592	220,262	(51)%	220,262	1,306,726	107,088	492,605	435,187
Franco/Lusophone Africa Market Group	4,422	5,729	75,712	76,812	73,738	3%	73,738	335,515	75,712	348,275	314,687
Latin America & Asia Market Group	15,164	15,522	141,791	123,733	148,352	(4)%	148,352	900,945	141,791	652,239	162,215
Foundation Market Group	2,797	3,430	37,004	46,654	40,411	(8)%	40,411	386,027	37,004	170,218	140,570
Inactive	-	-	-	-	-	-%	-	14,249	-	-	-
IUD 3	(125)	(20)	(57)	-	6,953	(101)%	6,953	6,896	(51)	(128)	(27)
Social Enterprise	(125)	(20)	(57)	-	6,953	(101)%	6,953	6,896	(51)	(128)	(27)
IUD 5	(5,436)	6,625	171,635	208,394	102,566	67%	102,566	4,557,494	154,472	509,756	124,188
Acceleration Market Group	48	24	362	2,500	472	(23)%	472	1,136,883	326	1,075	183
Anglophone Africa Market Group	-	(1)	(32)	-	(263)	-%	(263)	14,523	(29)	(95)	(96)
Latin America & Asia Market Group	(5,579)	6,348	40,646	94,294	22,736	79%	22,736	3,091,368	36,581	120,719	36,127

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	95	254	130,659	111,600	79,621	64%	79,621	310,994	117,593	388,057	87,975
Inactive	-	-	-	-	-	-%	-	3,726	-	-	-
IUD 5 Insertion	38,092	33,924	325,380	131,309	115,881	181%	115,881	1,481,666	325,380	1,073,754	289,835
Acceleration Market Group	27,103	20,992	162,738	65,000	51,661	215%	51,661	343,588	162,738	537,035	121,524
Anglophone Africa Market Group	-	1	162	-	345	(53)%	345	28,984	162	535	343
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	45	-	-	-
Latin America & Asia Market Group	10,962	12,906	162,215	65,998	63,576	155%	63,576	1,108,485	162,215	535,309	167,093
Foundation Market Group	27	24	265	311	299	(11)%	299	564	265	874	876
IUS 3	22	(95)	(328)	2,500	98	(435)%	98	(230)	(295)	(738)	(743)
Anglophone Africa Market Group	(65)	(82)	(379)	-	-	-%	-	(379)	(341)	(853)	(808)
Foundation Market Group	87	(12)	51	2,500	98	(48)%	98	149	46	115	65
IUS 3 Insertion	153	218	1,510	-	135	1,019%	135	1,645	1,510	3,775	2,510
Anglophone Africa Market Group	65	82	379	-	-	-%	-	379	379	948	898
Foundation Market Group	88	136	1,131	-	135	738%	135	1,266	1,131	2,828	1,611
IUS 5	(8)	(46)	803	5,128	126	537%	126	1,883	723	2,385	1,533
Anglophone Africa Market Group	(8)	(5)	395	(56)	126	213%	126	1,475	356	1,173	1,332
Foundation Market Group	-	10	(11)	-	-	-%	-	(11)	(10)	(33)	(81)
Social Enterprise	-	(51)	419	5,184	-	-%	-	419	377	1,244	282
IUS 5 Insertion	86	124	1,744	756	1,516	15%	1,516	4,253	1,744	5,755	5,993
Acceleration Market Group	75	103	1,102	-	775	42%	775	2,503	1,102	3,637	4,182
Anglophone Africa Market Group	8	21	550	756	739	(26)%	739	1,655	550	1,815	1,530
Latin America & Asia Market Group	3	1	10	-	2	400%	2	13	10	33	6
Foundation Market Group	-	-	82	-	-	-%	-	82	82	271	276
LifeStraw	-	-	-	-	-	-%	-	15,965	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,320	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	645	-	-	-
LLIN	1,547,796	1,186,194	9,265,240	18,656,324	31,104,885	(70)%	31,104,885	367,900,639	15,009,689	-	2,323,595

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	10,625	1,853	1,093,373	2,049,898	2,332,163	(53)%	2,332,163	65,044,809	1,771,264	-	41,770
Anglophone Africa Market Group	1	713	213,151	700,054	4,545,198	(95)%	4,545,198	56,897,553	345,305	-	11,557
Franco/Lusophone Africa Market Group	498,229	77,780	1,581,302	3,964,115	4,602,963	(66)%	4,602,963	54,057,803	2,561,709	-	156,725
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,197,868	-	-	-
Foundation Market Group	1,038,941	1,105,848	6,377,414	11,942,257	19,624,561	(68)%	19,624,561	182,641,487	10,331,411	-	2,113,544
Inactive	-	-	-	-	-	-%	-	4,061,119	-	-	-
LLIN (Hammock net)	-	-	781	1,350	1,259	(38)%	1,259	2,085	703	-	-
Latin America & Asia Market Group	-	-	781	1,350	1,259	(38)%	1,259	2,085	703	-	-
Lubricant	782,370	1,229,832	11,793,095	5,295,911	5,621,900	110%	5,621,900	89,574,969	-	-	-
Acceleration Market Group	271,000	286,000	2,318,836	70,000	51,861	4,371%	51,861	15,871,125	-	-	-
Anglophone Africa Market Group	245,469	324,724	2,926,726	1,900,761	2,574,286	14%	2,574,286	11,669,908	-	-	-
Franco/Lusophone Africa Market Group	2,184	2,667	11,039	-	45,024	(75)%	45,024	1,533,058	-	-	-
Latin America & Asia Market Group	43,136	350,729	2,810,451	731,208	1,423,274	97%	1,423,274	39,508,941	-	-	-
Foundation Market Group	197,340	265,160	3,676,834	2,500,000	1,223,813	200%	1,223,813	5,922,862	-	-	-
Social Enterprise	23,241	552	49,209	93,942	37,944	30%	37,944	635,465	-	-	-
Inactive	-	-	-	-	265,698	(100)%	265,698	14,433,610	-	-	-
Malaria PPT (ACT)	3,091,373	483,968	6,513,485	6,562,602	7,543,851	(14)%	7,543,851	141,646,077	5,862,137	-	1,926,050
Acceleration Market Group	1,089	391	174,362	182,270	256,333	(32)%	256,333	63,892,648	156,926	-	24,461
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10,387,257	-	-	-
Franco/Lusophone Africa Market Group	828	10,131	409,310	326,390	297,014	38%	297,014	2,112,118	368,379	-	113,695
Latin America & Asia Market Group	-	(24)	(227)	-	147	(254)%	147	2,839,503	(204)	-	(25)
Foundation Market Group	3,089,456	473,470	5,930,040	6,053,942	6,990,357	(15)%	6,990,357	62,414,551	5,337,036	-	1,787,919
Malaria PPT (Non-ACT)	7,224	40,808	223,754	83,621	(2,041)	-%	(2,041)	14,118,042	201,379	-	24,351
Acceleration Market Group	224	174	2,954	3,621	(1,900)	-%	(1,900)	5,116,468	2,659	-	414
Latin America & Asia Market Group	-	-	-	-	(141)	-%	(141)	(141)	-	-	-
Foundation Market Group	7,000	40,633	220,800	80,000	-	-%	-	9,001,715	198,720	-	23,936
Malaria RDK	992,370	632,355	3,857,675	4,357,458	12,180,985	(68)%	12,180,985	63,305,638	3,471,908	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	432,337	743,410	(100)%	743,410	12,836,467	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	263,260	-	-	-
Franco/Lusophone Africa Market Group	-	35,092	147,125	250,000	177,919	(17)%	177,919	1,244,684	132,413	-	-
Latin America & Asia Market Group	6,920	3,497	35,300	25,000	305,189	(88)%	305,189	7,090,196	31,770	-	-
Foundation Market Group	985,450	593,767	3,675,250	3,650,121	10,954,467	(66)%	10,954,467	41,871,031	3,307,725	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	-	-%	-	10,836	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	6,118	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,718	-	-	-
Male Vasodilator	80,000	5,467	1,766,180	3,029,400	-	-%	-	1,766,180	13,246	-	-
Social Enterprise	80,000	5,467	1,766,180	3,029,400	-	-%	-	1,766,180	13,246	-	-
Manual Vacuum Aspiration for PAC	7,637	10,745	120,829	20,937	70,499	71%	70,499	280,055	120,829	-	21,257
Acceleration Market Group	485	742	7,879	5,220	19,176	(59)%	19,176	32,351	7,879	-	6,309
Anglophone Africa Market Group	223	654	6,339	720	7,531	(16)%	7,531	16,860	6,339	-	943
Franco/Lusophone Africa Market Group	1,692	1,339	13,699	1,918	2,579	431%	2,579	18,082	13,699	-	6,214
Latin America & Asia Market Group	4,365	7,337	85,407	7,295	34,966	144%	34,966	191,371	85,407	-	4,157
Foundation Market Group	872	672	7,505	5,784	6,247	20%	6,247	21,391	7,505	-	3,633
Manual Vacuum Aspiration for SA	366	261	2,907	743	1,224	138%	1,224	4,131	2,907	-	965
Acceleration Market Group	-	-	-	-	-	-%	-	-	-	-	-
Anglophone Africa Market Group	35	67	805	-	411	96%	411	1,216	805	-	294
Franco/Lusophone Africa Market Group	310	138	1,406	507	562	150%	562	1,968	1,406	-	568
Latin America & Asia Market Group	21	56	696	236	251	177%	251	947	696	-	103
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
Medical Abortion	65,894	39,138	950,642	2,153,877	1,610,639	(41)%	1,610,639	6,378,182	855,578	-	92,659
Acceleration Market Group	-	652	2,000	9,000	-	-%	-	1,499,044	1,800	-	1,689
Anglophone Africa Market Group	711	1,449	10,999	9,331	13,999	(21)%	13,999	36,009	9,899	-	3,468
Franco/Lusophone Africa Market Group	132	200	2,359	19,550	172	1,272%	172	2,366	2,123	-	823
Latin America & Asia Market Group	29,143	20,692	363,772	459,996	457,334	(20)%	457,334	2,615,181	327,395	-	33,561

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	35,908	16,145	571,512	1,656,000	1,139,134	(50)%	1,139,134	2,225,582	514,361	-	53,118
Medical Abortion (Misoprostol) Provided	405	98	1,955	1,051	840	133%	840	2,795	1,955	-	660
Anglophone Africa Market Group	21	81	988	-	531	86%	531	1,519	988	-	309
Franco/Lusophone Africa Market Group	384	16	967	1,051	309	213%	309	1,276	967	-	351
Medical Abortion Provided	1,260	1,361	13,815	4,788	12,902	7%	12,902	35,498	13,815	-	1,589
Anglophone Africa Market Group	25	78	775	-	747	4%	747	2,143	775	-	271
Franco/Lusophone Africa Market Group	33	20	166	-	51	225%	51	407	166	-	62
Latin America & Asia Market Group	1,202	1,263	12,874	4,788	12,104	6%	12,104	32,948	12,874	-	1,255
Micronutrient Powder	11,539	33,427	326,950	35,000	8,746,552	(96)%	8,746,552	48,869,982	806	-	-
Acceleration Market Group	-	-	-	-	2,000,000	(100)%	2,000,000	9,499,690	-	-	-
Franco/Lusophone Africa Market Group	11,539	33,427	326,950	35,000	948,572	(66)%	948,572	8,297,562	806	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,502,912	-	-	-
Foundation Market Group	-	-	-	-	5,797,980	(100)%	5,797,980	20,562,598	-	-	-
Inactive	-	-	-	-	-	-%	-	1,007,220	-	-	-
Misoprostol for PAC Provided	12,898	12,652	125,102	26,807	86,914	44%	86,914	230,840	125,102	-	27,041
Acceleration Market Group	382	675	7,331	5,220	14,855	(51)%	14,855	22,186	7,331	-	6,952
Anglophone Africa Market Group	125	244	3,078	-	3,631	(15)%	3,631	7,914	3,078	-	623
Franco/Lusophone Africa Market Group	1,228	1,067	10,819	2,222	2,304	370%	2,304	14,199	10,819	-	5,930
Latin America & Asia Market Group	9,765	9,057	87,568	3,935	53,383	64%	53,383	144,675	87,568	-	5,209
Foundation Market Group	1,398	1,610	16,306	15,430	12,741	28%	12,741	41,866	16,306	-	8,327
Misoprostol for PPH	-	2,833	15,500	4,500	30,800	(50)%	30,800	6,332,438	4,650	-	101
Acceleration Market Group	-	-	-	-	-	-%	-	395,225	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	5,442,839	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	100,000	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	184,166	-	-	-
Foundation Market Group	-	2,833	15,500	4,500	30,800	(50)%	30,800	210,208	4,650	-	101
Misoprostol for Safe Abortion	396,982	453,480	5,680,307	5,447,828	6,085,267	(7)%	6,085,267	23,109,761	298,216	-	114,960

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	26,472	134,133	1,774,246	2,339,690	2,321,200	(24)%	2,321,200	6,080,296	93,148	-	78,213
Anglophone Africa Market Group	158,768	131,275	1,553,194	1,993,550	1,655,420	(6)%	1,655,420	10,593,170	81,543	-	17,241
Franco/Lusophone Africa Market Group	21,474	72,923	556,877	424,360	745,045	(25)%	745,045	2,527,771	29,236	-	10,879
Latin America & Asia Market Group	175,044	101,615	1,689,170	320,448	1,282,555	32%	1,282,555	3,737,897	88,681	-	6,731
Foundation Market Group	15,224	13,533	106,820	119,780	81,047	32%	81,047	170,627	5,608	-	1,897
Social Enterprise	-	-	-	250,000	-	-%	-	-	-	-	-
Multivitamin	126,780	123,987	1,436,450	2,256,202	2,424,220	(41)%	2,424,220	99,791,369	7,182	-	266
Acceleration Market Group	-	-	-	-	450,010	(100)%	450,010	3,531,010	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	12,270,645	-	-	-
Latin America & Asia Market Group	6,000	6,807	26,420	-	-	-%	-	11,510,725	132	-	25
Foundation Market Group	-	-	-	24,202	-	-%	-	-	-	-	-
Social Enterprise	120,780	117,180	1,410,030	2,232,000	1,974,210	(29)%	1,974,210	38,419,590	7,050	-	241
Inactive	-	-	-	-	-	-%	-	34,059,399	-	-	-
Naloxone	-	167	1,995	3,089	2,570	(22)%	2,570	70,246	1,796	-	2,722
Latin America & Asia Market Group	-	167	1,995	3,089	2,570	(22)%	2,570	34,452	1,796	-	2,722
Inactive	-	-	-	-	-	-%	-	35,794	-	-	-
Needle & Syringe	-	92,933	1,077,000	1,355,860	5,815,215	(81)%	5,815,215	33,442,758	3,757	-	11,984
Acceleration Market Group	-	-	10,100	-	-	-%	-	2,511,988	35	-	83
Latin America & Asia Market Group	-	92,933	1,066,900	1,355,860	5,815,215	(82)%	5,815,215	26,847,258	3,722	-	11,901
Inactive	-	-	-	-	-	-%	-	4,083,512	-	-	-
Neonates Receiving Essential Care	-	-	-	-	-	-%	-	174	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	174	-	-	-
NVP	-	-	-	-	-	-%	-	11,442	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	235	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	11,057	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	150	-	-	-
OCs	1,628,088	1,992,122	23,088,670	29,124,425	26,777,114	(14)%	26,777,114	658,745,207	1,385,320	1,385,320	418,287

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	750,138	996,206	9,114,680	10,222,400	9,492,397	(4)%	9,492,397	321,627,956	546,881	546,881	154,562
Anglophone Africa Market Group	15,301	208,582	1,545,840	2,258,175	2,600,283	(41)%	2,600,283	81,500,893	92,750	92,750	44,612
Franco/Lusophone Africa Market Group	198,011	89,289	1,647,001	851,499	1,347,096	22%	1,347,096	26,467,894	98,820	98,820	61,600
Latin America & Asia Market Group	290,792	509,620	7,120,821	6,917,751	6,484,744	10%	6,484,744	106,573,492	427,249	427,249	81,083
Foundation Market Group	167,144	142,346	2,317,388	1,777,420	2,094,239	11%	2,094,239	73,056,038	139,043	139,043	65,406
Social Enterprise	206,702	46,079	1,342,940	7,097,180	4,758,355	(72)%	4,758,355	17,426,340	80,576	80,576	11,023
Inactive	-	-	-	-	-	-%	-	32,092,594	-	-	-
OCs Provided	371,558	329,623	3,194,849	2,831,217	1,778,915	80%	1,778,915	7,564,163	212,990	212,990	85,645
Acceleration Market Group	144,657	101,057	756,782	181,469	151,894	398%	151,894	1,001,891	50,452	50,452	11,210
Anglophone Africa Market Group	29,805	42,815	535,112	357,372	321,499	66%	321,499	1,919,858	35,674	35,674	21,912
Franco/Lusophone Africa Market Group	43,694	62,377	530,857	683,520	367,827	44%	367,827	1,489,339	35,390	35,390	30,239
Latin America & Asia Market Group	151,667	122,220	1,359,110	1,601,361	921,067	48%	921,067	2,991,169	90,607	90,607	21,682
Foundation Market Group	1,735	1,155	12,988	7,495	16,628	(22)%	16,628	161,902	866	866	602
Inactive	-	-	-	-	-	-%	-	4	-	-	-
ORS	126,122	137,249	3,143,681	2,220,000	3,408,447	(8)%	3,408,447	443,579,240	1,414,656	-	62,922
Acceleration Market Group	38,020	124,149	847,044	600,000	514,198	65%	514,198	326,810,645	381,170	-	22,210
Anglophone Africa Market Group	-	-	-	-	-	-%	-	21,149,275	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	32,783,783	-	-	-
Latin America & Asia Market Group	12,797	28,283	648,134	-	500,000	30%	500,000	4,925,115	291,660	-	6,130
Foundation Market Group	79,104	1,080	299,226	300,000	1,249,743	(76)%	1,249,743	16,326,907	134,652	-	7,507
Social Enterprise	(3,799)	(16,263)	1,349,277	1,320,000	1,144,506	18%	1,144,506	2,820,211	607,175	-	27,074
Inactive	-	-	-	-	-	-%	-	38,763,304	-	-	-
ORS Provided	3,538	2,150	31,138	13,914	15,726	98%	15,726	112,100	31,138	-	1,549
Acceleration Market Group	-	-	2,043	-	2,217	(8)%	2,217	9,430	2,043	-	33
Foundation Market Group	3,538	2,150	29,095	13,914	13,509	115%	13,509	102,670	29,095	-	1,516
Pneumonia PPT	12,610	17,677	152,525	124,910	768,635	(80)%	768,635	7,277,183	137,273	-	55,974
Acceleration Market Group	-	-	-	28,910	-	-%	-	1,414,256	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	987,367	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	30,316	(100)%	30,316	474,924	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	119,990	-	-	-
Foundation Market Group	12,610	17,677	152,525	96,000	738,319	(79)%	738,319	4,280,646	137,273	-	55,974
Pneumonia PPT Provided	7,458	1,982	38,483	-	31,754	21%	31,754	194,155	38,483	-	29,781
Acceleration Market Group	4,452	662	21,771	-	20,179	8%	20,179	79,844	21,771	-	10,472
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,500	-	-	-
Foundation Market Group	3,006	1,320	16,712	-	11,575	44%	11,575	111,811	16,712	-	19,309
Positive RDTs	48,406	20,466	190,515	11,333	52,281	264%	52,281	2,496,855	190,515	-	-
Acceleration Market Group	426	351	4,386	-	9,712	(55)%	9,712	43,623	4,386	-	-
Anglophone Africa Market Group	42,667	17,029	155,419	-	-	-%	-	155,419	155,419	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	13,716	(100)%	13,716	40,358	-	-	-
Latin America & Asia Market Group	123	153	1,967	3,333	11,799	(83)%	11,799	40,540	1,967	-	-
Foundation Market Group	5,190	2,933	28,743	8,000	17,054	69%	17,054	2,216,915	28,743	-	-
Positive RDTs Given First Line Treatment	40,795	16,355	150,437	2,474	32,687	360%	32,687	2,295,492	150,437	-	-
Acceleration Market Group	417	348	4,242	-	8,937	(53)%	8,937	38,844	4,242	-	-
Anglophone Africa Market Group	40,275	15,902	144,641	-	-	-%	-	144,641	144,641	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	13,647	(100)%	13,647	39,926	-	-	-
Latin America & Asia Market Group	103	105	1,554	2,474	10,103	(85)%	10,103	37,102	1,554	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,034,979	-	-	-
Pregnancy Test	21,082	21,401	313,592	1,188,000	575,675	(46)%	575,675	1,819,716	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	575,317	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	222,334	-	-	-
Social Enterprise	21,082	21,401	313,592	1,188,000	575,675	(46)%	575,675	889,267	-	-	-
Inactive	-	-	-	-	-	-%	-	132,798	-	-	-
PrEP	3,845	3,866	46,921	35,111	34,437	36%	34,437	84,474	3,910	-	1,493
Acceleration Market Group	69	75	547	-	-	-%	-	547	46	-	23

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	3,776	3,791	46,374	35,111	34,437	35%	34,437	83,927	3,864	-	1,470
PUR	3,073,824	5,234,283	62,788,252	47,273,857	62,440,224	1%	62,440,224	694,317,579	516,068	-	1,518
Acceleration Market Group	2,779,200	2,809,843	32,575,220	19,000,000	28,508,349	14%	28,508,349	229,129,317	267,742	-	661
Anglophone Africa Market Group	294,624	2,424,440	30,213,032	28,273,857	33,931,875	(11)%	33,931,875	356,095,574	248,326	-	857
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	239,541	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	62,675,382	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	45,927,973	-	-	-
Inactive	-	-	-	-	-	-%	-	249,792	-	-	-
QAACTs Provided after Confirmatory Diagnosis	33,364	373	60,929	99,182	127,263	(52)%	127,263	2,267,422	60,929	-	10,169
Acceleration Market Group	33,218	108	58,000	95,000	101,767	(43)%	101,767	178,545	58,000	-	9,564
Franco/Lusophone Africa Market Group	-	-	-	-	13,647	(100)%	13,647	13,647	-	-	-
Latin America & Asia Market Group	59	95	1,181	2,254	9,977	(88)%	9,977	36,631	1,181	-	213
Foundation Market Group	87	170	1,748	1,928	1,872	(7)%	1,872	2,038,599	1,748	-	393
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17	265%	17	479	62	-	-
Anglophone Africa Market Group	-	2	62	136	17	265%	17	479	62	-	-
Referral to CD4/Clinical Staging	-	-	-	-	-	-%	-	34,138	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	30,613	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	18	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	143	-	-	-
Referral to Clinical Staging	-	-	-	-	-	-%	-	18,909	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,545	-	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67	(100)%	67	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	67	(100)%	67	67	-	-	-
Referral to Diabetes Management (non-gestational)	-	-	-	-	-	-%	-	1	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to Early Infant Male Circumcision	-	-	-	-	-	-%	-	94	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	94	-	-	-
Referral to Emergency Contraception	-	1	2	1	32	(94)%	32	252	2	-	-
Anglophone Africa Market Group	-	-	-	1	1	(100)%	1	143	-	-	-
Latin America & Asia Market Group	-	1	2	-	31	(94)%	31	109	2	-	-
Referral to HIV Testing Services	666	977	55,716	91,736	24,729	125%	24,729	366,176	55,716	-	1,823
Acceleration Market Group	-	-	21,265	-	-	-%	-	47,140	21,265	-	754
Anglophone Africa Market Group	666	976	34,434	82,130	24,714	39%	24,714	232,695	34,434	-	1,070
Franco/Lusophone Africa Market Group	-	-	-	9,600	-	-%	-	17,256	-	-	-
Latin America & Asia Market Group	-	1	17	6	10	70%	10	35,719	17	-	-
Foundation Market Group	-	-	-	-	5	(100)%	5	33,366	-	-	-
Referral to Hypertension Management	13	28	336	-	567	(41)%	567	1,466	336	-	-
Anglophone Africa Market Group	13	28	336	-	567	(41)%	567	1,466	336	-	-
Referral to Implant 3 Insertion	119	216	2,357	1,915	1,457	62%	1,457	19,928	2,357	2,946	658
Acceleration Market Group	-	-	-	-	-	-%	-	996	-	-	-
Anglophone Africa Market Group	-	-	293	1,915	2	14,550%	2	8,248	293	366	309
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-
Latin America & Asia Market Group	119	216	2,064	-	1,455	42%	1,455	5,831	2,064	2,580	349
Foundation Market Group	-	-	-	-	-	-%	-	1,674	-	-	-
Inactive	-	-	-	-	-	-%	-	3,178	-	-	-
Referral to Implant 5 Insertion	73	57	579	187	223	160%	223	20,308	579	1,100	259
Acceleration Market Group	-	-	-	-	-	-%	-	584	-	-	-
Anglophone Africa Market Group	-	-	11	187	2	450%	2	3,607	11	21	17
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,681	-	-	-
Latin America & Asia Market Group	73	57	568	-	221	157%	221	1,830	568	1,079	242
Foundation Market Group	-	-	-	-	-	-%	-	9,606	-	-	-
Referral to Implant Insertion (duration unknown)	-	4	20	-	-	-%	-	109	20	25	3

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	89	-	-	-
Latin America & Asia Market Group	-	4	20	-	-	-%	-	20	20	25	3
Referral to Injectable (duration unknown)	-	-	-	-	-	-%	-	773	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	110	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	663	-	-	-
Referral to Injectable 1	-	5	25	-	47	(47)%	47	436	25	1	-
Anglophone Africa Market Group	-	-	-	-	36	(100)%	36	400	-	-	-
Latin America & Asia Market Group	-	5	25	-	11	127%	11	36	25	1	-
Referral to Injectable 2	-	-	-	-	-	-%	-	56	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	56	-	-	-
Referral to Injectable 3	175	88	1,952	6,372	471	314%	471	25,425	1,952	244	92
Anglophone Africa Market Group	-	-	887	6,372	75	1,083%	75	7,834	887	111	69
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	8,596	-	-	-
Latin America & Asia Market Group	175	88	1,065	-	396	169%	396	8,995	1,065	133	23
Referral to IUD 10 Insertion	254	284	2,354	48	734	221%	734	135,617	2,354	5,414	973
Acceleration Market Group	-	-	-	-	-	-%	-	8,256	-	-	-
Anglophone Africa Market Group	-	-	4	48	5	(20)%	5	24,176	4	9	7
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,239	-	-	-
Latin America & Asia Market Group	254	284	2,350	-	729	222%	729	75,540	2,350	5,405	965
Foundation Market Group	-	-	-	-	-	-%	-	20,969	-	-	-
Inactive	-	-	-	-	-	-%	-	437	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	-	-%	-	498	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	440	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	58	-	-	-
Referral to IUD Insertion (duration unknown)	-	2	19	-	-	-%	-	35	19	31	4
Anglophone Africa Market Group	-	-	-	-	-	-%	-	16	-	-	-
Latin America & Asia Market Group	-	2	19	-	-	-%	-	19	19	31	4

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to IUS 3 Insertion	-	-	-	-	-	-%	-	26	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	26	-	-	-
Referral to Linkage to HIV Care	10,251	13,749	121,913	45,296	26,986	352%	26,986	174,978	121,913	-	97,130
Acceleration Market Group	-	242	5,843	12,150	-	-%	-	5,843	5,843	-	2,767
Anglophone Africa Market Group	9,980	13,204	112,751	29,940	24,186	366%	24,186	159,395	112,751	-	91,588
Franco/Lusophone Africa Market Group	-	-	-	1,279	-	-%	-	281	-	-	-
Latin America & Asia Market Group	271	304	3,319	1,627	2,800	19%	2,800	9,451	3,319	-	2,776
Foundation Market Group	-	-	-	300	-	-%	-	-	-	-	-
Inactive	-	-	-	-	-	-%	-	8	-	-	-
Referral to Manual Vacuum Aspiration - PAC	-	-	-	-	-	-%	-	46	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	46	-	-	-
Referral to Medication Abortion	-	-	-	-	-	-%	-	24	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	24	-	-	-
Referral to OCs	132	78	1,119	665	484	131%	484	11,219	1,119	37	8
Anglophone Africa Market Group	-	-	84	665	93	(10)%	93	3,389	84	3	2
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,392	-	-	-
Latin America & Asia Market Group	132	78	1,035	-	391	165%	391	6,438	1,035	34	6
Referral to Opioid Treatment	8	5	84	37	135	(38)%	135	556	84	-	-
Latin America & Asia Market Group	8	5	84	37	135	(38)%	135	556	84	-	-
Referral to PAC Service (unknown)	-	-	-	-	-	-%	-	488	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	488	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20	(85)%	20	253	3	-	-
Anglophone Africa Market Group	-	-	3	-	20	(85)%	20	253	3	-	-
Referral to STI Diagnosis (lab confirmed)	-	-	-	-	-	-%	-	332	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	332	-	-	-
Referral to STI Screening (syndromic)	-	-	-	112,000	7	(100)%	7	14,419	-	-	-
Anglophone Africa Market Group	-	-	-	112,000	7	(100)%	7	14,419	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to STI Treatment (unknown)	-	-	-	-	119	(100)%	119	9,012	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,690	-	-	-
Anglophone Africa Market Group	-	-	-	-	119	(100)%	119	4,864	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	128	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,330	-	-	-
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	30,963	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,898	-	-	-
Anglophone Africa Market Group	-	-	-	-	11	(100)%	11	16,052	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	11,013	-	-	-
Referral to TB DOTS (completion confirmed)	69	64	1,101	2,459	1,364	(19)%	1,364	4,627	1,101	-	3,191
Acceleration Market Group	69	55	1,020	2,349	1,214	(16)%	1,214	3,866	1,020	-	3,163
Anglophone Africa Market Group	-	-	-	-	2	(100)%	2	19	-	-	-
Latin America & Asia Market Group	-	9	81	110	148	(45)%	148	742	81	-	28
Referral to TB DOTS (completion unknown)	71	72	1,293	2,374	1,692	(24)%	1,692	10,981	1,293	-	3,599
Acceleration Market Group	71	72	1,289	2,374	1,575	(18)%	1,575	6,345	1,289	-	3,598
Anglophone Africa Market Group	-	-	-	-	74	(100)%	74	4,388	-	-	-
Latin America & Asia Market Group	-	-	4	-	43	(91)%	43	248	4	-	1
Referral to TB Screening	-	-	-	5,497	329	(100)%	329	115,621	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	85,548	-	-	-
Anglophone Africa Market Group	-	-	-	5,497	308	(100)%	308	29,857	-	-	-
Latin America & Asia Market Group	-	-	-	-	21	(100)%	21	216	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47	(100)%	47	119	-	-	-
Anglophone Africa Market Group	-	-	-	-	47	(100)%	47	119	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3	(100)%	3	12	-	-	-
Anglophone Africa Market Group	-	-	-	-	3	(100)%	3	12	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	2	(100)%	2	136	-	-	-
Anglophone Africa Market Group	-	-	-	112	2	(100)%	2	136	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	1	(100)%	1	137	-	-	-
Anglophone Africa Market Group	-	-	-	112	1	(100)%	1	137	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	53	(100)%	53	2,659	-	-	-
Anglophone Africa Market Group	-	-	-	336	53	(100)%	53	2,659	-	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-	-%	-	7,248	1	-	-
Anglophone Africa Market Group	-	-	1	-	-	-%	-	7,248	1	-	-
Referral to Tubal Ligation	-	-	-	-	2	(100)%	2	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	2	(100)%	2	6	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	61	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25	(96)%	25	1,100	1	-	-
Anglophone Africa Market Group	-	-	1	-	25	(96)%	25	1,100	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	10	560	48	(79)%	48	2,480	10	-	1
Anglophone Africa Market Group	-	-	10	560	48	(79)%	48	2,480	10	-	1
Referral to Vasectomy	-	-	1	-	-	-%	-	3	1	5	1
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2	-	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	1	5	1
Referral to Voluntary Medical Male Circumcision	-	-	3	-	139	(98)%	139	20,730	3	-	10
Acceleration Market Group	-	-	-	-	-	-%	-	3,382	-	-	-
Anglophone Africa Market Group	-	-	3	-	139	(98)%	139	17,348	3	-	10
Retreatment	-	-	-	-	-	-%	-	46,984,114	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	8,050,379	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	35,287,804	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,094,479	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1,275,789	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,009,438	-	-	-
Inactive	-	-	-	-	-	-%	-	266,225	-	-	-
Retreatment IconMaxx	-	-	-	-	-	-%	-	4,873,846	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2,297,300	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,576,546	-	-	-
Retreatment KO123	-	-	-	-	-	-%	-	9,124,110	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,106,836	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,013,192	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,082	-	-	-
Retreatment KO123 net	-	-	-	-	-	-%	-	10,259,477	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	2,151,532	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,107,945	-	-	-
Safe Injection Kit	-	-	-	-	-	-%	-	5	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5	-	-	-
Safe Water Solution	232,025	247,281	4,422,513	4,507,380	5,579,483	(21)%	5,579,483	167,764,778	3,684,335	-	13,843
Acceleration Market Group	71,700	71,529	1,418,258	1,160,000	1,114,276	27%	1,114,276	34,407,902	1,165,692	-	2,876
Anglophone Africa Market Group	54,269	78,236	1,052,196	1,915,700	2,248,493	(53)%	2,248,493	83,404,668	789,591	-	2,730
Franco/Lusophone Africa Market Group	106,032	94,703	1,581,666	1,400,000	870,831	82%	870,831	14,310,787	1,299,999	-	6,786
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,276,004	-	-	-
Foundation Market Group	24	2,813	370,393	31,680	1,345,883	(72)%	1,345,883	28,782,744	429,053	-	1,452
Inactive	-	-	-	-	-	-%	-	4,582,673	-	-	-
SD NVP w/o Baby ARV Prophylaxis	-	-	-	-	-	-%	-	271	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	271	-	-	-
SD NVP with Baby ARV Prophylaxis	-	-	-	-	-	-%	-	235	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	235	-	-	-
SDM (Cycle Beads)	(14)	393	1,264	306	6,654	(81)%	6,654	628,869	1,138	1,706	1,340
Acceleration Market Group	-	-	-	-	-	-%	-	201,447	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,591	-	-	-
Franco/Lusophone Africa Market Group	(10)	408	1,449	306	1,533	(5)%	1,533	49,478	1,304	1,956	1,500
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,494	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	(4)	(15)	(185)	-	5,121	(104)%	5,121	351,101	(167)	(250)	(160)
Inactive	-	-	-	-	-	-%	-	15,758	-	-	-
SDM (Cycle Beads) Provided	1,288	1,778	6,967	2,550	609	1,044%	609	19,632	6,967	10,451	8,155
Acceleration Market Group	1,252	1,755	6,606	-	3	220,100%	3	6,609	6,606	9,909	7,738
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Franco/Lusophone Africa Market Group	10	3	110	2,550	96	15%	96	507	110	165	127
Latin America & Asia Market Group	-	-	4	-	7	(43)%	7	130	4	6	1
Foundation Market Group	26	20	247	-	503	(51)%	503	12,376	247	371	289
Seasonal Malaria Chemoprevention	-	-	-	-	2,009,973	(100)%	2,009,973	4,420,982	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	344,748	(100)%	344,748	344,748	-	-	-
Foundation Market Group	-	-	-	-	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
Seasonal Malaria Chemoprevention_children reached	4,772,814	-	4,772,814	2,761,537	-	-%	-	4,772,814	4,772,814	-	1,409,957
Franco/Lusophone Africa Market Group	2,780,737	-	2,780,737	990,000	-	-%	-	2,780,737	2,780,737	-	471,469
Foundation Market Group	1,992,077	-	1,992,077	1,771,537	-	-%	-	1,992,077	1,992,077	-	938,488
Skilled Birth Attendance	9,052	3,180	45,944	66,196	45,970	-%	45,970	201,710	45,944	-	50,135
Acceleration Market Group	6,891	1,327	25,405	40,000	20,115	26%	20,115	87,574	25,405	-	21,117
Anglophone Africa Market Group	-	-	-	-	-	-%	-	50,567	-	-	-
Franco/Lusophone Africa Market Group	91	89	1,560	9,000	9,160	(83)%	9,160	27,895	1,560	-	1,976
Foundation Market Group	2,070	1,764	18,979	17,196	16,695	14%	16,695	35,674	18,979	-	27,042
STI Kit	-	-	-	-	-	-%	-	691,263	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	240,890	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	438,695	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	329	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,882	-	-	-
Inactive	-	-	-	-	-	-%	-	1,467	-	-	-
STI Kit (Non-Ulcerative)	-	489	4,732	1,869	6,655	(29)%	6,655	4,022,900	4,259	-	304
Acceleration Market Group	-	-	-	-	-	-%	-	742,374	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	489	4,732	1,869	6,655	(29)%	6,655	870,733	4,259	-	304
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	7,704	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	348,335	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,053,754	-	-	-
STI Kit (Ulcerative)	-	89	1,588	231	-	-%	-	1,855,742	1,429	-	305
Acceleration Market Group	-	-	-	-	-	-%	-	60,473	-	-	-
Anglophone Africa Market Group	-	89	1,588	231	-	-%	-	74,280	1,429	-	305
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	480	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,720,509	-	-	-
STI Screening	10,107	10,830	153,919	227,782	254,307	(39)%	254,307	1,440,307	153,919	-	-
Acceleration Market Group	842	1,085	16,593	-	27,221	(39)%	27,221	90,509	16,593	-	-
Anglophone Africa Market Group	7,745	8,329	118,274	144,457	75,388	57%	75,388	681,190	118,274	-	-
Franco/Lusophone Africa Market Group	626	628	9,457	-	8,747	8%	8,747	40,443	9,457	-	-
Latin America & Asia Market Group	23	48	265	-	99	168%	99	4,255	265	-	-
Foundation Market Group	871	740	9,330	83,325	142,852	(93)%	142,852	623,412	9,330	-	-
Inactive	-	-	-	-	-	-%	-	498	-	-	-
TB Diagnosis	3,829	3,890	52,626	28,643	62,691	(16)%	62,691	276,483	52,626	-	-
Acceleration Market Group	1,482	1,331	13,610	16,181	14,315	(5)%	14,315	101,005	13,610	-	-
Anglophone Africa Market Group	18	16	231	77	283	(18)%	283	1,708	231	-	-
Latin America & Asia Market Group	2,329	2,543	28,670	385	29,853	(4)%	29,853	114,306	28,670	-	-
Foundation Market Group	-	-	10,115	12,000	18,240	(45)%	18,240	49,245	10,115	-	-
Inactive	-	-	-	-	-	-%	-	10,219	-	-	-
TB DOTS	3,240	3,282	49,491	23,210	61,338	(19)%	61,338	434,057	49,491	-	234,269
Acceleration Market Group	948	1,179	12,584	13,173	12,891	(2)%	12,891	234,445	12,584	-	78,056
Anglophone Africa Market Group	3	3	35	77	35	-%	35	136	35	-	284
Latin America & Asia Market Group	2,289	2,100	25,764	-	26,012	(1)%	26,012	139,571	25,764	-	117,907
Foundation Market Group	-	-	11,108	9,960	22,400	(50)%	22,400	54,142	11,108	-	38,021

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	5,763	-	-	-
TB Screening	35,072	34,405	464,241	202,098	478,931	(3)%	478,931	2,644,521	464,241	-	-
Acceleration Market Group	8,077	9,721	118,645	149,616	103,950	14%	103,950	599,044	118,645	-	-
Anglophone Africa Market Group	17,982	19,005	241,495	34,396	225,880	7%	225,880	1,692,520	241,495	-	-
Latin America & Asia Market Group	9,013	5,679	65,241	4,086	72,433	(10)%	72,433	206,757	65,241	-	-
Foundation Market Group	-	-	38,860	14,000	76,668	(49)%	76,668	139,061	38,860	-	-
Inactive	-	-	-	-	-	-%	-	7,139	-	-	-
Toilets Constructed	-	-	-	-	-	-%	-	16,479	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	12,802	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	5	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,672	-	-	-
Toilets Sold	3,983	12,481	105,669	98,457	64,462	64%	64,462	374,180	514,069	-	14,812
Acceleration Market Group	-	7,881	68,647	60,000	50,363	36%	50,363	314,891	329,506	-	7,865
Anglophone Africa Market Group	2,028	2,929	20,460	25,600	5,651	262%	5,651	26,110	93,379	-	3,607
Franco/Lusophone Africa Market Group	1,948	1,493	15,356	8,107	4,017	282%	4,017	19,373	85,982	-	3,281
Latin America & Asia Market Group	-	175	1,113	750	4,405	(75)%	4,405	7,416	4,675	-	39
Foundation Market Group	6	3	93	4,000	27	239%	27	6,390	529	-	20
Toilets Sold - All	10,719	14,218	127,071	-	69,029	84%	69,029	196,100	612,561	-	-
Acceleration Market Group	6,161	7,881	74,808	-	50,363	49%	50,363	125,171	359,078	-	-
Anglophone Africa Market Group	2,028	3,968	27,092	-	7,266	273%	7,266	34,358	117,254	-	-
Franco/Lusophone Africa Market Group	2,403	2,113	22,150	-	5,726	287%	5,726	27,876	120,678	-	-
Latin America & Asia Market Group	-	175	1,113	-	4,159	(73)%	4,159	5,272	4,675	-	-
Foundation Market Group	127	81	1,908	-	1,515	26%	1,515	3,423	10,876	-	-
Treatment for Cervicitis	22	35	316	-	101	213%	101	735	316	-	15
Anglophone Africa Market Group	12	20	193	-	73	164%	73	556	193	-	15
Franco/Lusophone Africa Market Group	5	1	29	-	-	-%	-	42	29	-	-
Latin America & Asia Market Group	5	14	94	-	28	236%	28	137	94	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Treatment for Genital Herpes	34	54	612	17	70	774%	70	783	612	-	11
Anglophone Africa Market Group	11	27	135	17	28	382%	28	234	135	-	4
Franco/Lusophone Africa Market Group	23	26	476	-	42	1,033%	42	540	476	-	7
Latin America & Asia Market Group	-	-	1	-	-	-%	-	9	1	-	-
Treatment for Inguinal Bubo	6	5	99	-	89	11%	89	319	99	-	-
Anglophone Africa Market Group	1	-	18	-	3	500%	3	35	18	-	-
Franco/Lusophone Africa Market Group	4	4	55	-	33	67%	33	122	55	-	-
Foundation Market Group	1	1	26	-	53	(51)%	53	162	26	-	-
Treatment for Lower Abdominal Pain	122	189	1,963	54	1,571	25%	1,571	5,340	1,963	-	-
Anglophone Africa Market Group	33	62	465	54	78	496%	78	678	465	-	-
Franco/Lusophone Africa Market Group	54	87	997	-	693	44%	693	2,064	997	-	-
Latin America & Asia Market Group	-	2	7	-	-	-%	-	7	7	-	-
Foundation Market Group	35	38	494	-	800	(38)%	800	2,591	494	-	-
Treatment for Nonherpetic Genital Ulcer	182	195	2,444	94	6,745	(64)%	6,745	18,971	2,444	-	425
Anglophone Africa Market Group	40	39	663	94	546	21%	546	1,809	663	-	205
Franco/Lusophone Africa Market Group	95	103	1,093	-	1,027	6%	1,027	2,882	1,093	-	143
Latin America & Asia Market Group	-	1	2	-	-	-%	-	4	2	-	-
Foundation Market Group	47	53	686	-	5,172	(87)%	5,172	14,276	686	-	77
Treatment for Pre-Eclampsia (with MgSO4)	108	40	453	413	392	16%	392	966	453	-	1,461
Acceleration Market Group	21	6	43	60	49	(12)%	49	213	43	-	38
Foundation Market Group	87	34	410	353	343	20%	343	753	410	-	1,423
Treatment for Severe Acute Malnutrition	362	746	6,999	9,896	12,893	(46)%	12,893	61,542	6,999	-	26,679
Franco/Lusophone Africa Market Group	-	-	-	8	-	-%	-	4	-	-	-
Foundation Market Group	362	746	6,999	9,888	12,893	(46)%	12,893	61,538	6,999	-	26,679
Treatment for Urethral Discharge (Men)	613	501	6,451	195	7,519	(14)%	7,519	23,526	12,643	-	124
Anglophone Africa Market Group	61	67	741	195	292	154%	292	1,643	1,363	-	80
Franco/Lusophone Africa Market Group	151	158	2,005	-	1,631	23%	1,631	4,961	4,010	-	23

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	401	276	3,705	-	5,596	(34)%	5,596	16,922	7,270	-	21
Treatment for Urethral Discharge (Women)	669	341	4,783	2	2,577	86%	2,577	9,854	4,783	-	251
Anglophone Africa Market Group	104	107	1,141	2	507	125%	507	2,664	1,141	-	167
Franco/Lusophone Africa Market Group	283	234	3,359	-	2,054	64%	2,054	6,884	3,359	-	84
Latin America & Asia Market Group	-	-	1	-	1	-%	1	9	1	-	-
Foundation Market Group	282	-	282	-	15	1,780%	15	297	282	-	-
Treatment for Vaginitis	252	308	3,931	380	5,511	(29)%	5,511	18,211	3,931	-	90
Anglophone Africa Market Group	22	10	351	380	506	(31)%	506	2,563	351	-	62
Franco/Lusophone Africa Market Group	-	-	150	-	2	7,400%	2	157	150	-	-
Latin America & Asia Market Group	18	31	217	-	25	768%	25	245	217	-	-
Foundation Market Group	212	266	3,213	-	4,978	(35)%	4,978	15,246	3,213	-	28
Tubal Ligation	8,635	7,235	63,831	42,589	67,507	(5)%	67,507	435,387	63,831	769,998	261,292
Acceleration Market Group	7,964	4,709	44,513	25,000	38,957	14%	38,957	126,728	44,513	576,818	156,356
Anglophone Africa Market Group	667	1,525	10,713	17,589	16,391	(35)%	16,391	46,527	10,713	107,130	84,383
Franco/Lusophone Africa Market Group	-	-	-	-	204	(100)%	204	204	-	-	-
Latin America & Asia Market Group	3	996	8,574	-	11,913	(28)%	11,913	261,781	8,574	85,740	20,411
Foundation Market Group	1	4	31	-	42	(26)%	42	147	31	310	142
Type 2 Diabetes Diagnosis	26	-	27	-	4	575%	4	1,462	27	-	-
Anglophone Africa Market Group	-	-	-	-	3	(100)%	3	1,434	-	-	-
Latin America & Asia Market Group	-	-	1	-	1	-%	1	2	1	-	-
Foundation Market Group	26	-	26	-	-	-%	-	26	26	-	-
Type 2 Diabetes Screening	87	1,236	22,650	33,797	6,712	237%	6,712	39,243	22,650	-	-
Anglophone Africa Market Group	87	1,236	22,647	33,797	6,711	237%	6,711	39,237	22,647	-	-
Latin America & Asia Market Group	-	-	3	-	1	200%	1	6	3	-	-
Type 2 Diabetes Controlled Condition	-	-	2	-	6	(67)%	6	14	-	-	-
Anglophone Africa Market Group	-	-	-	-	6	(100)%	6	12	-	-	-
Latin America & Asia Market Group	-	-	2	-	-	-%	-	2	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Vaginal Wash	(39)	45	18,625	71,280	-	-%	-	18,625	-	-	-
Social Enterprise	(39)	45	18,625	71,280	-	-%	-	18,625	-	-	-
Vasectomy	252	368	2,024	1,029	709	185%	709	7,025	2,024	25,373	6,898
Acceleration Market Group	252	338	1,717	1,000	287	498%	287	5,673	1,717	22,303	6,046
Anglophone Africa Market Group	-	4	17	29	-	-%	-	57	17	170	148
Franco/Lusophone Africa Market Group	-	-	-	-	104	(100)%	104	104	-	-	-
Latin America & Asia Market Group	-	25	290	-	318	(9)%	318	1,191	290	2,900	704
Vivax Treatment after Confirmatory Diagnosis	218	180	2,286	248	3,400	(33)%	3,400	11,657	2,286	-	421
Acceleration Market Group	171	134	1,993	-	3,244	(39)%	3,244	11,199	1,993	-	365
Latin America & Asia Market Group	47	47	293	248	156	88%	156	458	293	-	55
Voluntary Medical Male Circumcision	27,148	25,169	373,926	396,145	424,870	(12)%	424,870	2,866,695	373,926	-	2,482,667
Acceleration Market Group	16,334	3,934	103,723	90,000	78,885	31%	78,885	411,498	103,723	-	730,557
Anglophone Africa Market Group	10,814	21,235	270,203	306,145	345,985	(22)%	345,985	2,393,932	270,203	-	1,752,110
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	61,265	-	-	-
Water Treatment Tablets	2,224,020	2,777,283	33,092,882	35,643,920	38,726,042	(15)%	38,726,042	851,881,198	543,993	-	3,920
Acceleration Market Group	10,800	5,760	708,480	300,000	501,290	41%	501,290	6,648,847	11,646	-	29
Anglophone Africa Market Group	16,800	1,157,540	6,229,910	8,068,408	6,957,142	(10)%	6,957,142	364,414,420	102,409	-	405
Franco/Lusophone Africa Market Group	2,148,220	1,176,133	21,225,440	20,485,262	20,217,570	5%	20,217,570	185,471,340	348,911	-	2,882
Latin America & Asia Market Group	4,000	1,417	74,110	80,000	91,160	(19)%	91,160	10,827,093	1,218	-	3
Foundation Market Group	44,200	436,433	4,854,942	6,710,250	10,958,880	(56)%	10,958,880	284,519,498	79,807	-	600
Woman Condom	-	-	1,920	-	97,728	(98)%	97,728	141,480	14	14	40
Anglophone Africa Market Group	-	-	1,920	-	97,728	(98)%	97,728	141,480	14	14	40
Zika Prevention Kit	-	-	-	-	725	(100)%	725	114,581	-	-	-
Latin America & Asia Market Group	-	-	-	-	725	(100)%	725	114,581	-	-	-
Zinc	-	873	2,822	-	512,836	(99)%	512,836	7,212,221	2,540	-	62
Acceleration Market Group	-	-	-	-	-	-%	-	953,402	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,034,758	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	669,429	-	-	-
Latin America & Asia Market Group	-	23	132	-	-	-%	-	481,381	119	-	1
Foundation Market Group	-	850	2,690	-	512,836	(99)%	512,836	4,073,251	2,421	-	61
Zinc Provided	3,650	2,152	28,688	12,189	11,834	142%	11,834	73,597	28,688	-	752
Foundation Market Group	3,650	2,152	28,688	12,189	11,834	142%	11,834	73,597	28,688	-	752

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

Acceleration Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Acceleration Market Group	41,942	-	-	3,129	3,382,778	4,670	1,501,143	1,085	564	123	3	26,663
India	-	-	-	-	1,199,348	350	628,605	-	257	-	-	3,805
Kenya	20,615	-	-	-	1,047,758	1,263	413,568	536	61	123	1	8,842
Myanmar	1,900	-	-	3,129	587,982	137	208,366	549	246	-	1	4,851
Nigeria	-	-	-	-	102,046	238	46,892	-	-	-	-	1,407
PSI Nigeria	-	-	-	-	445,644	2,681	203,712	-	-	-	-	7,759
South Africa	19,426	-	-	-	-	-	-	-	-	-	-	-

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group										3,382,778	3,642,740
Antiretroviral Treatment (Currently Enrolled)	15,532	15,167	174,024	170,176	152,003	14%	152,003	402,508	14,502	-	34,444
Antiretroviral Treatment (Newly Enrolled)	263	309	3,744	3,981	3,434	9%	3,434	13,330	3,744	-	-
Cervical Cancer-VIA and Cryotherapy	7	22	307	240	286	7%	286	4,580	307	-	73
Cervical Cancer-VIA and Refer to Conization	-	-	-	-	4	(100)%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	29	(100)%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	288	1,514	37,955	21,500	34,714	9%	34,714	325,684	37,955	-	-
Condom	3,408,750	4,118,821	45,303,579	41,769,999	38,017,548	19%	38,017,548	1,020,807,627	339,777	339,777	1,000,040
Diarrhea Treatment Kit Provided	-	-	15,147	29,000	18,226	(17)%	18,226	69,404	15,147	-	503
Emergency Contraception	-	333	1,000	-	5	19,900%	5	178,869	45	45	4
Emergency Contraception Provided	20,252	9,473	75,323	19,800	4,173	1,705%	4,173	80,924	3,766	3,766	561
Fecal Sludge Management (Households)	-	6	489	400	697	(30)%	697	2,768	2,347	-	-
Fecal Sludge Management (Liters)	-	30,000	1,914,000	2,000,000	4,011,000	(52)%	4,011,000	13,071,200	-	-	118
Female Condom	-	-	85,553	70,000	79,641	7%	79,641	1,556,019	642	642	461
Fever Cases Attended	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Tested with RDTs	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,951,296	520,128	-	-
Free Condom	-	2,400	1,920,960	35,500,000	68,170,320	(97)%	68,170,320	1,177,078,157	14,407	14,407	56,881
Free Female Condom	11,695	9,857	49,875	-	1,108,500	(96)%	1,108,500	5,080,475	374	374	269
HIV Self-Testing Kit	5,390	155,147	647,230	1,066,643	1,357,422	(52)%	1,357,422	2,004,652	582,507	-	-
HIV Testing Services	14,865	18,072	318,640	293,418	1,091,132	(71)%	1,091,132	6,376,603	318,640	-	12,203
Hypertension Diagnosis	19,902	1,061	51,351	20,000	57,768	(11)%	57,768	125,160	51,351	-	-
Hypertension Screening	27,633	1,934	108,524	50,000	176,640	(39)%	176,640	319,678	108,524	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Hypertension_Controlled Condition	16,777	824	39,737	-	43,499	(9)%	43,499	95,546	15,895	-	-
Implant 3	363	1,401	10,355	12,600	1,528	578%	1,528	829,031	9,320	23,299	15,549
Implant 3 Insertion	8,449	10,592	51,603	38,123	8,884	481%	8,884	63,968	51,603	129,008	98,957
Implant 4 Insertion	-	-	-	-	288	(100)%	288	288	-	-	-
Implant 5	(4,760)	(13)	(4,707)	(7,600)	2,423	(294)%	2,423	49,283	(4,236)	(16,098)	(11,752)
Implant 5 Insertion	8,863	10,126	117,879	62,915	82,547	43%	82,547	532,580	117,879	447,940	394,964
Injectable 1 Provided	6	5	44	-	37	19%	37	81	3	3	3
Injectable 2 Provided	1,175	1,296	13,459	-	5,875	129%	5,875	19,334	2,243	2,243	1,891
Injectable 3-IM	58,149	43,750	514,301	480,600	644,429	(20)%	644,429	16,277,946	115,718	115,718	25,256
Injectable 3-IM Provided	47,032	59,148	385,457	204,422	175,770	119%	175,770	756,511	96,364	96,364	44,273
Injectable 3-SC	3,278	2,602	31,405	32,150	-	-%	-	31,405	7,066	7,066	884
Injectable 3-SC Provided	897	1,258	9,727	-	-	-%	-	9,727	2,432	2,432	2,050
IPTp2	1,860	287	6,109	-	3,893	57%	3,893	20,406	6,109	-	228
IUD 10	(198)	3	(331)	(4,600)	684	(148)%	684	13,015	(298)	(1,370)	(1,500)
IUD 10 Insertion	8,223	10,578	101,968	103,790	90,084	13%	90,084	631,496	101,968	469,053	450,542
IUD 5	48	24	362	2,500	472	(23)%	472	141,764	326	1,075	183
IUD 5 Insertion	27,103	20,992	162,738	65,000	51,661	215%	51,661	337,261	162,738	537,035	121,524
IUS 5 Insertion	75	103	1,102	-	775	42%	775	2,503	1,102	3,637	4,182
LLIN	10,625	1,853	1,093,373	2,049,898	2,332,163	(53)%	2,332,163	24,776,100	1,771,264	-	41,770
Lubricant	271,000	286,000	2,318,836	70,000	51,861	4,371%	51,861	7,551,522	-	-	-
Malaria PPT (ACT)	1,089	391	174,362	182,270	256,333	(32)%	256,333	3,363,258	156,926	-	24,461

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Malaria PPT (Non-ACT)	224	174	2,954	3,621	(1,900)	-%	(1,900)	107,280	2,659	-	414
Malaria RDK	-	-	-	432,337	743,410	(100)%	743,410	4,731,974	-	-	-
Manual Vacuum Aspiration for PAC	485	742	7,879	5,220	19,176	(59)%	19,176	27,055	7,879	-	6,309
Medical Abortion	-	652	2,000	9,000	-	-%	-	2,000	1,800	-	1,689
Micronutrient Powder	-	-	-	-	2,000,000	(100)%	2,000,000	9,499,690	-	-	-
Misoprostol for PAC Provided	382	675	7,331	5,220	14,855	(51)%	14,855	22,186	7,331	-	6,952
Misoprostol for Safe Abortion	26,472	134,133	1,774,246	2,339,690	2,321,200	(24)%	2,321,200	4,095,446	93,148	-	78,213
Multivitamin	-	-	-	-	450,010	(100)%	450,010	883,520	-	-	-
Needle & Syringe	-	-	10,100	-	-	-%	-	1,956,069	35	-	83
OCs	750,138	996,206	9,114,680	10,222,400	9,535,861	(4)%	9,535,861	74,987,578	546,881	546,881	154,562
OCs Provided	144,657	101,057	756,782	181,469	151,894	398%	151,894	1,001,891	50,452	50,452	11,210
ORS	38,020	124,149	847,044	600,000	514,198	65%	514,198	2,077,898	381,170	-	22,210
ORS Provided	-	-	2,043	-	2,217	(8)%	2,217	9,430	2,043	-	33
Pneumonia PPT	-	-	-	28,910	-	-%	-	-	-	-	-
Pneumonia PPT Provided	4,452	662	21,771	-	20,179	8%	20,179	79,844	21,771	-	10,472
Positive RDTs	426	351	4,386	-	9,712	(55)%	9,712	39,857	4,386	-	-
Positive RDTs Given First Line Treatment	417	348	4,242	-	8,937	(53)%	8,937	35,245	4,242	-	-
PrEP	69	75	547	-	-	-%	-	547	46	-	23
PUR	2,779,200	2,809,843	32,575,220	19,000,000	28,508,349	14%	28,508,349	213,355,146	267,742	-	661
QAACs Provided after Confirmatory Diagnosis	33,218	108	58,000	95,000	101,767	(43)%	101,767	178,545	58,000	-	9,564
Referral to HIV Testing Services	-	-	21,265	-	-	-%	-	21,265	21,265	-	754

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	-	242	5,843	12,150	-	-%	-	5,843	5,843	-	2,767
Referral to TB DOTS (completion confirmed)	69	55	1,020	2,349	1,214	(16)%	1,214	2,527	1,020	-	3,163
Referral to TB DOTS (completion unknown)	71	72	1,289	2,374	1,575	(18)%	1,575	2,864	1,289	-	3,598
Safe Water Solution	71,700	71,529	1,418,258	1,160,000	1,114,276	27%	1,114,276	22,892,158	1,165,692	-	2,876
SDM (Cycle Beads) Provided	1,252	1,755	6,606	-	3	220,100%	3	6,609	6,606	9,909	7,738
Skilled Birth Attendance	6,891	1,327	25,405	40,000	20,115	26%	20,115	87,574	25,405	-	21,117
STI Screening	842	1,085	16,593	-	27,221	(39)%	27,221	77,102	16,593	-	-
TB Diagnosis	1,482	1,331	13,610	16,181	14,315	(5)%	14,315	73,214	13,610	-	-
TB DOTS	948	1,179	12,584	13,173	12,891	(2)%	12,891	230,035	12,584	-	78,056
TB Screening	8,077	9,721	118,645	149,616	103,950	14%	103,950	490,852	118,645	-	-
Toilets Sold	-	7,881	68,647	60,000	50,363	36%	50,363	119,010	329,506	-	7,865
Toilets Sold - All	6,161	7,881	74,808	-	50,363	49%	50,363	125,171	359,078	-	-
Treatment for Pre-Eclampsia (with MgSO4)	21	6	43	60	49	(12)%	49	213	43	-	38
Tubal Ligation	7,964	4,709	44,513	25,000	38,957	14%	38,957	126,716	44,513	576,818	156,356
Vasectomy	252	338	1,717	1,000	287	498%	287	5,672	1,717	22,303	6,046
Vivax Treatment after Confirmatory Diagnosis	171	134	1,993	-	3,244	(39)%	3,244	11,199	1,993	-	365
Voluntary Medical Male Circumcision	16,334	3,934	103,723	90,000	78,885	31%	78,885	255,950	103,723	-	730,557
Water Treatment Tablets	10,800	5,760	708,480	300,000	501,290	41%	501,290	6,645,680	11,646	-	29

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group											3,382,778	3,642,740
India											1,199,348	299,908
Emergency Contraception Provided	19,269	8,490	69,642	18,000	2,574		2606%	2,574	72,216	3,482	3,482	444
Non-PSI Emergency Contraception Provided	19,269	8,490	69,642	18,000	2,574		2,606%	2,574	72,216	3,482	3,482	444
Fecal Sludge Management (Households)	-	6	489	400	697		(30)%	697	2,768	2,347	-	-
Fecal Sludge Management (Households)	-	6	489	400	697		(30)%	697	2,768	2,347	-	-
Fecal Sludge Management (Liters)	-	30,000	1,914,000	2,000,000	4,011,000		(52)%	4,011,000	13,071,200	-	-	118
Fecal Sludge Management (Liters)	-	30,000	1,914,000	2,000,000	4,011,000		(52)%	4,011,000	13,071,200	-	-	118
Hypertension Diagnosis	19,246	-	19,246	-	-		0%	-	19,246	19,246	-	-
Hypertension Diagnosis	19,246	-	19,246	-	-		-%	-	19,246	19,246	-	-
Hypertension Screening	26,346	-	26,346	-	-		0%	-	26,346	26,346	-	-
Hypertension Screening	26,346	-	26,346	-	-		-%	-	26,346	26,346	-	-
Hypertension_Controlled Condition	16,293	-	16,293	-	-		0%	-	16,293	6,517	-	-
Hypertension_Controlled Condition	16,293	-	16,293	-	-		-%	-	16,293	6,517	-	-
Injectable 3-IM Provided	13,107	11,380	98,086	35,000	16,479		495%	16,479	149,515	24,522	24,522	4,103
Non-PSI Injectable 3 IM Provided	13,107	11,380	98,086	35,000	16,479		495%	16,479	149,515	24,522	24,522	4,103
IUD 10 Insertion	-	-	-	-	41		(100)%	41	2,526	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	41		(100)%	41	2,526	-	-	-
IUD 5 Insertion	26,999	20,903	161,532	65,000	49,622		226%	49,622	277,319	161,532	533,056	120,847
Non-PSI IUD 5 Inserted	26,999	20,903	161,532	65,000	49,622		226%	49,622	277,319	161,532	533,056	120,847
OCs Provided	135,882	89,453	680,972	150,000	100,521		577%	100,521	845,629	45,398	45,398	8,013
Non-PSI OCs Provided	135,882	89,453	680,972	150,000	100,521		577%	100,521	845,629	45,398	45,398	8,013
TB Diagnosis	-	-	-	400	-		0%	-	-	-	-	-
TB Diagnosis	-	-	-	400	-		-%	-	-	-	-	-
TB DOTS	-	-	-	500	-		0%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB DOTS	-	-	-	500	-		-%	-	-	-	-	-
TB Screening	-	-	-	100,000	-		0%	-	-	-	-	-
TB Screening	-	-	-	100,000	-		-%	-	-	-	-	-
Toilets Sold	-	7,881	68,647	60,000	50,363		36%	50,363	119,010	329,506	-	7,865
Toilets Sold	-	7,881	68,647	60,000	50,363		36%	50,363	119,010	329,506	-	7,865
Toilets Sold - All	6,161	7,881	74,808	-	50,363		49%	50,363	125,171	359,078	-	-
Toilets Sold - All	6,161	7,881	74,808	-	50,363		49%	50,363	125,171	359,078	-	-
Tubal Ligation	7,902	4,524	43,896	25,000	38,957		13%	38,957	126,099	43,896	570,648	152,512
Tubal Ligation	7,902	4,524	43,896	25,000	38,957		13%	38,957	126,099	43,896	570,648	152,512
Vasectomy	249	337	1,711	1,000	287		496%	287	5,666	1,711	22,243	6,008
Vasectomy	249	337	1,711	1,000	287		496%	287	5,666	1,711	22,243	6,008
Kenya											1,047,758	1,610,141
Antiretroviral Treatment (Currently Enrolled)	8,244	8,032	94,314	92,100	85,622		10%	85,622	208,766	7,859	-	20,519
Antiretroviral Treatment (Currently Enrolled)	8,244	8,032	94,314	92,100	85,622		10%	85,622	208,766	7,859	-	20,519
Antiretroviral Treatment (Newly Enrolled)	124	124	1,427	1,754	1,227		16%	1,227	4,847	1,427	-	-
Antiretroviral Treatment (Newly Enrolled)	124	124	1,427	1,754	1,227		16%	1,227	4,847	1,427	-	-
Cervical Cancer-VIA and Cryotherapy	-	4	174	200	227		(23)%	227	3,490	174	-	40
Cervical Cancer-VIA and Cryotherapy	-	4	174	200	227	7/13	(23)%	227	3,490	174	-	40
Cervical Cancer-VIA and Refer to Conization	-	-	-	-	4		(100)%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Conization	-	-	-	-	4		(100)%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	29		(100)%	29	48	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	29	12/14	(100)%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	-	1,168	34,361	18,000	31,803		8%	31,803	314,735	34,361	-	-
Cervical Cancer-VIA/VILI Screening	-	1,168	34,361	18,000	31,803		8%	31,803	314,735	34,361	-	-
Condom	2,536,128	2,650,825	31,033,515	26,249,999	25,124,074		24%	25,124,074	593,836,832	232,751	232,751	921,740

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Trust	2,190,312	2,225,784	25,288,945	20,922,493	19,627,309	10/93	29%	19,627,309	527,517,193	189,667	189,667	751,118
Trust Ribbed	44,280	43,872	706,873	591,117	701,493	5/14	1%	701,493	4,399,736	5,302	5,302	20,995
Trust Scented	-	-	216	-	60,552	5/14	(100)%	60,552	3,301,903	2	2	6
Trust Studded	301,536	381,168	5,037,481	4,736,389	4,734,720	1/08	6%	4,734,720	58,618,000	37,781	37,781	149,620
Diarrhea Treatment Kit Provided	-	-	15,147	29,000	18,226		(17)%	18,226	69,404	15,147	-	503
Non-PSI Diarrhea Treatment Kit Provided	-	-	15,147	29,000	18,226		(17)%	18,226	69,404	15,147	-	503
Emergency Contraception	-	-	-	-	(126)		0%	(126)	(1,554)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(126)		-%	(126)	(1,554)	-	-	-
Emergency Contraception Provided	977	972	5,618	1,800	1,539		265%	1,539	8,585	281	281	116
Non-PSI Emergency Contraception Provided	977	972	5,618	1,800	1,413		298%	1,413	7,031	281	281	116
PSI Emergency Contraception Provided	-	-	-	-	126		(100)%	126	1,554	-	-	-
Free Condom	-	-	1,913,760	35,000,000	28,851,120		(93)%	28,851,120	92,411,197	14,353	14,353	56,841
Free Male Condom - NASCOP	-	-	1,913,760	35,000,000	28,851,120	5/11	(93)%	28,851,120	92,411,197	14,353	14,353	56,841
HIV Self-Testing Kit	5,390	4,458	48,552	37,343	69,171		(30)%	69,171	117,723	43,697	-	-
INSTI HIVST (Blood based)	2,820	1,293	6,698	25,000	40,000		(83)%	40,000	46,698	6,028	-	-
INSTI-ORAQUICK HIVST BUNDLE	-	-	-	-	1,000		(100)%	1,000	1,000	-	-	-
ORAQUICK HIV Self-Testing Kit (Saliva based)	2,570	3,166	41,854	12,343	28,171		49%	28,171	70,025	37,669	-	-
HIV Testing Services	9,213	9,417	209,881	165,478	212,997		(1)%	212,997	1,397,443	209,881	-	8,767
VCT Individual (HIV-Negative)	9,039	9,245	206,369	161,373	209,785	9/11	(2)%	209,785	1,359,589	206,369	-	8,620
VCT Individual (HIV-Positive)	174	172	3,512	4,105	3,212	9/11	9%	3,212	37,854	3,512	-	147
Implant 3	-	1,333	9,150	6,000	1		914900%	1	816,143	8,235	20,588	15,088
Implanon	-	1,333	9,150	6,000	1	3/14	914,900%	1	816,143	8,235	20,588	15,088
Implant 3 Insertion	6,612	8,738	32,827	38,123	-		0%	-	32,827	32,827	82,068	60,144
Non-PSI Implant 3 Inserted	6,612	8,738	32,827	38,123	-		-%	-	32,827	32,827	82,068	60,144

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5	(4,760)	(13)	(4,800)	(7,600)	2,423		(298)%	2,423	49,083	(4,320)	(16,416)	(11,805)
Jadelle	-	2,470	18,820	2,400	23,710	1/09	(21)%	23,710	203,748	16,938	64,364	46,284
(b)PSI Implant 5 Distributed Inserted	(4,760)	(2,483)	(23,620)	(10,000)	(21,287)		-%	(21,287)	(154,665)	(21,258)	(80,780)	(58,089)
Implant 5 Insertion	5,160	5,501	71,230	35,000	50,514		41%	50,514	363,029	71,230	270,674	194,640
Non-PSI Implant 5 Inserted	400	3,018	47,610	25,000	29,227		63%	29,227	208,364	47,610	180,918	130,097
PSI Implant 5 Inserted	4,760	2,483	23,620	10,000	21,287		11%	21,287	154,665	23,620	89,756	64,543
Injectable 3-IM	2,160	11,150	115,590	79,400	117,204		(1)%	117,204	5,832,784	26,008	26,008	14,038
Femiplan Injectable	2,160	11,150	115,590	79,400	267,954	3/00	(57)%	267,954	6,143,868	26,008	26,008	14,038
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	(150,750)		-%	(150,750)	(311,084)	-	-	-
Injectable 3-IM Provided	32,357	45,962	268,996	169,422	150,750		78%	150,750	580,080	67,249	67,249	36,298
Non-PSI Injectable 3 IM Provided	32,357	45,962	268,996	169,422	-		-%	-	268,996	67,249	67,249	36,298
PSI Injectable 3 IM Provided	-	-	-	-	150,750		(100)%	150,750	311,084	-	-	-
IPTp2	1,860	287	6,109	-	3,893		57%	3,893	20,406	6,109	-	228
IPTp2	1,860	287	6,109	-	3,893		57%	3,893	20,406	6,109	-	228
IUD 10	(228)	-	(588)	(4,600)	605		(197)%	605	9,439	(529)	(2,434)	(1,670)
CU 380A (Copper T)	-	47	190	2,400	10,551	3/09	(98)%	10,551	99,414	171	787	540
(b)PSI IUD 10 Distributed Inserted	(228)	(47)	(778)	(7,000)	(9,946)		-%	(9,946)	(89,975)	(700)	(3,221)	(2,210)
IUD 10 Insertion	3,810	4,454	31,353	27,350	17,347		81%	17,347	210,607	31,353	144,224	98,961
Non-PSI IUD 10 Inserted	3,582	4,407	30,575	20,350	7,401		313%	7,401	120,632	30,575	140,645	96,506
PSI IUD 10 Inserted	228	47	778	7,000	9,946		(92)%	9,946	89,975	778	3,579	2,456
LLIN	743	828	907,433	1,824,672	2,332,163		(61)%	2,332,163	24,552,080	1,470,041	-	29,927
ANC LLIN	-	-	-	1,800,000	-	7/08	-%	-	19,189,925	-	-	-
Supanet Conical	270	431	8,212	8,578	8,447	10/16	(3)%	8,447	23,840	13,303	-	271
Supanet Rectangular	473	397	7,390	16,094	13,913	10/16	(47)%	13,913	26,013	11,972	-	244

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Supanet XtraPower BL PNET USAID	-	-	891,831	-	2,309,803	3/14	(61)%	2,309,803	5,312,302	1,444,766	-	29,413
OCs	172,080	338,778	3,139,760	3,418,400	3,635,514		(14)%	3,635,514	41,786,533	188,386	188,386	107,270
Famipill	-	-	9,000	-	140,628	5/18	(94)%	140,628	149,628	540	540	307
Femi Girl Oral Pills	-	496	4,792	15,900	162,192	11/16	(97)%	162,192	176,728	288	288	164
Femiplan Pill	172,080	338,282	3,125,968	3,402,500	3,376,158	3/00	(7)%	3,376,158	41,532,720	187,558	187,558	106,798
(b)PSI OCs Distributed Provided	-	-	-	-	(43,464)		-%	(43,464)	(72,543)	-	-	-
OCs Provided	7,429	10,076	60,847	31,469	44,411		37%	44,411	134,337	4,056	4,056	2,310
Non-PSI OCs Provided	7,429	10,076	60,847	31,469	947		6,325%	947	61,794	4,056	4,056	2,310
PSI OCs Provided	-	-	-	-	43,464		(100)%	43,464	72,543	-	-	-
ORS Provided	-	-	2,043	-	2,217		(8)%	2,217	9,430	2,043	-	33
Non-PSI ORS Provided	-	-	2,043	-	2,217		(8)%	2,217	9,430	2,043	-	33
Pneumonia PPT	-	-	-	28,910	-		0%	-	-	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	28,910	-		-%	-	-	-	-	-
Pneumonia PPT Provided	4,452	662	21,771	-	20,179		8%	20,179	79,844	21,771	-	10,472
Non-PSI Pneumonia PPT Provided	4,452	662	21,771	-	20,179		8%	20,179	79,844	21,771	-	10,472
PrEP	69	75	547	-	-		0%	-	547	46	-	23
PrEP	69	75	547	-	-		-%	-	547	46	-	23
PUR	2,779,200	2,809,843	32,575,220	19,000,000	27,875,040		17%	27,875,040	197,497,356	267,742	-	661
PuR	2,779,200	2,809,843	32,575,220	19,000,000	27,875,040	2/06	17%	27,875,040	197,497,356	267,742	-	661
QAACTs Provided after Confirmatory Diagnosis	33,091	-	56,824	95,000	96,981		(41)%	96,981	157,730	56,824	-	9,348
Non-PSI QAACTs Provided after Confirmed Diagnosis	33,091	-	56,824	95,000	96,981		(41)%	96,981	157,730	56,824	-	9,348
Safe Water Solution	71,700	71,529	1,418,258	1,160,000	1,114,276		27%	1,114,276	22,892,158	1,165,692	-	2,876
WaterGuard	71,700	71,529	1,418,258	1,160,000	1,114,276	5/03	27%	1,114,276	22,892,158	1,165,692	-	2,876
SDM (Cycle Beads) Provided	1,248	1,749	6,494	-	-		0%	-	6,494	6,494	9,741	7,534
Non-PSI SDM (Cycle Beads) Provided	1,248	1,749	6,494	-	-		-%	-	6,494	6,494	9,741	7,534

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Skilled Birth Attendance	6,891	1,327	25,405	40,000	20,115		26%	20,115	87,574	25,405	-	21,117
Skilled Birth Attendance	6,891	1,327	25,405	40,000	20,115		26%	20,115	87,574	25,405	-	21,117
TB Diagnosis	-	20	349	281	56		523%	56	1,020	349	-	-
TB Diagnosis	-	20	349	281	56		523%	56	1,020	349	-	-
TB Screening	-	2,337	40,435	7,816	6,339		538%	6,339	120,813	40,435	-	-
TB Screening	-	2,337	40,435	7,816	6,339		538%	6,339	120,813	40,435	-	-
Treatment for Pre-Eclampsia (with MgSO4)	21	6	43	60	49		(12)%	49	213	43	-	38
Treatment for Pre-Eclampsia (with MgSO4)	21	6	43	60	49		(12)%	49	213	43	-	38
Tubal Ligation	62	185	617	-	-		0%	-	617	617	6,170	3,845
Tubal Ligation	62	185	617	-	-		-%	-	617	617	6,170	3,845
Vasectomy	3	1	6	-	-		0%	-	6	6	60	38
Vasectomy	3	1	6	-	-		-%	-	6	6	60	38
Voluntary Medical Male Circumcision	-	-	31	-	-		0%	-	31	31	-	173
Voluntary Medical Male Circumcision	-	-	31	-	-		-%	-	31	31	-	173
Water Treatment Tablets	10,800	5,760	708,480	300,000	501,290		41%	501,290	6,645,680	11,646	-	29
Aquatab	10,800	5,760	708,480	300,000	501,290	3/09	41%	501,290	6,645,680	11,646	-	29
Myanmar											587,982	301,075
Antiretroviral Treatment (Currently Enrolled)	7,288	7,135	79,710	78,076	66,381		20%	66,381	193,742	6,642	-	13,925
Antiretroviral Treatment (Currently Enrolled)	7,288	7,135	79,710	78,076	66,381		20%	66,381	193,742	6,642	-	13,925
Antiretroviral Treatment (Newly Enrolled)	139	184	2,317	2,227	2,207		5%	2,207	8,483	2,317	-	-
Antiretroviral Treatment (Newly Enrolled)	139	184	2,317	2,227	2,207		5%	2,207	8,483	2,317	-	-
Cervical Cancer-VIA and Cryotherapy	7	19	133	40	59		125%	59	1,090	133	-	33
Cervical Cancer-VIA and Cryotherapy	7	19	133	40	59	11/12	125%	59	1,090	133	-	33
Cervical Cancer-VIA/VILI Screening	288	346	3,594	3,500	2,911		23%	2,911	10,949	3,594	-	-
Cervical Cancer-VIA/VILI Screening	288	346	3,594	3,500	2,911		23%	2,911	10,949	3,594	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Condom	872,622	1,467,996	14,270,064	15,520,000	12,893,474		11%	12,893,474	426,970,795	107,025	107,025	78,300
Aphaw	214,980	305,320	3,945,874	-	2,515,280	7/96	57%	2,515,280	195,211,553	29,594	29,594	21,651
Aphaw - Natural Touch	105,438	210,789	1,169,451	1,953,000	1,039,098	8/12	13%	1,039,098	15,947,124	8,771	8,771	6,417
Aphaw Deluxe GL (3x1)	-	-	-	3,515,400	-		-%	-	-	-	-	-
Aphaw Flavors	542,524	643,408	4,985,368	5,208,000	5,926,276	10/01	(16)%	5,926,276	181,806,059	37,390	37,390	27,355
Aphaw Studded	7,680	183,679	1,620,297	2,343,600	1,050,858	7/12	54%	1,050,858	20,068,842	12,152	12,152	8,891
Generic Male Condom	2,000	124,800	2,543,500	2,500,000	2,270,400	1/08	12%	2,270,400	8,702,429	19,076	19,076	13,956
OK Condom	-	-	5,574	-	91,562	5/03	(94)%	91,562	5,234,788	42	42	31
Emergency Contraception	-	333	1,000	-	5		19900%	5	178,869	45	45	4
Levonorgestrel 1.5 mg Tablet	-	333	1,000	-	-		-%	-	1,000	45	45	4
OK EC	-	-	-	-	5	8/07	(100)%	5	177,869	-	-	-
Female Condom	-	-	85,553	70,000	79,641		7%	79,641	1,556,019	642	642	461
Generic Female Condom	-	-	85,553	70,000	79,641	5/08	7%	79,641	1,556,019	642	642	461
Fever Cases Attended	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Attended	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Tested with RDTs	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Tested with RDTs	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Free Condom	-	2,400	7,200	-	-		0%	-	7,200	54	54	40
Free Male Condoms	-	2,400	7,200	-	-		-%	-	7,200	54	54	40
Free Female Condom	11,695	9,857	49,875	-	-		0%	-	49,875	374	374	269
FC2 Female Condom	11,695	9,857	49,875	-	-	11/16	-%	-	49,875	374	374	269
HIV Testing Services	5,652	5,510	61,315	64,440	48,784		26%	48,784	456,109	61,315	-	73
VCT Individual (HIV-Negative)	5,426	5,278	58,510	59,647	45,712	12/09	28%	45,712	425,467	58,510	-	70
VCT Individual (HIV-Positive)	226	232	2,805	4,793	3,072	12/09	(9)%	3,072	30,642	2,805	-	3

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Hypertension Diagnosis	656	1,061	32,105	20,000	57,768		(44)%	57,768	105,914	32,105	-	-
Hypertension Diagnosis	656	1,061	32,105	20,000	57,768		(44)%	57,768	105,914	32,105	-	-
Hypertension Screening	1,287	1,934	82,178	50,000	176,640		(53)%	176,640	293,332	82,178	-	-
Hypertension Screening	1,287	1,934	82,178	50,000	176,640		(53)%	176,640	293,332	82,178	-	-
Hypertension_Controlled Condition	484	824	23,444	-	43,499		(46)%	43,499	79,253	9,378	-	-
Hypertension_Controlled Condition	484	824	23,444	-	43,499		(46)%	43,499	79,253	9,378	-	-
Implant 3	363	68	1,205	6,600	1,527		(21)%	1,527	12,888	1,085	2,711	461
Implanon NXT	897	554	7,374	6,600	6,278	12/15	17%	6,278	27,289	6,637	16,592	2,821
(b)PSI Implant 3 Distributed Inserted	(534)	(486)	(6,169)	-	(4,751)		-%	(4,751)	(14,401)	(5,552)	(13,880)	(2,360)
Implant 3 Insertion	534	486	6,169	-	4,751		30%	4,751	14,401	6,169	15,423	2,622
PSI Implant 3 Inserted	534	486	6,169	-	4,751		30%	4,751	14,401	6,169	15,423	2,622
Implant 5	-	-	93	-	-		0%	-	200	84	318	53
Jadelle	-	-	93	-	-	5/16	-%	-	200	84	318	53
Injectable 3-IM	55,989	32,600	398,711	401,200	376,475		6%	376,475	10,134,078	89,710	89,710	11,218
OK-3 Injection	55,989	32,600	398,711	401,200	376,475	9/01	6%	376,475	10,134,078	89,710	89,710	11,218
Injectable 3-SC	3,278	2,602	31,405	32,150	-		0%	-	31,405	7,066	7,066	884
Sayana Press	3,278	2,602	31,405	32,150	-		-%	-	31,405	7,066	7,066	884
IUD 10	30	3	257	-	79		225%	79	3,576	231	1,064	170
OK IUD (Copper T Cu 380A)	30	3	257	-	79	10/14	225%	79	3,576	231	1,064	170
IUD 5	48	24	362	2,500	472		(23)%	472	141,764	326	1,075	183
OK IUD	-	-	-	2,500	1,206	5/03	(100)%	1,206	198,833	-	-	-
OK IUD (Inara Cu 375 Slek)	152	113	1,568	-	768		104%	768	2,336	1,411	4,657	792
(b)PSI IUD 5 Distributed Inserted	(104)	(89)	(1,206)	-	(1,502)		-%	(1,502)	(59,405)	(1,085)	(3,582)	(609)
IUD 5 Insertion	104	89	1,206	-	1,502		(20)%	1,502	59,405	1,206	3,980	677
PSI IUD 5 Inserted	104	89	1,206	-	1,502		(20)%	1,502	59,405	1,206	3,980	677

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
LLIN	9,882	1,025	185,940	225,226	-		0%	-	224,020	301,223	-	11,842
LLIN	9,882	1,025	185,940	225,226	-	11/16	-%	-	224,020	301,223	-	11,842
Lubricant	271,000	286,000	2,318,836	70,000	51,861		4371%	51,861	7,551,522	-	-	-
Aphaw Gel - Sachet	271,000	286,000	2,286,002	40,000	250	10/06	914,301%	250	6,714,310	-	-	-
Aphaw Gel - Tube 20 cc	-	-	12,378	30,000	51,611	10/06	(76)%	51,611	694,058	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	-	-	20,456	-	-	10/14	-%	-	143,154	-	-	-
Malaria PPT (ACT)	1,089	391	174,362	182,270	256,333		(32)%	256,333	3,363,258	156,926	-	24,461
AL 1	248	80	2,847	126	3,413	7/12	(17)%	3,413	19,849	2,562	-	399
AL 2	250	70	2,906	126	3,390	7/12	(14)%	3,390	20,659	2,615	-	408
AL 3	260	88	3,251	379	3,470	1/11	(6)%	3,470	55,645	2,926	-	456
AL 4	188	214	5,324	5,689	13,664	1/11	(61)%	13,664	281,746	4,792	-	747
Arte+1	62	10	815	2,500	-	8/14	-%	-	23,094	734	-	114
Arte+2	66	10	818	2,500	-	8/14	-%	-	23,996	736	-	115
Arte+3	63	10	2,016	3,000	-	8/14	-%	-	28,558	1,814	-	283
Arte+4	79	17	74,629	79,975	114,680	8/14	(35)%	114,680	655,997	67,166	-	10,470
(b)PSI QAACTs Distributed Provided after Diagnosis	(127)	(108)	(1,176)	-	(4,786)		-%	(4,786)	(20,815)	(1,058)	-	(165)
Supa Arte 1	-	-	1,503	2,500	-	9/12	-%	-	122,214	1,353	-	211
Supa Arte 2	-	-	1,503	2,500	-	9/12	-%	-	118,055	1,353	-	211
Supa Arte 3	-	-	1,503	3,000	-	9/12	-%	-	197,962	1,353	-	211
Supa Arte 4	-	-	78,423	79,975	122,502	9/12	(36)%	122,502	1,836,298	70,581	-	11,002
Malaria PPT (Non-ACT)	224	174	2,954	3,621	(1,900)		0%	(1,900)	107,280	2,659	-	414
Chloroquine 10's	395	308	4,938	-	-		-%	-	4,938	4,444	-	693
(b)PSI Vivax Tx Distributed Provided after Diagnosis	(171)	(134)	(1,993)	-	(3,244)		-%	(3,244)	(11,199)	(1,794)	-	(280)
Vivax Treatment Kit	-	-	9	3,621	1,344	6/11	(99)%	1,344	113,541	8	-	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Malaria RDK	-	-	-	432,337	743,410		(100)%	743,410	4,731,974	-	-	-
Malaria RDT (Diagnosis)	-	-	-	432,337	743,410	3/11	(100)%	743,410	4,731,974	-	-	-
Micronutrient Powder	-	-	-	-	2,000,000		(100)%	2,000,000	9,499,690	-	-	-
Happy Kid (Micronutrient powder)	-	-	-	-	2,000,000	9/16	(100)%	2,000,000	9,499,690	-	-	-
Multivitamin	-	-	-	-	450,010		(100)%	450,010	883,520	-	-	-
May May Vita Plus	-	-	-	-	450,010	6/17	(100)%	450,010	883,520	-	-	-
Needle & Syringe	-	-	10,100	-	-		0%	-	1,956,069	35	-	83
Needle & Syringe (LDS)	-	-	10,100	-	-	10/15	-%	-	1,956,069	35	-	83
OCs	578,058	657,428	5,974,920	6,804,000	5,856,883		2%	5,856,883	33,128,502	358,495	358,495	47,293
OK Pills	578,016	656,643	5,961,595	6,804,000	5,831,882	9/01	2%	5,831,882	33,078,555	357,696	357,696	47,187
OK Pills (Zinnia F)	42	785	13,325	-	25,001	11/16	(47)%	25,001	49,947	800	800	105
ORS	38,020	124,149	847,044	600,000	514,198		65%	514,198	2,077,898	381,170	-	22,210
ORS	38,020	124,149	847,044	600,000	514,198	1/08	65%	514,198	2,077,898	381,170	-	22,210
Positive RDTs	426	351	4,386	-	9,712		(55)%	9,712	39,857	4,386	-	-
Positive RDTs	426	351	4,386	-	9,712		(55)%	9,712	39,857	4,386	-	-
Positive RDTs Given First Line Treatment	417	348	4,242	-	8,937		(53)%	8,937	35,245	4,242	-	-
Positive RDTs Given First Line Treatment	417	348	4,242	-	8,937		(53)%	8,937	35,245	4,242	-	-
PUR	-	-	-	-	633,309		(100)%	633,309	15,857,790	-	-	-
Purifier of Water	-	-	-	-	633,309	4/14	(100)%	633,309	15,857,790	-	-	-
QAACs Provided after Confirmatory Diagnosis	127	108	1,176	-	4,786		(75)%	4,786	20,815	1,176	-	216
PSI QAACs Provided after Confirmed Diagnosis	127	108	1,176	-	4,786		(75)%	4,786	20,815	1,176	-	216
Referral to TB DOTS (completion confirmed)	69	55	1,020	2,349	1,214		(16)%	1,214	2,527	1,020	-	3,163
Referral to TB DOTS (completion confirmed)	69	55	1,020	2,349	1,214		(16)%	1,214	2,527	1,020	-	3,163
Referral to TB DOTS (completion unknown)	71	72	1,289	2,374	1,575		(18)%	1,575	2,864	1,289	-	3,598
Referral to TB DOTS (completion unknown)	71	72	1,289	2,374	1,575		(18)%	1,575	2,864	1,289	-	3,598

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
STI Screening	842	1,085	16,593	-	27,221		(39)%	27,221	77,102	16,593	-	-
STI Screening	842	1,085	16,593	-	27,221		(39)%	27,221	77,102	16,593	-	-
TB Diagnosis	1,482	1,311	13,261	15,500	14,259		(7)%	14,259	72,194	13,261	-	-
TB Diagnosis	1,482	1,311	13,261	15,500	14,259		(7)%	14,259	72,194	13,261	-	-
TB DOTS	948	1,179	12,584	12,673	12,891		(2)%	12,891	230,035	12,584	-	78,056
TB DOTS	948	1,179	12,584	12,673	12,891	12/04	(2)%	12,891	230,035	12,584	-	78,056
TB Screening	8,077	7,385	78,210	41,800	97,611		(20)%	97,611	370,039	78,210	-	-
TB Screening	8,077	7,385	78,210	41,800	97,611		(20)%	97,611	370,039	78,210	-	-
Vivax Treatment after Confirmatory Diagnosis	171	134	1,993	-	3,244		(39)%	3,244	11,199	1,993	-	365
PSI Vivax Treatment after Confirmed Diagnosis	171	134	1,993	-	3,244		(39)%	3,244	11,199	1,993	-	365
Nigeria											102,046	112,654
Emergency Contraception Provided	-	-	10	-	60		(83)%	60	70	1	1	-
Non-PSI Emergency Contraception Provided	-	-	10	-	60		(83)%	60	70	1	1	-
HIV Testing Services	-	-	-	-	609,489		(100)%	609,489	2,485,606	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	604,543	12/09	(100)%	604,543	2,342,815	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	4,946	12/09	(100)%	4,946	142,791	-	-	-
Implant 3 Insertion	1,303	1,368	12,607	-	4,133		205%	4,133	16,740	12,607	31,518	36,190
Non-PSI Implant 3 Inserted	1,303	1,368	12,607	-	4,133		205%	4,133	16,740	12,607	31,518	36,190
Implant 4 Insertion	-	-	-	-	288		(100)%	288	288	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	288		(100)%	288	288	-	-	-
Implant 5 Insertion	1,113	1,332	12,195	-	2,833		330%	2,833	105,897	12,195	46,341	52,369
Non-PSI Implant 5 Inserted	1,113	1,332	12,195	-	2,833	3/16	330%	2,833	105,897	12,195	46,341	52,369
Injectable 1 Provided	6	5	44	-	37		19%	37	81	3	3	3
Non-PSI Injectable 1 Provided	6	5	44	-	37		19%	37	81	3	3	3
Injectable 2 Provided	1,175	1,296	13,459	-	5,875		129%	5,875	19,334	2,243	2,243	1,891

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 2 Provided	1,175	1,296	13,459	-	5,875		129%	5,875	19,334	2,243	2,243	1,891
Injectable 3-IM Provided	1,558	1,802	18,189	-	6,118		197%	6,118	24,307	4,547	4,547	3,833
Non-PSI Injectable 3 IM Provided	1,558	1,802	18,189	-	6,118		197%	6,118	24,307	4,547	4,547	3,833
Injectable 3-SC Provided	897	1,258	9,727	-	-		0%	-	9,727	2,432	2,432	2,050
Non-PSI Injectable 3 SC Provided	897	1,258	9,727	-	-		-%	-	9,727	2,432	2,432	2,050
IUD 10 Insertion	155	163	2,325	-	-		0%	-	277,377	2,325	10,695	11,576
Non-PSI IUD 10 Inserted	155	163	2,325	-	-	3/16	-%	-	277,377	2,325	10,695	11,576
IUD 5 Insertion	-	-	-	-	479		(100)%	479	479	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	479		(100)%	479	479	-	-	-
IUS 5 Insertion	75	103	1,102	-	716		54%	716	2,444	1,102	3,637	4,182
Non-PSI IUS 5 Inserted	75	103	1,102	-	716		54%	716	2,444	1,102	3,637	4,182
OCs Provided	892	1,008	9,451	-	5,586		69%	5,586	15,037	630	630	560
Non-PSI OCs Provided	892	1,008	9,451	-	5,586		69%	5,586	15,037	630	630	560
SDM (Cycle Beads) Provided	-	-	-	-	3		(100)%	3	3	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	3		(100)%	3	3	-	-	-
PSI Nigeria											445,644	581,695
Emergency Contraception Provided	6	11	53	-	-		0%	-	53	3	3	2
Non-PSI Emergency Contraception Provided	6	11	53	-	-		-%	-	53	3	3	2
Implant 5 Insertion	2,590	3,293	34,454	27,915	29,200		18%	29,200	63,654	34,454	130,925	147,955
Non-PSI Implant 5 Inserted	2,590	3,293	34,454	27,915	29,200		18%	29,200	63,654	34,454	130,925	147,955
Injectable 3-IM Provided	10	3	186	-	2,423		(92)%	2,423	2,609	47	47	39
Non-PSI Injectable 3 IM Provided	10	3	186	-	2,423		(92)%	2,423	2,609	47	47	39
IUD 10 Insertion	4,258	5,961	68,290	76,440	72,696		(6)%	72,696	140,986	68,290	314,134	340,005
Non-PSI IUD 10 Inserted	4,258	5,961	68,290	76,440	72,696		(6)%	72,696	140,986	68,290	314,134	340,005
IUD 5 Insertion	-	-	-	-	58		(100)%	58	58	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 5 Inserted	-	-	-	-	58		(100)%	58	58	-	-	-
IUS 5 Insertion	-	-	-	-	59		(100)%	59	59	-	-	-
Non-PSI IUS 5 Inserted	-	-	-	-	59		(100)%	59	59	-	-	-
Manual Vacuum Aspiration for PAC	485	742	7,879	5,220	19,176		(59)%	19,176	27,055	7,879	-	6,309
MVA for PAC	485	742	7,879	5,220	19,176		(59)%	19,176	27,055	7,879	-	6,309
Medical Abortion	-	652	2,000	9,000	-		0%	-	2,000	1,800	-	1,689
Combipack	-	-	-	9,000	-		-%	-	-	-	-	-
Mariprist	-	652	2,000	-	-		-%	-	2,000	1,800	-	1,689
Misoprostol for PAC Provided	382	675	7,331	5,220	14,855		(51)%	14,855	22,186	7,331	-	6,952
PSI Misoprostol for PAC Provided	382	675	7,331	5,220	14,855		(51)%	14,855	22,186	7,331	-	6,952
Misoprostol for Safe Abortion	26,472	134,133	1,774,246	2,339,690	2,321,200		(24)%	2,321,200	4,095,446	93,148	-	78,213
Misoclear	28,000	136,833	1,803,570	2,360,570	2,380,620	3/18	(24)%	2,380,620	4,184,190	94,687	-	79,506
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,528)	(2,700)	(29,324)	(20,880)	(59,420)		-%	(59,420)	(88,744)	(1,540)	-	(1,293)
OCs Provided	454	520	5,512	-	1,376		301%	1,376	6,888	367	367	327
Non-PSI OCs Provided	454	520	5,512	-	1,376		301%	1,376	6,888	367	367	327
SDM (Cycle Beads) Provided	4	6	112	-	-		0%	-	112	112	168	204
Non-PSI SDM (Cycle Beads) Provided	4	6	112	-	-		-%	-	112	112	168	204
South Africa											-	737,267
Free Condom	-	-	-	500,000	39,319,200		(100)%	39,319,200	1,084,659,760	-	-	-
Public Distribution	-	-	-	500,000	39,319,200	1/04	(100)%	39,319,200	1,084,659,760	-	-	-
Free Female Condom	-	-	-	-	1,108,500		(100)%	1,108,500	5,030,600	-	-	-
Female Condom GOSA	-	-	-	-	1,108,500	10/13	(100)%	1,108,500	5,030,600	-	-	-
HIV Self-Testing Kit	-	150,688	598,678	1,029,300	1,288,251		(54)%	1,288,251	1,886,929	538,810	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	150,688	598,678	1,029,300	1,288,251		(54)%	1,288,251	1,886,929	538,810	-	-
HIV Testing Services	-	3,145	47,444	63,500	219,862		(78)%	219,862	2,037,445	47,444	-	3,362

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Negative)	-	2,903	39,651	50,000	206,993	12/09	(81)%	206,993	1,869,831	39,651	-	2,810
VCT Individual (HIV-Positive)	-	242	7,793	13,500	12,869	12/09	(39)%	12,869	167,614	7,793	-	552
Referral to HIV Testing Services	-	-	21,265	-	-		0%	-	21,265	21,265	-	754
Referral to HIV Testing Services	-	-	21,265	-	-		-%	-	21,265	21,265	-	754
Referral to Linkage to HIV Care	-	242	5,843	12,150	-		0%	-	5,843	5,843	-	2,767
Referral to Linkage to HIV Care	-	242	5,843	12,150	-		-%	-	5,843	5,843	-	2,767
Voluntary Medical Male Circumcision	16,334	3,934	103,692	90,000	78,885		31%	78,885	255,919	103,692	-	730,384
Voluntary Medical Male Circumcision	16,334	3,934	103,692	90,000	78,885		31%	78,885	255,919	103,692	-	730,384

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Anglophone Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Anglophone Africa Market Group	95,551	23	-	5	4,012,517	4,161	1,661,065	803	144	-	55	40,258
Ethiopia	2,675	13	-	-	106,827	46	30,146	-	119	-	-	781
Ghana	-	-	-	-	174,384	134	62,417	-	2	-	-	863
Lesotho	1,304	-	-	5	14,154	11	4,486	-	-	-	-	77
Malawi	16,037	-	-	-	701,509	1,216	274,013	64	3	-	-	6,616
Namibia	53	-	-	-	1,160	-	326	-	-	-	-	3
PSI Uganda	756	-	-	-	1,681,799	1,626	768,935	-	2	-	1	19,859
Rwanda	4,808	-	-	-	129,188	57	37,689	-	3	-	-	841
Swaziland	13,016	3	-	-	89,885	55	25,304	-	-	-	-	437
Tanzania	2	-	-	-	499,961	549	230,957	739	6	-	-	5,862
Uganda	7,501	-	-	-	144,136	80	40,576	-	-	-	-	1,041
Zambia	6,502	-	-	-	237,004	133	103,469	-	9	-	-	2,630
Zimbabwe	42,896	8	-	-	232,509	255	82,746	-	-	-	54	1,250

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group										4,012,517	7,098,951
Antiretroviral Treatment (Currently Enrolled)	14,751	14,210	163,277	105,390	148,026	10%	148,026	430,536	13,606	-	29,008
Antiretroviral Treatment (Newly Enrolled)	607	685	7,255	4,695	6,634	9%	6,634	30,120	7,255	-	-
Basic Care Package	-	-	-	-	1	(100)%	1	1	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	544	(100)%	544	9,414	-	-	-
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-	-%	-	10	10	-	4
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3	167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Refer to any Treat	1	-	2	-	-	-%	-	13	2	-	-
Cervical Cancer-HPV DNA Screening	333	582	3,346	-	-	-%	-	3,346	3,346	-	-
Cervical Cancer-Pap and Conization	-	-	1,753	-	-	-%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-	-%	-	10	9	-	2
Cervical Cancer-VIA and Conization	11	18	245	290	126	94%	126	549	245	-	88
Cervical Cancer-VIA and Cryotherapy	2	18	1,598	307	639	150%	639	8,078	1,598	-	561
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25	240%	25	396	85	-	15
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	98	(77)%	98	2,057	23	-	4
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	10	(100)%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	1,325	4,178	45,450	88,793	95,922	(53)%	95,922	386,536	45,450	-	-
Chlorhexidine	263	777	6,590	16,755	23,622	(72)%	23,622	43,255	5,931	-	458
Clean Delivery Kit	-	-	-	-	3,449	(100)%	3,449	181,765	-	-	-
Condom	2,463,283	3,785,709	46,603,378	49,703,561	65,266,786	(29)%	65,266,786	1,488,455,193	349,525	349,525	932,948
Emergency Contraception	19,641	11,004	123,300	7,000	180,947	(32)%	180,947	1,186,470	5,549	5,549	2,145
Emergency Contraception Provided	1,578	1,144	91,980	30,493	6,887	1,236%	6,887	100,032	4,599	4,599	2,329

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Expanded Clean Delivery Kit	-	-	-	-	13,160	(100)%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	669	973	11,709	20,285	14,531	(19)%	14,531	26,857	10,538	-	1,713
Female Condom	1,124	13,751	174,851	533,000	469,229	(63)%	469,229	28,559,177	1,311	1,311	5,678
Fever Cases Attended	67,555	25,845	238,868	-	-	-%	-	238,868	238,868	-	-
Fever Cases Tested with RDTs	64,534	24,741	227,984	-	-	-%	-	227,984	227,984	-	-
Free Condom	5,912,539	4,297,117	61,742,141	44,434,784	77,319,731	(20)%	77,319,731	464,059,341	463,066	463,066	1,352,880
Free Female Condom	47,550	367,230	1,398,332	251,000	623,007	124%	623,007	6,280,158	10,487	10,487	31,104
HIV Self-Testing Kit	240,457	27,198	756,647	641,306	996,954	(24)%	996,954	2,123,148	680,982	-	-
HIV Testing Services	18,061	24,893	315,263	518,172	541,424	(42)%	541,424	6,136,279	315,263	-	23,436
Hypertension Diagnosis	1,951	2,141	21,416	-	16,890	27%	16,890	56,821	21,416	-	-
Hypertension Screening	74,748	92,591	917,675	36,477	813,698	13%	813,698	2,570,110	917,675	-	-
Hypertension_Controlled Condition	5	9	105	-	91	15%	91	262	42	-	-
Implant 3	20,120	11,143	74,741	73,620	23,285	221%	23,285	305,501	67,267	168,167	171,357
Implant 3 Insertion	12,604	19,783	217,237	201,554	240,316	(10)%	240,316	869,677	217,237	543,093	515,191
Implant 4	(436)	81	18,459	-	(3,883)	-%	(3,883)	14,576	16,613	53,162	47,669
Implant 4 Insertion	835	1,644	10,829	-	33,884	(68)%	33,884	44,829	10,829	34,653	31,072
Implant 5	4,956	5,823	54,899	26,000	34,917	57%	34,917	450,734	49,409	187,755	180,053
Implant 5 Insertion	8,796	15,523	175,768	175,505	154,215	14%	154,215	677,951	175,768	667,918	601,310
Injectable 1 Provided	-	2	42	36	537	(92)%	537	1,809	3	3	2
Injectable 2 Provided	2,923	2,009	21,725	29,000	22,699	(4)%	22,699	56,068	3,621	3,621	2,453
Injectable 3-IM	16,948	35,134	721,284	605,251	1,798,175	(60)%	1,798,175	8,898,393	162,289	162,289	82,874

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM Provided	21,679	32,953	416,171	357,197	342,639	21%	342,639	1,108,394	104,043	104,043	68,817
Injectable 3-SC	1,959	12,052	91,046	53,892	55,900	63%	55,900	146,946	20,485	20,485	15,188
Injectable 3-SC Provided	11,900	6,214	33,304	-	-	-%	-	33,304	8,326	8,326	6,144
ITN	-	421,834	1,265,503	-	-	-%	-	1,265,503	2,050,115	-	45,033
IUD 10	26,966	17,835	118,862	93,709	111,944	6%	111,944	439,801	106,976	492,089	468,770
IUD 10 Insertion	4,852	10,992	107,088	188,592	220,262	(51)%	220,262	1,228,529	107,088	492,605	435,187
IUD 5	-	(1)	(32)	-	(134)	-%	(134)	(166)	(29)	(95)	(96)
IUD 5 Insertion	-	1	162	-	345	(53)%	345	28,727	162	535	343
IUS 3	(65)	(82)	(379)	-	-	-%	-	(379)	(341)	(853)	(808)
IUS 3 Insertion	65	82	379	-	-	-%	-	379	379	948	898
IUS 5	(8)	(5)	395	(56)	126	213%	126	1,475	356	1,173	1,332
IUS 5 Insertion	8	21	550	756	739	(26)%	739	1,655	550	1,815	1,530
LLIN	1	713	213,151	700,054	4,545,198	(95)%	4,545,198	12,902,398	345,305	-	11,557
Lubricant	245,469	324,724	2,926,726	1,900,761	2,574,286	14%	2,574,286	8,635,021	-	-	-
Manual Vacuum Aspiration for PAC	223	654	6,339	720	7,531	(16)%	7,531	16,860	6,339	-	943
Manual Vacuum Aspiration for SA	35	67	805	-	411	96%	411	2,414	805	-	294
Medical Abortion	711	1,449	10,999	9,331	16,535	(33)%	16,535	27,534	9,899	-	3,468
Medical Abortion (Misoprostol) Provided	21	81	988	-	531	86%	531	1,519	988	-	309
Medical Abortion Provided	25	78	775	-	747	4%	747	2,143	775	-	271
Misoprostol for PAC Provided	125	244	3,078	-	3,631	(15)%	3,631	7,914	3,078	-	623
Misoprostol for Safe Abortion	158,768	131,275	1,553,194	1,993,550	1,659,272	(6)%	1,659,272	8,167,266	81,543	-	17,241

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
OCs	15,301	208,582	1,545,840	2,258,175	2,600,349	(41)%	2,600,349	17,752,358	92,750	92,750	44,612
OCs Provided	29,805	42,815	535,112	357,372	321,499	66%	321,499	1,879,346	35,674	35,674	21,912
Positive RDTs	42,667	17,029	155,419	-	-	-%	-	155,419	155,419	-	-
Positive RDTs Given First Line Treatment	40,275	15,902	144,641	-	-	-%	-	144,641	144,641	-	-
PrEP	3,776	3,791	46,374	35,111	34,437	35%	34,437	83,927	3,864	-	1,470
PUR	294,624	2,424,440	30,213,032	28,273,857	33,931,875	(11)%	33,931,875	234,872,031	248,326	-	857
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17	265%	17	479	62	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67	(100)%	67	67	-	-	-
Referral to Emergency Contraception	-	-	-	1	1	(100)%	1	134	-	-	-
Referral to HIV Testing Services	666	976	34,434	82,130	24,714	39%	24,714	204,242	34,434	-	1,070
Referral to Hypertension Management	13	28	336	-	567	(41)%	567	1,466	336	-	-
Referral to Implant 3 Insertion	-	-	293	1,915	2	14,550%	2	1,441	293	366	309
Referral to Implant 5 Insertion	-	-	11	187	2	450%	2	1,307	11	21	17
Referral to Injectable 1	-	-	-	-	36	(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	887	6,372	75	1,083%	75	4,717	887	111	69
Referral to IUD 10 Insertion	-	-	4	48	5	(20)%	5	352	4	9	7
Referral to Linkage to HIV Care	9,980	13,204	112,751	29,940	24,186	366%	24,186	159,395	112,751	-	91,588
Referral to OCs	-	-	84	665	93	(10)%	93	2,389	84	3	2
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20	(85)%	20	253	3	-	-
Referral to STI Screening (syndromic)	-	-	-	112,000	7	(100)%	7	14,416	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	119	(100)%	119	2,584	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	255	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	2	(100)%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	74	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	5,497	308	(100)%	308	29,857	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3	(100)%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	2	(100)%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	1	(100)%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Mer	-	-	-	336	53	(100)%	53	113	-	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-	-%	-	9	1	-	-
Referral to Tubal Ligation	-	-	-	-	2	(100)%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25	(96)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	10	560	48	(79)%	48	557	10	-	1
Referral to Voluntary Medical Male Circumcision	-	-	3	-	139	(98)%	139	15,555	3	-	10
Safe Water Solution	54,269	78,236	1,052,196	1,915,700	2,248,493	(53)%	2,248,493	74,763,319	789,591	-	2,730
STI Kit (Non-Ulcerative)	-	489	4,732	1,869	6,655	(29)%	6,655	836,263	4,259	-	304
STI Kit (Ulcerative)	-	89	1,588	231	-	-%	-	73,816	1,429	-	305
STI Screening	7,745	8,329	118,274	144,457	75,388	57%	75,388	681,190	118,274	-	-
TB Diagnosis	18	16	231	77	283	(18)%	283	1,708	231	-	-
TB DOTS	3	3	35	77	35	-%	35	136	35	-	284
TB Screening	17,982	19,005	241,495	34,396	225,880	7%	225,880	1,692,520	241,495	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Toilets Sold	2,028	2,929	20,460	25,600	5,651	262%	5,651	26,110	93,379	-	3,607
Toilets Sold - All	2,028	3,968	27,092	-	7,266	273%	7,266	34,358	117,254	-	-
Treatment for Cervicitis	12	20	193	-	73	164%	73	556	193	-	15
Treatment for Genital Herpes	11	27	135	17	28	382%	28	215	135	-	4
Treatment for Inguinal Bubo	1	-	18	-	3	500%	3	35	18	-	-
Treatment for Lower Abdominal Pain	33	62	465	54	78	496%	78	678	465	-	-
Treatment for Nonherpetic Genital Ulcer	40	39	663	94	546	21%	546	1,809	663	-	205
Treatment for Urethral Discharge (Men)	61	67	741	195	292	154%	292	1,643	1,363	-	80
Treatment for Urethral Discharge (Women)	104	107	1,141	2	507	125%	507	2,664	1,141	-	167
Treatment for Vaginitis	22	10	351	380	506	(31)%	506	2,563	351	-	62
Tubal Ligation	667	1,525	10,713	17,589	16,391	(35)%	16,391	46,527	10,713	107,130	84,383
Type 2 Diabetes Diagnosis	-	-	-	-	3	(100)%	3	8	-	-	-
Type 2 Diabetes Screening	87	1,236	22,647	33,797	6,711	237%	6,711	39,237	22,647	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	6	(100)%	6	12	-	-	-
Vasectomy	-	4	17	29	-	-%	-	17	17	170	148
Voluntary Medical Male Circumcision	10,814	21,235	270,203	306,145	345,985	(22)%	345,985	984,225	270,203	-	1,752,110
Water Treatment Tablets	16,800	1,157,540	6,229,910	8,068,408	6,957,142	(10)%	6,957,142	126,574,261	102,409	-	405
Woman Condom	-	-	1,920	-	97,728	(98)%	97,728	141,480	14	14	40

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group											4,012,517	7,098,951
Ethiopia											106,827	165,192
Antiretroviral Treatment (Currently Enrolled)	838	1,037	13,267	18,804	16,938		(22)%	16,938	40,517	1,106	-	2,123
Antiretroviral Treatment (Newly Enrolled)	45	41	521	1,155	1,115		(53)%	1,115	3,091	521	-	-
Free Condom	2,346,080	629,133	14,086,380	11,820,960	23,871,707		(41)%	23,871,707	178,649,825	105,648	105,648	153,969
No Logo Condom	2,346,080	629,133	12,807,680	11,820,960	5,869,000	8/09	118%	5,869,000	22,792,680	96,058	96,058	139,993
Protector Plus	-	-	1,278,700	-	18,002,707	12/12	(93)%	18,002,707	155,857,145	9,590	9,590	13,977
Free Female Condom	500	5,000	89,231	138,000	138,000		(35)%	138,000	988,320	669	669	932
Free Female Condoms	500	5,000	89,231	138,000	138,000	10/13	(35)%	138,000	988,320	669	669	932
HIV Self-Testing Kit	-	293	958	3,000	14,958		(94)%	14,958	15,916	862	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	293	958	3,000	14,958		(94)%	14,958	15,916	862	-	-
HIV Testing Services	3,412	2,763	38,841	31,606	219,864		(82)%	219,864	1,228,055	38,841	-	207
VCT Individual (HIV-Negative)	3,164	2,586	36,820	30,390	213,839	3/13	(83)%	213,839	1,197,906	36,820	-	196
VCT Individual (HIV-Positive)	248	178	2,021	1,216	6,025	3/13	(66)%	6,025	30,149	2,021	-	11
Hypertension Diagnosis	1,931	2,114	21,145	-	16,612		27%	16,612	55,992	21,145	-	-
Hypertension Screening	69,252	83,113	783,040	-	665,905		18%	665,905	1,937,022	783,040	-	-
LLIN	-	-	14	-	-		0%	-	305,347	23	-	1
PermaNet NGO Bag	-	-	14	-	-	9/04	-%	-	305,347	23	-	1
Lubricant	5,100	4,828	20,309	761	62,647		(68)%	62,647	82,956	-	-	-
Lubricant gel 4.5 g	5,100	4,828	20,309	761	62,647		(68)%	62,647	82,956	-	-	-
PrEP	264	273	2,464	-	-		0%	-	2,464	205	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PrEP	264	273	2,464	-	-		-%	-	2,464	205	-	-
PUR	6,600	1,960,187	18,892,846	19,333,057	20,446,684		(8)%	20,446,684	103,605,251	155,284	-	557
P&G Purifier of Water	6,600	1,960,187	18,892,846	19,333,057	20,446,684	11/15	(8)%	20,446,684	103,605,251	155,284	-	557
Referral to Emergency Contraception	-	-	-	1	1		(100)%	1	134	-	-	-
Referral to Emergency Contraception	-	-	-	1	1	2/15	(100)%	1	134	-	-	-
Referral to HIV Testing Services	-	-	-	30,390	9		(100)%	9	119,940	-	-	-
Referral to HIV Testing Services	-	-	-	30,390	9	12/13	(100)%	9	119,940	-	-	-
Referral to Implant 3 Insertion	-	-	293	1,915	-		0%	-	1,430	293	366	309
Referral to Implant 3 Insertion	-	-	293	1,915	-	12/14	-%	-	1,430	293	366	309
Referral to Implant 5 Insertion	-	-	11	187	-		0%	-	315	11	21	17
Referral to Implant 5 Insertion	-	-	11	187	-	12/14	-%	-	315	11	21	17
Referral to Injectable 3	-	-	887	6,372	-		0%	-	3,301	887	111	69
Referral to Injectable 3	-	-	887	6,372	-	1/15	-%	-	3,301	887	111	69
Referral to IUD 10 Insertion	-	-	4	48	-		0%	-	143	4	9	7
Referral to IUD 10 Insertion	-	-	4	48	-	12/14	-%	-	143	4	9	7
Referral to Linkage to HIV Care	213	161	1,780	1,216	33		5294%	33	4,613	1,780	-	905
Referral to Linkage to HIV Care	213	161	1,780	1,216	33		5,294%	33	4,613	1,780	-	905
Referral to OCs	-	-	84	665	-		0%	-	974	84	3	2
Referral to OCs	-	-	84	665	-	1/15	-%	-	974	84	3	2
Referral to STI Screening (syndromic)	-	-	-	112,000	4		(100)%	4	14,311	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	112,000	4		(100)%	4	14,311	-	-	-
Referral to TB Screening	-	-	-	319	4		(100)%	4	13,488	-	-	-
Referrals to TB Screening	-	-	-	319	4		(100)%	4	13,488	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-		0%	-	-	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-	12/14	-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-		0%	-	-	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-	12/14	-%	-	-	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	-		0%	-	-	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	-	12/14	-%	-	-	-	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	-	560	-		0%	-	-	-	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	-	560	-	12/14	-%	-	-	-	-	-
Safe Water Solution	39,855	77,608	659,686	740,700	791,708		(17)%	791,708	25,233,577	542,208	-	1,946
Wuha Agar	39,855	77,608	659,686	740,700	791,708	2/06	(17)%	791,708	25,233,577	542,208	-	1,946
STI Kit (Non-Ulcerative)	-	489	4,732	1,869	6,655		(29)%	6,655	836,263	4,259	-	304
STI kit for Urethral Discharge	-	280	2,542	882	2,397	11/10	6%	2,397	452,641	2,288	-	140
STI Kit for Vaginal Discharge	-	209	2,190	987	4,258	11/10	(49)%	4,258	383,622	1,971	-	165
STI Kit (Ulcerative)	-	89	1,588	231	-		0%	-	73,816	1,429	-	305
STI Kit for Genital Ulcer	-	89	1,588	231	-	11/10	-%	-	73,816	1,429	-	305
STI Screening	3,787	2,289	29,237	112,000	33,336		(12)%	33,336	469,287	29,237	-	-
STI Screening	3,787	2,289	29,237	112,000	33,336		(12)%	33,336	469,287	29,237	-	-
TB Screening	3,885	2,552	33,046	31,910	31,664		4%	31,664	451,788	33,046	-	-
TB Screening	3,885	2,552	33,046	31,910	31,664		4%	31,664	451,788	33,046	-	-
Toilets Sold	2,028	2,813	19,723	25,000	5,471		261%	5,471	25,194	90,726	-	3,536
Toilets Sold	2,028	2,813	19,723	25,000	5,471		261%	5,471	25,194	90,726	-	3,536
Toilets Sold - All	2,028	2,813	19,723	-	5,471		261%	5,471	25,194	90,726	-	-
Toilets Sold - All	2,028	2,813	19,723	-	5,471		261%	5,471	25,194	90,726	-	-
Treatment for Inguinal Bubo	-	-	1	-	-		0%	-	1	1	-	-
Treatment for Inguinal Bubo	-	-	1	-	-		-%	-	1	1	-	-
Treatment for Lower Abdominal Pain	-	1	3	-	4		(25)%	4	70	3	-	-
Treatment for Lower Abdominal Pain	-	1	3	-	4		(25)%	4	70	3	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Nonherpetic Genital Ulcer	-	-	8	-	16		(50)%	16	79	8	-	1
Treatment for Nonherpetic Genital Ulcer	-	-	8	-	16		(50)%	16	79	8	-	1
Treatment for Urethral Discharge (Men)	3	2	21	-	5		320%	5	166	42	-	-
Treatment for Urethral Discharge (Men)	3	2	21	-	5		320%	5	166	42	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	12		(100)%	12	76	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	12		(100)%	12	76	-	-	-
Treatment for Vaginitis	12	9	117	-	116		1%	116	1,352	117	-	2
Treatment for Vaginitis	12	9	117	-	116		1%	116	1,352	117	-	2
Ghana											174,384	69,948
Condom	-	-	-	412,211	14,700		(100)%	14,700	799,268	-	-	-
Protector	-	-	-	412,211	14,700		(100)%	14,700	799,268	-	-	-
Injectable 3-IM	-	7,400	455,554	495,534	1,376,081		(67)%	1,376,081	3,596,197	102,500	102,500	40,152
Famplan	-	7,400	455,554	495,534	1,376,481		(67)%	1,376,481	3,596,597	102,500	102,500	40,152
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	(400)		-%	(400)	(400)	-	-	-
Injectable 3-IM Provided	-	-	-	-	400		(100)%	400	400	-	-	-
PSI Injectable 3 IM Provided	-	-	-	-	400		(100)%	400	400	-	-	-
OCs	-	154,980	1,198,080	2,068,038	1,969,134		(39)%	1,969,134	5,590,439	71,885	71,885	29,706
(b)PSI OCs Distributed Provided	-	-	-	-	(66)		-%	(66)	(66)	-	-	-
Secure	-	154,980	1,198,080	2,068,038	1,969,200		(39)%	1,969,200	5,590,505	71,885	71,885	29,706
OCs Provided	-	-	-	-	66		(100)%	66	66	-	-	-
PSI OCs Provided	-	-	-	-	66		(100)%	66	66	-	-	-
Toilets Sold	-	115	737	600	180		311%	180	916	2,653	-	72
Toilets Sold	-	115	737	600	180		311%	180	916	2,653	-	72
Toilets Sold - All	-	1,154	7,369	-	1,795		311%	1,795	9,164	26,528	-	-
Toilets Sold - All	-	1,154	7,369	-	1,795		311%	1,795	9,164	26,528	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Water Treatment Tablets	-	19,067	461,800	1,066,668	844,900		(45)%	844,900	1,400,100	7,591	-	18
Aquatabs 67 mg (20 L)	-	19,067	461,800	1,066,668	844,900	7/17	(45)%	844,900	1,400,100	7,591	-	18
Lesotho											14,154	59,567
Antiretroviral Treatment (Currently Enrolled)	1,369	1,361	16,092	1,443	18,922		(15)%	18,922	54,571	1,341	-	3,046
Antiretroviral Treatment (Currently Enrolled)	1,369	1,361	16,092	1,443	18,922		(15)%	18,922	54,571	1,341	-	3,046
Antiretroviral Treatment (Newly Enrolled)	5	9	97	169	110		(12)%	110	325	97	-	-
Antiretroviral Treatment (Newly Enrolled)	5	9	97	169	110		(12)%	110	325	97	-	-
Emergency Contraception Provided	15	25	178	25	20		790%	20	349	9	9	3
Non-PSI Emergency Contraception Provided	15	25	178	25	20		790%	20	349	9	9	3
Female Condom	120	206	1,606	3,000	96,546		(98)%	96,546	2,512,688	12	12	46
Generic	120	206	1,606	3,000	96,546	1/08	(98)%	96,546	2,512,688	12	12	46
Free Condom	36,136	118,959	976,636	193,872	13,845,256		(93)%	13,845,256	33,185,018	7,325	7,325	28,420
Camouflage Free	-	-	56,900	13,872	747,700	1/16	(92)%	747,700	3,015,000	427	427	1,656
Vibe Condom	36,136	118,959	919,736	180,000	13,097,556	9/14	(93)%	13,097,556	30,170,018	6,898	6,898	26,764
HIV Self-Testing Kit	16,878	17,762	119,625	111,335	56,275		113%	56,275	175,900	107,663	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	16,878	17,762	119,625	111,335	56,275		113%	56,275	175,900	107,663	-	-
HIV Testing Services	6,672	7,672	114,646	137,092	158,712		(28)%	158,712	1,217,407	114,646	-	12,011
VCT Individual (HIV-Negative)	6,170	7,157	108,695	129,331	153,406	12/09	(29)%	153,406	1,145,877	108,695	-	11,387
VCT Individual (HIV-Positive)	502	515	5,951	7,761	5,306	12/09	12%	5,306	71,530	5,951	-	623
Hypertension Screening	6	49	743	4,020	2,494		(70)%	2,494	14,439	743	-	-
Hypertension Screening	6	49	743	4,020	2,494		(70)%	2,494	14,439	743	-	-
Implant 3 Insertion	-	-	10	10	6		67%	6	850	10	25	15
Non-PSI Implant 3 Inserted	-	-	10	10	6		67%	6	850	10	25	15
Implant 5 Insertion	-	-	8	20	12		(33)%	12	135	8	30	18
Non-PSI Implant 5 Inserted	-	-	8	20	12		(33)%	12	135	8	30	18

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	-	-	1	-	-		0%	-	9	-	-	-
Non-PSI Injectable 1 Provided	-	-	1	-	-		-%	-	9	-	-	-
Injectable 2 Provided	1,324	719	4,767	1,000	2,864		66%	2,864	9,689	795	795	359
Non-PSI Injectable 2 Provided	1,324	719	4,767	1,000	2,864		66%	2,864	9,689	795	795	359
Injectable 3-IM Provided	554	1,667	17,973	19,508	12,574		43%	12,574	42,682	4,493	4,493	2,030
Non-PSI Injectable 3 IM Provided	554	1,667	17,973	19,508	12,574		43%	12,574	42,682	4,493	4,493	2,030
OCs Provided	764	1,111	21,974	20,147	17,197		28%	17,197	66,229	1,465	1,465	698
Non-PSI OCs Provided	764	1,111	21,974	20,147	17,197		28%	17,197	66,229	1,465	1,465	698
PrEP	71	68	688	84	14		4814%	14	702	57	-	57
PrEP	71	68	688	84	14		4,814%	14	702	57	-	57
Referral to HIV Testing Services	-	-	-	1,740	1,299		(100)%	1,299	26,462	-	-	-
Referral to HIV Testing Services	-	-	-	1,740	1,299	3/16	(100)%	1,299	26,462	-	-	-
Referral to Linkage to HIV Care	297	365	4,257	6,985	3,328		28%	3,328	15,005	4,257	-	2,559
Referral to Linkage to HIV Care	297	365	4,257	6,985	3,328		28%	3,328	15,005	4,257	-	2,559
TB Diagnosis	4	1	33	77	41		(20)%	41	119	33	-	-
TB Diagnosis	4	1	33	77	41		(20)%	41	119	33	-	-
TB DOTS	3	3	35	77	31		13%	31	82	35	-	284
TB DOTS	3	3	35	77	31		13%	31	82	35	-	284
TB Screening	1,394	1,409	19,017	1,443	21,329		(11)%	21,329	47,045	19,017	-	-
TB Screening	1,394	1,409	19,017	1,443	21,329		(11)%	21,329	47,045	19,017	-	-
Type 2 Diabetes Screening	-	1	30	1,340	395		(92)%	395	3,969	30	-	-
Type 2 Diabetes Screening	-	1	30	1,340	395		(92)%	395	3,969	30	-	-
Voluntary Medical Male Circumcision	107	175	767	500	2,962		(74)%	2,962	4,398	767	-	10,020
Voluntary Medical Male Circumcision	107	175	767	500	2,962		(74)%	2,962	4,398	767	-	10,020
Malawi											701,509	1,161,833

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA/VILI Screening	1,060	1,798	14,788	10,000	19,630		(25)%	19,630	34,418	14,788	-	-
Cervical Cancer-VIA/VILI Screening	1,060	1,798	14,788	10,000	19,630		(25)%	19,630	34,418	14,788	-	-
Condom	498,528	1,043,016	13,907,980	12,000,000	17,252,824		(19)%	17,252,824	239,372,906	104,310	104,310	285,883
Chishango	498,528	1,043,016	13,907,980	12,000,000	17,252,824	10/94	(19)%	17,252,824	239,372,906	104,310	104,310	285,883
Emergency Contraception	4,318	5,990	51,274	7,000	11,120		361%	11,120	159,614	2,307	2,307	1,171
Levonorgestrel Tablet 0.75 mg x 2's	5,840	7,030	141,636	-	1,545		9,067%	1,545	143,181	6,374	6,374	3,233
NORLEVO (Norlevo 1.5mg)	-	-	-	35,000	13,994	2/14	(100)%	13,994	111,455	-	-	-
(b)PSI Emergency Contraception Distributed Provided	(1,522)	(1,040)	(90,362)	(28,000)	(4,419)		-%	(4,419)	(95,022)	(4,066)	(4,066)	(2,063)
Emergency Contraception Provided	1,523	1,067	90,453	28,000	4,419		1947%	4,419	95,113	4,523	4,523	2,294
Non-PSI Emergency Contraception Provided	1	27	91	-	-		-%	-	91	5	5	2
PSI Emergency Contraception Provided	1,522	1,040	90,362	28,000	4,419		1,945%	4,419	95,022	4,518	4,518	2,292
Female Condom	4	878	78,045	90,000	86,203		(9)%	86,203	870,528	585	585	1,563
Care	4	878	78,045	90,000	86,203	1/08	(9)%	86,203	870,528	585	585	1,563
Free Condom	710,128	1,315,220	15,496,066	11,069,952	10,466,262		48%	10,466,262	45,075,945	116,220	116,220	318,526
Blue Gold Condoms	-	-	-	-	590,724	8/17	(100)%	590,724	1,856,634	-	-	-
Free Male Condoms	-	41,564	1,000,080	-	-	2/14	-%	-	2,659,852	7,501	7,501	20,557
Generic Male Condom	-	-	-	395,000	-		-%	-	-	-	-	-
Key Population Male Condom	710,128	1,273,656	14,495,986	10,000,000	9,131,741	7/16	59%	9,131,741	34,764,859	108,720	108,720	297,969
One Community Male Condom	-	-	-	-	743,797	7/16	(100)%	743,797	5,247,751	-	-	-
VMMC Male Condom	-	-	-	674,952	-	1/15	-%	-	546,849	-	-	-
Free Female Condom	2,800	6,224	51,483	-	151,992		(66)%	151,992	459,324	386	386	1,031
Free Female Condoms	2,800	6,224	51,483	-	68,719	2/14	(25)%	68,719	359,389	386	386	1,031
Key Population Female Condom	-	-	-	-	83,273	12/17	(100)%	83,273	99,935	-	-	-
HIV Self-Testing Kit	750	2,063	178,804	173,086	258,868		(31)%	258,868	526,669	160,924	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
INSTI HIVST (Blood based)	750	2,062	9,376	-	-		-%	-	9,376	8,438	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	1	169,078	173,086	258,868	8/17	(35)%	258,868	516,943	152,170	-	-
Sure Check HIV Self-Test	-	-	350	-	-		-%	-	350	315	-	-
HIV Testing Services	4,164	7,556	76,528	35,408	76,101		1%	76,101	318,477	76,528	-	3,255
VCT Individual (HIV-Negative)	4,023	7,328	74,351	34,571	72,736	12/14	2%	72,736	309,891	74,351	-	3,163
VCT Individual (HIV-Positive)	141	227	2,177	837	3,365	12/14	(35)%	3,365	8,586	2,177	-	93
Implant 3	(1,093)	(462)	(2,609)	1,000	(11,432)		0%	(11,432)	4,073	(2,348)	(5,870)	(5,333)
Implanon	-	-	-	1,000	18,883	10/12	(100)%	18,883	84,144	-	-	-
Implanon NXT	121	1,617	23,465	-	2,901		709%	2,901	26,366	21,119	52,796	47,962
(b)PSI Implant 3 Distributed Inserted	(1,214)	(2,079)	(26,074)	-	(33,216)		-%	(33,216)	(106,437)	(23,467)	(58,667)	(53,295)
Implant 3 Insertion	2,252	3,346	33,105	49,000	33,272		(1)%	33,272	113,524	33,105	82,763	75,185
Non-PSI Implant 3 Inserted	1,038	1,267	7,031	49,000	56		12,455%	56	7,087	7,031	17,578	15,968
PSI Implant 3 Inserted	1,214	2,079	26,074	-	33,216		(22)%	33,216	106,437	26,074	65,185	59,217
Implant 4	(436)	81	18,459	-	(3,883)		0%	(3,883)	14,576	16,613	53,162	47,669
Levonplant	250	513	25,503	-	30,000		(15)%	30,000	55,503	22,953	73,449	65,859
(b)PSI Implant 4 Distributed Inserted	(686)	(432)	(7,044)	-	(33,883)		-%	(33,883)	(40,927)	(6,340)	(20,287)	(18,191)
Implant 4 Insertion	835	1,644	10,829	-	33,883		(68)%	33,883	44,712	10,829	34,653	31,072
Non-PSI Implant 4 Inserted	149	1,212	3,785	-	-		-%	-	3,785	3,785	12,112	10,861
PSI Implant 4 Inserted	686	432	7,044	-	33,883		(79)%	33,883	40,927	7,044	22,541	20,212
Implant 5	(1,211)	(154)	1,106	1,000	(9,003)		0%	(9,003)	11,677	995	3,783	3,387
Jadelle	180	2,203	25,456	1,000	27,995	10/12	(9)%	27,995	146,846	22,910	87,060	77,949
(b)PSI Implant 5 Distributed Inserted	(1,391)	(2,357)	(24,350)	-	(36,998)	3/16	-%	(36,998)	(135,169)	(21,915)	(83,277)	(74,563)
Implant 5 Insertion	1,971	3,377	29,893	55,000	37,102		(19)%	37,102	140,816	29,893	113,593	101,707
Non-PSI Implant 5 Inserted	580	1,020	5,543	55,000	104		5,230%	104	5,647	5,543	21,063	18,859

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Implant 5 Inserted	1,391	2,357	24,350	-	36,998	3/16	(34)%	36,998	135,169	24,350	92,530	82,847
Injectable 3-IM	(2,698)	5,215	79,713	35,000	60,576		32%	60,576	1,908,550	17,935	17,935	11,942
Depo-Provera	4,934	12,487	165,251	-	9,721		1,600%	9,721	174,972	37,181	37,181	24,758
(b)PSI Injectable 3 IM Distributed Provided	(7,632)	(7,272)	(85,538)	-	(66,440)		-%	(66,440)	(159,318)	(19,246)	(19,246)	(12,815)
SafePlan Inj3	-	-	-	35,000	117,295	1/08	(100)%	117,295	1,892,896	-	-	-
Injectable 3-IM Provided	8,973	10,172	96,789	84,000	67,465		43%	67,465	171,594	24,197	24,197	16,112
Non-PSI Injectable 3 IM Provided	1,341	2,900	11,251	84,000	1,025		998%	1,025	12,276	2,813	2,813	1,873
PSI Injectable 3 IM Provided	7,632	7,272	85,538	-	66,440		29%	66,440	159,318	21,385	21,385	14,239
Injectable 3-SC	(141)	648	3,446	-	-		0%	-	3,446	775	775	516
(b)PSI Injectable 3 SC Distributed Provided	(509)	(85)	(775)	-	-		-%	-	(775)	(174)	(174)	(116)
Sayana Press	368	733	4,221	-	-		-%	-	4,221	950	950	632
Injectable 3-SC Provided	934	106	1,263	-	-		0%	-	1,263	316	316	210
Non-PSI Injectable 3 SC Provided	425	21	488	-	-		-%	-	488	122	122	81
PSI Injectable 3 SC Provided	509	85	775	-	-		-%	-	775	194	194	129
ITN	-	1,603	4,808	-	-		0%	-	4,808	7,789	-	212
PBO Net	-	1,603	4,808	-	-		-%	-	4,808	7,789	-	212
IUD 10	77	60	1,587	500	(818)		0%	(818)	6,839	1,428	6,570	5,644
IUD Copper T 380A	250	266	5,025	500	5,154	10/12	(3)%	5,154	22,174	4,523	20,803	17,872
(b)PSI IUD 10 Distributed Inserted	(173)	(206)	(3,438)	-	(5,972)	3/16	-%	(5,972)	(15,335)	(3,094)	(14,233)	(12,228)
IUD 10 Insertion	308	459	4,375	5,136	5,972		(27)%	5,972	16,272	4,375	20,125	17,290
Non-PSI IUD 10 Inserted	135	253	937	5,136	-		-%	-	937	937	4,310	3,703
PSI IUD 10 Inserted	173	206	3,438	-	5,972	3/16	(42)%	5,972	15,335	3,438	15,815	13,587
LLIN	1	713	68,507	45,000	34,209		100%	34,209	500,550	110,981	-	4,290
Super Chitetezo Net	1	713	68,507	45,000	34,209	2/11	100%	34,209	500,550	110,981	-	4,290

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Lubricant	154,369	159,910	1,549,435	1,300,000	1,071,889		45%	1,071,889	4,627,783	-	-	-
Personal Lubricant Water 4.5 g	154,369	159,910	1,549,435	1,300,000	1,071,889	12/12	45%	1,071,889	4,627,783	-	-	-
OCs	(104)	14,143	125,327	65,000	164,930		(24)%	164,930	942,285	7,520	7,520	5,282
Microgynon	-	2,607	36,996	-	150,604	11/11	(75)%	150,604	842,736	2,220	2,220	1,559
Microgynon combination 3	2,633	15,419	210,866	65,000	13,640		1,446%	13,640	224,506	12,652	12,652	8,887
Microlut	-	-	-	-	47,803	8/17	(100)%	47,803	58,879	-	-	-
(b)PSI OCs Distributed Provided	(2,737)	(3,883)	(122,535)	-	(47,117)		-%	(47,117)	(183,836)	(7,352)	(7,352)	(5,164)
OCs Provided	3,850	6,716	137,790	35,000	58,051		137%	58,051	210,025	9,186	9,186	6,453
Non-PSI OCs Provided	1,113	2,832	15,255	35,000	10,934		40%	10,934	26,189	1,017	1,017	714
PSI OCs Provided	2,737	3,883	122,535	-	47,117		160%	47,117	183,836	8,169	8,169	5,738
PUR	-	-	6,811,200	4,540,800	5,781,185		18%	5,781,185	66,919,640	55,982	-	170
PuR WaterGuard Waufa	-	-	6,811,200	4,540,800	5,781,185	3/06	18%	5,781,185	66,919,640	55,982	-	170
Safe Water Solution	-	-	716	-	143,085		(99)%	143,085	8,496,271	588	-	2
WaterGuard	-	-	716	-	143,085	12/02	(99)%	143,085	8,496,271	588	-	2
STI Screening	245	413	3,162	-	2,620		21%	2,620	5,782	3,162	-	-
STI Screening	245	413	3,162	-	2,620		21%	2,620	5,782	3,162	-	-
Treatment for Cervicitis	2	9	34	-	-		0%	-	34	34	-	-
Treatment for Cervicitis	2	9	34	-	-		-%	-	34	34	-	-
Treatment for Genital Herpes	1	1	7	-	-		0%	-	7	7	-	-
Treatment for Genital Herpes	1	1	7	-	-		-%	-	7	7	-	-
Treatment for Lower Abdominal Pain	32	58	368	-	-		0%	-	368	368	-	-
Treatment for Lower Abdominal Pain	32	58	368	-	-		-%	-	368	368	-	-
Treatment for Nonherpetic Genital Ulcer	3	7	91	-	-		0%	-	91	91	-	-
Treatment for Nonherpetic Genital Ulcer	3	7	91	-	-		-%	-	91	91	-	-
Treatment for Urethral Discharge (Men)	14	16	119	-	-		0%	-	119	119	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Men)	14	16	119	-	-		-%	-	119	119	-	-
Treatment for Urethral Discharge (Women)	26	32	235	-	-		0%	-	235	235	-	-
Treatment for Urethral Discharge (Women)	26	32	235	-	-		-%	-	235	235	-	-
Treatment for Vaginitis	10	-	10	-	-		0%	-	10	10	-	-
Treatment for Vaginitis	10	-	10	-	-		-%	-	10	10	-	-
Tubal Ligation	666	1,486	10,447	17,281	16,027		(35)%	16,027	45,613	10,447	104,470	82,084
Tubal Ligation	666	1,486	10,447	17,281	16,027	1/15	(35)%	16,027	45,613	10,447	104,470	82,084
Voluntary Medical Male Circumcision	926	3,457	40,008	56,645	53,033		(25)%	53,033	133,468	40,008	-	144,214
Voluntary Medical Male Circumcision	926	3,457	40,008	56,645	53,033		(25)%	53,033	133,468	40,008	-	144,214
Namibia											1,160	2,252
Free Condom	-	18,937	151,681	-	-		0%	-	16,697,726	1,138	1,138	2,209
Smile	-	18,937	151,681	-	-	1/08	-%	-	16,697,726	1,138	1,138	2,209
Free Female Condom	-	299	3,005	-	-		0%	-	513,071	23	23	43
Femidom Free	-	299	3,005	-	-	2/07	-%	-	513,071	23	23	43
HIV Self-Testing Kit	-	753	17,384	-	-		0%	-	17,384	15,646	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	753	17,384	-	-	1/18	-%	-	17,384	15,646	-	-
Lubricant	-	21,686	140,982	-	-		0%	-	140,982	-	-	-
Personal Lubricant 4.5 g	-	21,686	140,982	-	-	1/18	-%	-	140,982	-	-	-
PSI Uganda											1,681,799	1,675,134
Basic Care Package	-	-	-	-	1		(100)%	1	1	-	-	-
PLP Kit - NFB (with WaterGuard Tab)	-	-	-	-	1		(100)%	1	1	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	6	74	-	150		(51)%	150	224	74	-	28
Cervical Cancer-VIA and Cryotherapy	-	6	74	-	150		(51)%	150	224	74	-	28
Cervical Cancer-VIA/VILI Screening	-	1,517	15,275	60,000	38,866		(61)%	38,866	54,141	15,275	-	-
Cervical Cancer-VIA/VILI Screening	-	1,517	15,275	60,000	38,866		(61)%	38,866	54,141	15,275	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Chlorhexidine	263	777	6,590	16,755	23,211		(72)%	23,211	29,801	5,931	-	458
Chlorhexidine Gel, 5 g tube	263	777	6,590	16,755	23,211		(72)%	23,211	29,801	5,931	-	458
Clean Delivery Kit	-	-	-	-	2,840		(100)%	2,840	2,840	-	-	-
Maama Kit	-	-	-	-	572		(100)%	572	572	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	2,268		(100)%	2,268	2,268	-	-	-
Condom	447,192	155,856	2,446,488	2,633,850	1,604,736		52%	1,604,736	4,051,224	18,349	18,349	42,753
Trust	115,776	39,168	737,424	675,000	630,504		17%	630,504	1,367,928	5,531	5,531	12,887
Trust Ribbed	117,288	42,144	592,632	665,550	87,408		578%	87,408	680,040	4,445	4,445	10,356
Trust Scented	100,008	36,240	566,496	652,050	349,272		62%	349,272	915,768	4,249	4,249	9,900
Trust Studded	114,120	38,304	549,936	641,250	537,552		2%	537,552	1,087,488	4,125	4,125	9,610
Emergency Contraception	-	(6)	(60)	-	(107)		0%	(107)	(167)	(3)	(3)	(2)
(b)PSI Emergency Contraception Distributed Provided	-	(6)	(60)	-	(107)		-%	(107)	(167)	(3)	(3)	(2)
Emergency Contraception Provided	-	13	102	-	109		(6)%	109	211	5	5	3
Non-PSI Emergency Contraception Provided	-	7	42	-	2		2,000%	2	44	2	2	1
PSI Emergency Contraception Provided	-	6	60	-	107		(44)%	107	167	3	3	2
Expanded Clean Delivery Kit	-	-	-	-	13,160		(100)%	13,160	13,160	-	-	-
Mama Kit Expanded(Chlorhexidine 400gm&Misoprostol)	-	-	-	-	13,160		(100)%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	669	973	11,709	20,285	13,837		(15)%	13,837	25,546	10,538	-	1,713
Mama Kit with Chlorhexidine	669	973	11,709	20,285	13,837		(15)%	13,837	25,546	10,538	-	1,713
Free Condom	-	-	-	-	576,000		(100)%	576,000	576,000	-	-	-
Generic Male Condom	-	-	-	-	576,000		(100)%	576,000	576,000	-	-	-
Implant 3	21,213	11,606	77,791	72,620	34,268		127%	34,268	112,059	70,012	175,030	177,226
Implanon	8,446	7,355	63,640	92,900	55,110		15%	55,110	118,750	57,276	143,190	144,987
Levonplant	12,957	6,483	34,207	-	-		-%	-	34,207	30,786	76,966	77,931

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Implant 3 Distributed Inserted	(190)	(2,232)	(20,056)	(20,280)	(20,842)		-%	(20,842)	(40,898)	(18,050)	(45,126)	(45,692)
Implant 3 Insertion	8,414	10,312	114,111	100,280	99,913		14%	99,913	214,024	114,111	285,278	288,857
Non-PSI Implant 3 Inserted	8,224	8,080	94,055	80,000	79,071		19%	79,071	173,126	94,055	235,138	238,088
PSI Implant 3 Inserted	190	2,232	20,056	20,280	20,842		(4)%	20,842	40,898	20,056	50,140	50,769
Implant 5	4,509	4,523	49,558	25,000	41,363		20%	41,363	90,921	44,602	169,488	168,680
Jadelle	4,580	5,600	59,210	40,000	53,160		11%	53,160	112,370	53,289	202,498	201,532
(b)PSI Implant 5 Distributed Inserted	(71)	(1,077)	(9,652)	(15,000)	(11,797)		-%	(11,797)	(21,449)	(8,687)	(33,010)	(32,852)
Implant 5 Insertion	3,095	4,311	57,179	45,160	33,335		72%	33,335	90,514	57,179	217,280	216,244
Non-PSI Implant 5 Inserted	3,024	3,234	47,527	30,160	21,538		121%	21,538	69,065	47,527	180,603	179,741
PSI Implant 5 Inserted	71	1,077	9,652	15,000	11,797		(18)%	11,797	21,449	9,652	36,678	36,503
Injectable 3-IM	19,196	22,557	162,766	48,097	59,649		173%	59,649	222,415	36,622	36,622	27,261
Depo-Provera	19,450	25,192	187,350	68,097	82,175		128%	82,175	269,525	42,154	42,154	31,378
(b)PSI Injectable 3 IM Distributed Provided	(254)	(2,634)	(24,584)	(20,000)	(22,526)		-%	(22,526)	(47,110)	(5,531)	(5,531)	(4,117)
Injectable 3-IM Provided	263	2,683	25,418	21,700	24,298		5%	24,298	49,716	6,355	6,355	4,730
Non-PSI Injectable 3 IM Provided	9	49	834	1,700	1,772		(53)%	1,772	2,606	209	209	155
PSI Injectable 3 IM Provided	254	2,634	24,584	20,000	22,526		9%	22,526	47,110	6,146	6,146	4,575
Injectable 3-SC	2,100	11,404	87,600	53,892	55,900		57%	55,900	143,500	19,710	19,710	14,672
Sayana Press	2,100	11,404	87,600	53,892	55,900		57%	55,900	143,500	19,710	19,710	14,672
IUD 10	25,588	17,399	117,001	90,759	112,806		4%	112,806	229,807	105,301	484,384	460,982
Copper T 380	24,000	13,685	107,755	87,000	110,545		(3)%	110,545	218,300	96,980	446,106	424,553
IUD PACK CU T380A	1,933	6,524	30,334	60,000	43,587		(30)%	43,587	73,921	27,301	125,583	119,515
PPIUD Cu T380A	-	78	2,025	1,359	2,675		(24)%	2,675	4,700	1,823	8,383	7,978
(b)PSI IUD 10 Distributed Inserted	(345)	(2,888)	(23,113)	(57,600)	(44,001)		-%	(44,001)	(67,114)	(20,802)	(95,688)	(91,065)
IUD 10 Insertion	2,838	6,409	57,538	112,680	89,907		(36)%	89,907	147,445	57,538	264,675	251,887

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 10 Inserted	2,493	3,520	34,425	55,080	45,906		(25)%	45,906	80,331	34,425	158,355	150,704
PSI IUD 10 Inserted	345	2,888	23,113	57,600	44,001		(47)%	44,001	67,114	23,113	106,320	101,183
IUD 5	-	(1)	(32)	-	(134)		0%	(134)	(166)	(29)	(95)	(96)
(b)PSI IUD 5 Distributed Inserted	-	(1)	(32)	-	(134)		-%	(134)	(166)	(29)	(95)	(96)
IUD 5 Insertion	-	1	34	-	135		(75)%	135	169	34	112	114
Non-PSI IUD 5 Inserted	-	-	2	-	1		100%	1	3	2	7	7
PSI IUD 5 Inserted	-	1	32	-	134		(76)%	134	166	32	106	107
Manual Vacuum Aspiration for PAC	9	66	861	720	469		84%	469	1,330	861	-	253
MVA for PAC	9	66	861	720	469		84%	469	1,330	861	-	253
Manual Vacuum Aspiration for SA	35	67	805	-	261		208%	261	1,066	805	-	294
Manual Vacuum Aspiration for SA	35	67	805	-	261		208%	261	1,066	805	-	294
Medical Abortion	711	1,449	10,999	9,331	16,535		(33)%	16,535	27,534	9,899	-	3,468
Divabo - Combipack (1+4's)	736	1,528	11,774	9,331	16,804		(30)%	16,804	28,578	10,597	-	3,712
(b)PSI Medical Abortion Distributed Provided	(25)	(78)	(775)	-	(269)		-%	(269)	(1,044)	(698)	-	(244)
Medical Abortion (Misoprostol) Provided	21	81	988	-	344		187%	344	1,332	988	-	309
PSI Medical Abortion (Misoprostol) Provided	21	81	988	-	344		187%	344	1,332	988	-	309
Medical Abortion Provided	25	78	775	-	269		188%	269	1,044	775	-	271
PSI Medical Abortion Provided	25	78	775	-	269		188%	269	1,044	775	-	271
Misoprostol for PAC Provided	5	48	858	-	586		46%	586	1,444	858	-	294
PSI Misoprostol for PAC Provided	5	48	858	-	586		46%	586	1,444	858	-	294
Misoprostol for Safe Abortion	96,528	66,831	668,042	893,550	452,048		48%	452,048	1,120,090	35,072	-	10,957
Misoprostol 200 mcg Tablet	96,800	68,000	521,230	-	-		-%	-	521,230	27,365	-	8,549
Misoprostol for Safe Abortion	-	-	162,100	893,550	458,520		(65)%	458,520	620,620	8,510	-	2,659
(b)PSI Misoprostol for Safe Abortion Dist Provided	(272)	(1,169)	(15,288)	-	(6,472)		-%	(6,472)	(21,760)	(803)	-	(251)
OCs	8,205	5,400	63,013	45,277	43,581		45%	43,581	106,594	3,781	3,781	2,969

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Combination 3	-	167	3,100	-	7,900		(61)%	7,900	11,000	186	186	146
Family Planning Pills	-	-	-	26,280	28,590		(100)%	28,590	28,590	-	-	-
Microlut - Oral Contraceptive	1,332	1,614	8,096	2,000	699		1,058%	699	8,795	486	486	381
(b)PSI OCs Distributed Provided	(16)	(321)	(2,682)	(3,003)	(2,890)		-%	(2,890)	(5,572)	(161)	(161)	(126)
Zinnia	6,889	3,940	54,499	20,000	9,282		487%	9,282	63,781	3,270	3,270	2,568
OCs Provided	16	331	2,821	3,103	3,066		(8)%	3,066	5,887	188	188	148
Non-PSI OCs Provided	-	10	139	100	176		(21)%	176	315	9	9	7
PSI OCs Provided	16	321	2,682	3,003	2,890		(7)%	2,890	5,572	179	179	140
PUR	288,000	304,080	3,387,421	3,400,000	6,413,745		(47)%	6,413,745	9,801,166	27,842	-	111
PuR	288,000	304,080	3,387,421	3,400,000	6,413,745		(47)%	6,413,745	9,801,166	27,842	-	111
Referral to HIV Testing Services	-	-	-	-	11,703		(100)%	11,703	11,703	-	-	-
Referral to HIV Testing Services	-	-	-	-	11,703		(100)%	11,703	11,703	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	4,614		(100)%	4,614	4,614	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	4,614		(100)%	4,614	4,614	-	-	-
Tubal Ligation	-	2	47	-	46		2%	46	93	47	470	404
Tubal Ligation	-	2	47	-	46		2%	46	93	47	470	404
Vasectomy	-	4	17	-	-		0%	-	17	17	170	148
Vasectomy	-	4	17	-	-		-%	-	17	17	170	148
Rwanda											129,188	253,361
Condom	729,268	1,504,655	15,062,917	16,437,500	13,673,659		10%	13,673,659	215,967,803	112,972	112,972	242,349
Plaisir	239,049	280,660	3,300,189	2,000,000	1,688,521	2/13	95%	1,688,521	19,880,209	24,751	24,751	53,097
Prudence Plus	490,219	1,223,995	11,762,728	14,437,500	11,985,138	2/13	(2)%	11,985,138	196,087,594	88,220	88,220	189,252
Free Condom	131	40	386	-	22,662		(98)%	22,662	2,390,794	3	3	6
Military Condom	131	40	386	-	22,662	4/14	(98)%	22,662	2,390,794	3	3	6

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM	450	-	26,582	26,620	42,020		(37)%	42,020	108,194	5,981	5,981	3,850
Confiance Depo-Provera	450	-	26,582	26,620	42,020	2/13	(37)%	42,020	108,194	5,981	5,981	3,850
OCs	7,200	34,170	170,539	79,860	170,171		0%	170,171	537,342	10,232	10,232	6,948
Microgynon	7,200	34,170	170,539	79,860	170,171	6/15	-%	170,171	537,342	10,232	10,232	6,948
PUR	24	160,173	1,121,565	1,000,000	1,286,421		(13)%	1,286,421	13,982,194	9,218	-	19
PuR	24	160,173	1,121,565	1,000,000	1,286,421	2/13	(13)%	1,286,421	13,982,194	9,218	-	19
Safe Water Solution	14,414	596	114,438	275,000	250,823		(54)%	250,823	4,180,021	94,059	-	190
Sur Eau	14,414	596	114,438	275,000	250,823	2/13	(54)%	250,823	4,180,021	94,059	-	190
Swaziland											89,885	564,666
Antiretroviral Treatment (Currently Enrolled)	1,715	1,561	15,930	19,040	9,037		76%	9,037	26,840	1,327	-	3,277
Antiretroviral Treatment (Currently Enrolled)	1,715	1,561	15,930	19,040	9,037		76%	9,037	26,840	1,327	-	3,277
Antiretroviral Treatment (Newly Enrolled)	27	55	728	359	593		23%	593	1,890	728	-	-
Antiretroviral Treatment (Newly Enrolled)	27	55	728	359	593		23%	593	1,890	728	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
Cervical Cancer-VIA/VILI Screening	8	26	85	-	-		0%	-	86	85	-	-
Cervical Cancer-VIA/VILI Screening	8	26	85	-	-		-%	-	86	85	-	-
Condom	-	-	-	-	5,072,763		(100)%	5,072,763	24,040,979	-	-	-
Lovers Plus	-	-	-	-	288	2/01	(100)%	288	1,271,986	-	-	-
Lovers Plus C&F	-	-	-	-	253	1/05	(100)%	253	188,237	-	-	-
Lovers Plus R&S	-	-	-	-	80	5/10	(100)%	80	111,824	-	-	-
Trust Regular BGF	-	-	-	-	234	7/08	(100)%	234	74,421	-	-	-
Trust Studded	-	-	-	-	1,908	1/05	(100)%	1,908	5,550,730	-	-	-
Trust Workplace	-	-	-	-	5,070,000	2/06	(100)%	5,070,000	16,843,781	-	-	-
Emergency Contraception Provided	-	-	3	-	2		50%	2	10	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Emergency Contraception Provided	-	-	3	-	2		50%	2	10	-	-	-
Female Condom	1,000	12,667	94,000	60,000	116,500		(19)%	116,500	1,126,727	705	705	4,040
Female Condom	1,000	12,667	94,000	60,000	116,500	7/06	(19)%	116,500	1,126,727	705	705	4,040
Free Condom	477,000	1,159,000	11,877,000	6,000,000	11,994,690		(1)%	11,994,690	85,118,108	89,077	89,077	515,030
Generic	279,000	920,000	8,589,000	3,750,000	11,283,000	4/05	(24)%	11,283,000	70,727,544	64,417	64,417	372,450
Vanilla & Strawberry	198,000	239,000	3,288,000	2,250,000	711,000		362%	711,000	3,999,000	24,660	24,660	142,580
Workplace	-	-	-	-	690	10/01	(100)%	690	10,391,564	-	-	-
HIV Self-Testing Kit	3,086	5,311	27,687	27,000	36,575		(24)%	36,575	64,262	24,918	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	3,086	5,311	27,687	27,000	36,575		(24)%	36,575	64,262	24,918	-	-
HIV Testing Services	1,178	1,546	33,375	32,457	37,788		(12)%	37,788	653,346	33,375	-	4,538
VCT Individual (HIV-Negative)	1,027	1,192	28,812	27,006	32,716	12/09	(12)%	32,716	596,609	28,812	-	3,917
VCT Individual (HIV-Positive)	151	354	4,563	5,451	5,072	12/09	(10)%	5,072	56,737	4,563	-	620
Hypertension Screening	123	779	6,115	32,457	3,270		87%	3,270	14,619	6,115	-	-
Hypertension Screening	123	779	6,115	32,457	3,270		87%	3,270	14,619	6,115	-	-
Implant 3 Insertion	-	-	25	33	170		(85)%	170	197	25	63	42
Non-PSI Implant 3 Inserted	-	-	25	33	170		(85)%	170	197	25	63	42
Injectable 1 Provided	-	1	41	36	537		(92)%	537	1,800	3	3	2
Non-PSI Injectable 1 Provided	-	1	41	36	537		(92)%	537	1,800	3	3	2
Injectable 3-IM Provided	-	1	121	102	1,194		(90)%	1,194	2,954	30	30	15
Non-PSI Injectable 3 IM Provided	-	1	121	102	1,194		(90)%	1,194	2,954	30	30	15
Lubricant	53,000	101,333	795,000	600,000	1,342,000		(41)%	1,342,000	2,810,000	-	-	-
Lifestyles Liquid Personal Lubricant (4.5 g)	53,000	101,333	795,000	600,000	1,342,000	8/11	(41)%	1,342,000	2,810,000	-	-	-
OCs Provided	-	1	97	70	692		(86)%	692	2,308	6	6	3
Non-PSI OCs Provided	-	1	97	70	692		(86)%	692	2,308	6	6	3
PrEP	13	13	177	-	78		127%	78	255	15	-	10

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PrEP	13	13	177	-	78		127%	78	255	15	-	10
Referral to Hypertension Management	-	-	1	-	3		(67)%	3	46	1	-	-
Referral to Hypertension Management	-	-	1	-	3		(67)%	3	46	1	-	-
Referral to Injectable 1	-	-	-	-	36		(100)%	36	384	-	-	-
Referral to Injectable 1	-	-	-	-	36		(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	-	-	55		(100)%	55	646	-	-	-
Referral to Injectable 3	-	-	-	-	55		(100)%	55	646	-	-	-
Referral to Linkage to HIV Care	68	178	2,374	5,178	2,541		(7)%	2,541	8,977	2,374	-	1,551
Referral to Linkage to HIV Care	68	178	2,374	5,178	2,541		(7)%	2,541	8,977	2,374	-	1,551
Referral to OCs	-	-	-	-	76		(100)%	76	547	-	-	-
Referral to OCs	-	-	-	-	76		(100)%	76	547	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	26		(100)%	26	247	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	26	12/14	(100)%	26	247	-	-	-
Referral to TB Screening	-	-	-	5,178	303		(100)%	303	4,032	-	-	-
Referrals to TB Screening	-	-	-	5,178	303		(100)%	303	4,032	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	19		(100)%	19	4,737	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	19	12/14	(100)%	19	4,737	-	-	-
STI Screening	1,188	1,586	33,799	32,457	37,972		(11)%	37,972	143,247	33,799	-	-
STI Screening	1,188	1,586	33,799	32,457	37,972		(11)%	37,972	143,247	33,799	-	-
TB Screening	1,357	1,683	33,964	1,043	37,910		(10)%	37,910	134,261	33,964	-	-
TB Screening	1,357	1,683	33,964	1,043	37,910		(10)%	37,910	134,261	33,964	-	-
Treatment for Genital Herpes	1	4	24	17	17		41%	17	68	24	-	2
Treatment for Genital Herpes	1	4	24	17	17		41%	17	68	24	-	2
Treatment for Inguinal Bubo	-	-	-	-	1		(100)%	1	5	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	1		(100)%	1	5	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Lower Abdominal Pain	-	-	64	54	54		19%	54	173	64	-	-
Treatment for Lower Abdominal Pain	-	-	64	54	54		19%	54	173	64	-	-
Treatment for Nonherpetic Genital Ulcer	-	3	80	94	94		(15)%	94	319	80	-	31
Treatment for Nonherpetic Genital Ulcer	-	3	80	94	94		(15)%	94	319	80	-	31
Treatment for Urethral Discharge (Men)	6	13	270	195	195		38%	195	684	540	-	38
Treatment for Urethral Discharge (Men)	6	13	270	195	195		38%	195	684	540	-	38
Treatment for Urethral Discharge (Women)	-	-	3	2	2		50%	2	7	3	-	1
Treatment for Urethral Discharge (Women)	-	-	3	2	2		50%	2	7	3	-	1
Treatment for Vaginitis	-	1	216	380	380		(43)%	380	1,182	216	-	57
Treatment for Vaginitis	-	1	216	380	380		(43)%	380	1,182	216	-	57
Type 2 Diabetes Screening	54	1,200	22,275	32,457	658		3285%	658	23,192	22,275	-	-
Type 2 Diabetes Screening	54	1,200	22,275	32,457	658		3,285%	658	23,192	22,275	-	-
Voluntary Medical Male Circumcision	68	115	2,580	4,000	2,766		(7)%	2,766	9,447	2,580	-	36,031
Voluntary Medical Male Circumcision	68	115	2,580	4,000	2,766		(7)%	2,766	9,447	2,580	-	36,031
Tanzania											499,961	470,523
Cervical Cancer-VIA/VILI Screening	-	-	-	-	39		(100)%	39	19,810	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	39		(100)%	39	19,810	-	-	-
Condom	-	1,440	10,368	220,000	9,719,136		(100)%	9,719,136	614,748,380	78	78	119
Salama Halisi	-	432	1,296	-	4,191,696	2/11	(100)%	4,191,696	345,729,800	10	10	15
Salama Scented	-	-	-	220,000	4,398,624	8/06	(100)%	4,398,624	136,918,956	-	-	-
Salama Studded	-	1,008	9,072	-	1,128,816	6/04	(99)%	1,128,816	132,099,624	68	68	104
Emergency Contraception	-	-	(484)	-	(779)		0%	(779)	(1,312)	(22)	(22)	(10)
(b)PSI Emergency Contraception Distributed Provided	-	-	(484)	-	(779)		-%	(779)	(1,312)	(22)	(22)	(10)
Emergency Contraception Provided	25	29	1,135	2,468	2,258		(50)%	2,258	3,533	57	57	27
Non-PSI Emergency Contraception Provided	25	29	651	2,468	1,479		(56)%	1,479	2,221	33	33	16

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Emergency Contraception Provided	-	-	484	-	779		(38)%	779	1,312	24	24	12
Implant 3 Insertion	698	4,808	55,755	49,779	73,748		(24)%	73,748	219,156	55,755	139,388	118,923
Non-PSI Implant 3 Inserted	698	4,808	55,755	49,779	73,748		(24)%	73,748	219,156	55,755	139,388	118,923
Implant 5	260	-	260	-	-		0%	-	84,260	234	889	744
Jadelle	260	-	260	-	-	11/09	-%	-	84,260	234	889	744
Implant 5 Insertion	1,298	4,398	43,609	32,829	45,509		(4)%	45,509	148,671	43,609	165,714	138,730
Non-PSI Implant 5 Inserted	1,298	4,398	43,609	32,829	45,509		(4)%	45,509	148,671	43,609	165,714	138,730
Injectable 3-IM	-	-	(650)	-	241,911		(100)%	241,911	1,900,188	(146)	(146)	(92)
Familia Injectable 3 Kit	-	-	-	-	246,600	1/10	(100)%	246,600	1,913,951	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	-	(650)	-	(4,689)		-%	(4,689)	(13,763)	(146)	(146)	(92)
Injectable 3-IM Provided	1,489	4,082	43,198	7,419	37,606		15%	37,606	149,635	10,800	10,800	6,786
Non-PSI Injectable 3 IM Provided	1,489	4,082	42,548	7,419	32,917		29%	32,917	135,872	10,637	10,637	6,684
PSI Injectable 3 IM Provided	-	-	650	-	4,689		(86)%	4,689	13,763	163	163	102
ITN	-	420,232	1,260,695	-	-		0%	-	1,260,695	2,042,326	-	44,820
PBO Net	-	420,232	1,260,695	-	-		-%	-	1,260,695	2,042,326	-	44,820
IUD 10	1,313	413	1,313	2,450	-		0%	-	(35,659)	1,182	5,436	4,342
Familia IUD Kit	-	413	2,340	2,450	12,820	11/09	(82)%	12,820	255,969	2,106	9,688	7,739
Pregna IUD (no safe load)	1,313	-	1,313	-	-	3/17	-%	-	18,650	1,182	5,436	4,342
(b)PSI IUD 10 Distributed Inserted	-	-	(2,340)	-	(12,820)		-%	(12,820)	(310,278)	(2,106)	(9,688)	(7,739)
IUD 10 Insertion	1,279	3,329	37,319	66,000	96,804		(61)%	96,804	616,923	37,319	171,667	137,134
Non-PSI IUD 10 Inserted	1,279	3,329	34,979	66,000	83,984		(58)%	83,984	306,645	34,979	160,903	128,535
PSI IUD 10 Inserted	-	-	2,340	-	12,820		(82)%	12,820	310,278	2,340	10,764	8,599
LLIN	-	-	144,630	655,054	4,510,989		(97)%	4,510,989	12,096,501	234,301	-	7,266
"New Brand" (School Net Program)	-	-	-	-	97,352		(100)%	97,352	1,255,210	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Olyset Nets Health Facility	-	-	59,760	-	486,680		(88)%	486,680	546,440	96,811	-	3,002
Permanet (180x160x180 CM) SI	-	-	-	-	978,840	2/16	(100)%	978,840	7,261,864	-	-	-
Permanet Health Facility	-	-	84,496	655,054	91,648		(8)%	91,648	176,144	136,884	-	4,245
Permanet Nets School	-	-	374	-	2,856,469		(100)%	2,856,469	2,856,843	606	-	19
Manual Vacuum Aspiration for PAC	214	588	5,478	-	6,674		(18)%	6,674	13,226	5,478	-	690
MVA for PAC	214	588	5,478	-	6,674		(18)%	6,674	13,226	5,478	-	690
Misoprostol for PAC Provided	120	196	2,220	-	2,547		(13)%	2,547	4,818	2,220	-	329
PSI Misoprostol for PAC Provided	120	196	2,220	-	2,547		(13)%	2,547	4,818	2,220	-	329
Misoprostol for Safe Abortion	62,240	64,444	885,152	1,100,000	1,207,224		(27)%	1,207,224	7,047,176	46,470	-	6,283
Misoprostol Cipla 200 mcg	62,720	65,227	894,032	1,100,000	776,776		15%	776,776	1,670,808	46,937	-	6,346
Misoprostol for Safe Abortion	-	-	-	-	440,636	3/18	(100)%	440,636	5,395,640	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	(480)	(783)	(8,880)	-	(10,188)		-%	(10,188)	(19,272)	(466)	-	(63)
OCs	-	-	(969)	-	287,100		(100)%	287,100	10,206,220	(58)	(58)	(39)
Familia [OC]	-	-	-	-	295,056	2/08	(100)%	295,056	10,228,009	-	-	-
(b)PSI OCs Distributed Provided	-	-	(969)	-	(7,956)		-%	(7,956)	(21,789)	(58)	(58)	(39)
OCs Provided	1,638	10,823	92,392	11,708	75,344		23%	75,344	212,657	6,159	6,159	4,083
Non-PSI OCs Provided	1,638	10,823	91,423	11,708	67,388		36%	67,388	190,868	6,095	6,095	4,040
PSI OCs Provided	-	-	969	-	7,956		(88)%	7,956	21,789	65	65	43
Water Treatment Tablets	16,800	1,138,473	5,768,110	7,001,740	6,112,242		(6)%	6,112,242	125,174,161	94,818	-	387
Aquatab Tubs 8.68g	-	-	-	1,740	960	3/16	(100)%	960	446,520	-	-	-
WaterGuard Tablet ENF	-	-	1,166,640	7,000,000	6,111,282	7/12	(81)%	6,111,282	52,372,322	19,178	-	78
WaterGuard Tablets	16,800	1,138,473	4,601,470	-	-	11/05	-%	-	72,355,319	75,641	-	308
Uganda											144,136	419,148
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	74		(100)%	74	2,360	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	74	11/13	(100)%	74	2,360	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	18,884		(100)%	18,884	176,960	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	18,884		(100)%	18,884	176,960	-	-	-
Chlorhexidine	-	-	-	-	411		(100)%	411	13,454	-	-	-
Chlorhexidine Gel, 5 g tube	-	-	-	-	411	11/16	(100)%	411	13,454	-	-	-
Clean Delivery Kit	-	-	-	-	609		(100)%	609	178,925	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	609	8/10	(100)%	609	178,925	-	-	-
Condom	-	-	-	-	180,648		(100)%	180,648	46,911,638	-	-	-
Trust	-	-	-	-	49,392	6/06	(100)%	49,392	44,987,870	-	-	-
Trust Ribbed	-	-	-	-	39,528	11/15	(100)%	39,528	610,632	-	-	-
Trust Scented	-	-	-	-	42,408	11/15	(100)%	42,408	649,224	-	-	-
Trust Studded	-	-	-	-	49,320	11/15	(100)%	49,320	663,912	-	-	-
Expanded Clean Delivery Kit (+CHX)	-	-	-	-	694		(100)%	694	1,311	-	-	-
Mama Kit with Chlorhexidine	-	-	-	-	694	11/17	(100)%	694	1,311	-	-	-
Fever Cases Attended	67,555	25,845	238,868	-	-		0%	-	238,868	238,868	-	-
Fever Cases Attended	67,555	25,845	238,868	-	-		-%	-	238,868	238,868	-	-
Fever Cases Tested with RDTs	64,534	24,741	227,984	-	-		0%	-	227,984	227,984	-	-
Fever Cases Tested with RDTs	64,534	24,741	227,984	-	-		-%	-	227,984	227,984	-	-
Free Condom	2,343,064	1,055,827	19,153,992	15,350,000	16,543,154		16%	16,543,154	102,365,925	143,655	143,655	334,720
Generic	2,112,664	911,827	13,251,432	10,350,000	13,304,596	1/99	-%	13,304,596	93,224,807	99,386	99,386	231,571
Ulinzi Condoms	230,400	144,000	5,902,560	5,000,000	3,238,558		82%	3,238,558	9,141,118	44,269	44,269	103,148
Free Female Condom	26,000	4,273	64,080	100,000	105,995		(40)%	105,995	2,374,710	481	481	1,082
Female Condom Free	26,000	4,273	64,080	100,000	105,995	11/09	(40)%	105,995	2,374,710	481	481	1,082
HIV Testing Services	-	1,010	3,031	-	-		0%	-	130,754	3,031	-	188
VCT Individual (HIV-Negative)	-	996	2,987	-	-	8/13	-%	-	126,391	2,987	-	186

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Positive)	-	15	44	-	-	8/13	-%	-	4,363	44	-	3
Implant 3	-	-	-	-	(5,778)		0%	(5,778)	105,174	-	-	-
Implanon	-	-	-	-	932	12/08	(100)%	932	192,634	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	(6,710)		-%	(6,710)	(87,460)	-	-	-
Implant 3 Insertion	-	-	-	-	27,489		(100)%	27,489	292,024	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	20,779		(100)%	20,779	204,564	-	-	-
PSI Implant 3 Inserted	-	-	-	-	6,710		(100)%	6,710	87,460	-	-	-
Implant 5	-	-	-	-	(4,540)		0%	(4,540)	95,981	-	-	-
Jadelle	-	-	-	-	760	12/08	(100)%	760	181,319	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(5,300)		-%	(5,300)	(85,338)	-	-	-
Implant 5 Insertion	-	-	-	-	5,464		(100)%	5,464	114,325	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	164		(100)%	164	28,987	-	-	-
PSI Implant 5 Inserted	-	-	-	-	5,300		(100)%	5,300	85,338	-	-	-
Injectable 3-IM	-	-	-	-	3,950		(100)%	3,950	263,573	-	-	-
Depo-Provera	-	-	-	-	3,950	11/11	(100)%	3,950	263,573	-	-	-
IUD 10	-	-	-	-	(16,307)		0%	(16,307)	1,791	-	-	-
IUD PACK CU T380A	-	-	-	-	890	4/11	(100)%	890	238,341	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(17,197)		-%	(17,197)	(236,550)	-	-	-
IUD 10 Insertion	-	-	-	-	23,549		(100)%	23,549	426,314	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	6,352		(100)%	6,352	189,765	-	-	-
PSI IUD 10 Inserted	-	-	-	-	17,197		(100)%	17,197	236,550	-	-	-
IUD 5	-	-	-	-	(129)		0%	(129)	(17,342)	-	-	-
(b)PSI IUD 5 Distributed Inserted	-	-	-	-	(129)		-%	(129)	(17,342)	-	-	-
IUD 5 Insertion	-	-	-	-	130		(100)%	130	28,350	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 5 Inserted	-	-	-	-	1		(100)%	1	11,007	-	-	-
PSI IUD 5 Inserted	-	-	-	-	129		(100)%	129	17,342	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	388		(100)%	388	2,304	-	-	-
MVA for PAC	-	-	-	-	388	3/16	(100)%	388	2,304	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	150		(100)%	150	1,348	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	150		(100)%	150	1,348	-	-	-
Medical Abortion	-	-	-	-	(2,536)		0%	(2,536)	8,475	-	-	-
Divabo - Combipack (1+4's)	-	-	-	-	(2,058)	5/17	-%	(2,058)	9,574	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(478)		-%	(478)	(1,099)	-	-	-
Medical Abortion (Misoprostol) Provided	-	-	-	-	187		(100)%	187	187	-	-	-
Non-PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	26		(100)%	26	26	-	-	-
PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	161		(100)%	161	161	-	-	-
Medical Abortion Provided	-	-	-	-	478		(100)%	478	1,099	-	-	-
PSI Medical Abortion Provided	-	-	-	-	478		(100)%	478	1,099	-	-	-
Misoprostol for PAC Provided	-	-	-	-	498		(100)%	498	1,652	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	18		(100)%	18	36	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	480		(100)%	480	1,616	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(3,852)		0%	(3,852)	(8,396)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(3,852)		-%	(3,852)	(8,396)	-	-	-
OCs	-	-	-	-	1,425		(100)%	1,425	394,086	-	-	-
Family Planning Pills	-	-	-	-	1,425	11/11	(100)%	1,425	394,086	-	-	-
Positive RDTs	42,667	17,029	155,419	-	-		0%	-	155,419	155,419	-	-
Positive RDTs	42,667	17,029	155,419	-	-		-%	-	155,419	155,419	-	-
Positive RDTs Given First Line Treatment	40,275	15,902	144,641	-	-		0%	-	144,641	144,641	-	-
Positive RDTs Given First Line Treatment	40,275	15,902	144,641	-	-		-%	-	144,641	144,641	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PUR	-	-	-	-	3,840		(100)%	3,840	40,563,780	-	-	-
PuR	-	-	-	-	3,840	10/04	(100)%	3,840	40,563,780	-	-	-
Referral to HIV Testing Services	666	976	34,434	50,000	11,703		194%	11,703	46,137	34,434	-	1,070
Referral to HIV Testing Services	666	976	34,434	50,000	11,703		194%	11,703	46,137	34,434	-	1,070
Referral to Linkage to HIV Care	8,794	11,736	96,237	16,561	4,614		1986%	4,614	100,851	96,237	-	82,089
Referral to Linkage to HIV Care	8,794	11,736	96,237	16,561	4,614		1,986%	4,614	100,851	96,237	-	82,089
Tubal Ligation	-	-	-	-	10		(100)%	10	123	-	-	-
Tubal Ligation	-	-	-	-	10		(100)%	10	123	-	-	-
Zambia											237,004	489,201
Emergency Contraception Provided	10	-	11	-	1		1000%	1	12	1	1	-
Non-PSI Emergency Contraception Provided	10	-	11	-	1		1,000%	1	12	1	1	-
Free Female Condom	-	-	-	13,000	3,020		(100)%	3,020	192,200	-	-	-
Free Female Condoms	-	-	-	13,000	3,020	1/12	(100)%	3,020	192,200	-	-	-
HIV Self-Testing Kit	500	1,017	136,450	326,885	394,250		(65)%	394,250	811,250	122,805	-	-
HIV Self Testing Kits-Blood based	500	667	5,000	-	-		-%	-	5,000	4,500	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	350	131,450	326,885	394,250	5/16	(67)%	394,250	806,250	118,305	-	-
Implant 3 Insertion	1,194	1,193	11,040	-	4,567		142%	4,567	16,504	11,040	27,600	27,856
Non-PSI Implant 3 Inserted	1,194	1,193	11,040	-	4,567		142%	4,567	16,504	11,040	27,600	27,856
Implant 4 Insertion	-	-	-	-	1		(100)%	1	117	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	1		(100)%	1	117	-	-	-
Implant 5 Insertion	1,728	2,230	30,475	30,000	24,703		23%	24,703	78,318	30,475	115,805	115,046
Non-PSI Implant 5 Inserted	1,728	2,230	30,475	30,000	24,703		23%	24,703	78,318	30,475	115,805	115,046
Injectable 2 Provided	1,599	1,291	16,958	28,000	19,835		(15)%	19,835	46,379	2,826	2,826	2,094
Non-PSI Injectable 2 Provided	1,599	1,291	16,958	28,000	19,835		(15)%	19,835	46,379	2,826	2,826	2,094
Injectable 3-IM Provided	7,869	11,425	186,823	172,000	157,477		19%	157,477	427,734	46,706	46,706	34,601

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 3 IM Provided	7,869	11,425	186,823	172,000	157,477		19%	157,477	427,734	46,706	46,706	34,601
Injectable 3-SC Provided	10,966	6,108	32,041	-	-		0%	-	32,041	8,010	8,010	5,934
Non-PSI Injectable 3 SC Provided	10,966	6,108	32,041	-	-		-%	-	32,041	8,010	8,010	5,934
IUD 10 Insertion	347	611	5,135	3,000	2,175		136%	2,175	9,253	5,135	23,621	22,479
Non-PSI IUD 10 Inserted	347	611	5,135	3,000	2,175		136%	2,175	9,253	5,135	23,621	22,479
IUS 3	(65)	(82)	(379)	-	-		0%	-	(379)	(341)	(853)	(808)
(b)PSI IUS 3 Distributed Inserted	(65)	(82)	(379)	-	-		-%	-	(379)	(341)	(853)	(808)
IUS 3 Insertion	65	82	379	-	-		0%	-	379	379	948	898
PSI IUS 3 Inserted	65	82	379	-	-		-%	-	379	379	948	898
IUS 5	-	-	500	-	-		0%	-	1,300	450	1,485	1,501
LNG-IUS	-	-	500	-	-		-%	-	1,300	450	1,485	1,501
IUS 5 Insertion	-	-	353	700	595		(41)%	595	1,126	353	1,165	1,178
Non-PSI IUS 5 Inserted	-	-	353	700	595		(41)%	595	1,126	353	1,165	1,178
OCs Provided	11,475	10,628	112,295	100,000	64,379		74%	64,379	210,088	7,486	7,486	5,851
Non-PSI OCs Provided	11,475	10,628	112,295	100,000	64,379		74%	64,379	210,088	7,486	7,486	5,851
Safe Water Solution	-	32	277,356	900,000	930,072		(70)%	930,072	36,072,791	152,736	-	592
Clorin	-	32	277,356	900,000	930,072	11/98	(70)%	930,072	36,072,791	152,736	-	592
Tubal Ligation	1	37	219	308	308		(29)%	308	698	219	2,190	1,896
Tubal Ligation	1	37	219	308	308		(29)%	308	698	219	2,190	1,896
Vasectomy	-	-	-	29	-		0%	-	-	-	-	-
Vasectomy	-	-	-	29	-		-%	-	-	-	-	-
Voluntary Medical Male Circumcision	4,926	1,641	36,201	45,000	43,253		(16)%	43,253	183,600	36,201	-	270,043
Voluntary Medical Male Circumcision	4,926	1,641	36,201	45,000	43,253		(16)%	43,253	183,600	36,201	-	270,043
Woman Condom	-	-	1,920	-	97,728		(98)%	97,728	141,480	14	14	40
MAXIMUM DIVA	-	-	1,920	-	97,728	4/16	(98)%	97,728	141,480	14	14	40

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Zimbabwe											232,509	1,768,125
Antiretroviral Treatment (Currently Enrolled)	10,829	10,251	117,988	66,103	103,129		14%	103,129	308,608	9,832	-	20,562
Antiretroviral Treatment (Currently Enrolled)	10,829	10,251	117,988	66,103	103,129		14%	103,129	308,608	9,832	-	20,562
Antiretroviral Treatment (Newly Enrolled)	530	580	5,909	3,012	4,816		23%	4,816	24,814	5,909	-	-
Antiretroviral Treatment (Newly Enrolled)	530	580	5,909	3,012	4,816		23%	4,816	24,814	5,909	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-		0%	-	10	10	-	4
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-		-%	-	10	10	-	4
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3		167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3		167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Refer to any Treatm	1	-	2	-	-		0%	-	13	2	-	-
Cervical Cancer-HPV DNA and Refer to any Treatment	1	-	2	-	-		-%	-	13	2	-	-
Cervical Cancer-HPV DNA Screening	333	582	3,346	-	-		0%	-	3,346	3,346	-	-
Cervical Cancer-HPV DNA Screening	333	582	3,346	-	-		-%	-	3,346	3,346	-	-
Cervical Cancer-Pap and Conization	-	-	1,753	-	-		0%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Conization	-	-	1,753	-	-		-%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-		0%	-	10	9	-	2
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-		-%	-	10	9	-	2
Cervical Cancer-VIA and Conization	11	18	245	290	126		94%	126	549	245	-	88
Cervical Cancer-VIA and Conization	11	18	245	290	126		94%	126	549	245	-	88
Cervical Cancer-VIA and Cryotherapy	2	12	1,524	307	415		267%	415	5,494	1,524	-	533
Cervical Cancer-VIA and Cryotherapy	2	12	1,524	307	415	11/13	267%	415	5,494	1,524	-	533
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25		240%	25	396	85	-	15
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25	1/15	240%	25	396	85	-	15

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	98		(77)%	98	2,057	23	-	4
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	98	12/14	(77)%	98	2,057	23	-	4
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	10		(100)%	10	459	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	10	12/14	(100)%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	257	838	15,302	18,793	18,503		(17)%	18,503	101,121	15,302	-	-
Cervical Cancer-VIA/VILI Screening	257	838	15,302	18,793	18,503		(17)%	18,503	101,121	15,302	-	-
Condom	788,295	1,080,742	15,175,625	18,000,000	17,748,320		(14)%	17,748,320	342,562,995	113,817	113,817	361,844
Protector Plus	180,600	212,117	2,928,600	3,600,000	3,626,960	1/08	(19)%	3,626,960	279,624,450	21,964	21,964	69,829
Protector Plus Flavors	607,695	868,625	12,247,025	14,400,000	14,121,360	3/14	(13)%	14,121,360	62,938,545	91,853	91,853	292,015
Emergency Contraception	15,323	5,020	72,570	-	170,713		(57)%	170,713	1,028,335	3,266	3,266	986
Pregnon	-	-	37,805	-	160,767	9/10	(76)%	160,767	900,767	1,701	1,701	514
(b)PSI Emergency Contraception Distributed Provided	(5)	(9)	(92)	-	(54)		-%	(54)	(589)	(4)	(4)	(1)
Revoke-72	15,328	5,030	34,857	-	10,000	12/15	249%	10,000	128,157	1,569	1,569	474
Emergency Contraception Provided	5	9	98	-	78		26%	78	804	5	5	1
Non-PSI Emergency Contraception Provided	-	-	6	-	24		(75)%	24	215	-	-	-
PSI Emergency Contraception Provided	5	9	92	-	54		70%	54	589	5	5	1
Female Condom	-	-	1,200	380,000	169,980		(99)%	169,980	24,049,234	9	9	28
Care	-	-	1,200	380,000	169,980	6/97	(99)%	169,980	24,049,234	9	9	28
Free Female Condom	18,250	351,433	1,190,533	-	224,000		431%	224,000	1,752,533	8,929	8,929	28,015
Care (Free Distribution)	18,250	351,433	1,190,533	-	224,000	12/11	431%	224,000	1,752,533	8,929	8,929	28,015
HIV Self-Testing Kit	219,243	-	275,739	-	236,028		17%	236,028	511,767	248,165	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	219,243	-	275,739	-	236,028		17%	236,028	511,767	248,165	-	-
HIV Testing Services	2,635	4,346	48,842	281,609	48,959		0%	48,959	2,588,240	48,842	-	3,238
VCT Individual (HIV-Negative)	1,801	2,995	34,401	264,340	31,915	12/09	8%	31,915	2,281,571	34,401	-	2,280
VCT Individual (HIV-Positive)	834	1,351	14,441	17,269	17,044	12/09	(15)%	17,044	306,669	14,441	-	957

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Hypertension Diagnosis	20	27	271	-	278		(3)%	278	829	271	-	-
Hypertension Diagnosis	20	27	271	-	278		(3)%	278	829	271	-	-
Hypertension Screening	5,367	8,651	127,777	-	142,029		(10)%	142,029	604,030	127,777	-	-
Hypertension Screening	5,367	8,651	127,777	-	142,029		(10)%	142,029	604,030	127,777	-	-
Hypertension_Controlled Condition	5	9	105	-	91		15%	91	262	42	-	-
Hypertension_Controlled Condition	5	9	105	-	91		15%	91	262	42	-	-
Implant 3	-	(1)	(441)	-	(483)		0%	(483)	(3,265)	(397)	(992)	(536)
(b)PSI Implant 3 Distributed Inserted	-	(1)	(441)	-	(483)		-%	(483)	(3,265)	(397)	(992)	(536)
Implant 3 Insertion	46	124	3,191	2,452	1,151		177%	1,151	13,398	3,191	7,978	4,313
Non-PSI Implant 3 Inserted	46	123	2,750	2,452	668	3/16	312%	668	10,133	2,750	6,875	3,717
PSI Implant 3 Inserted	-	1	441	-	483		(9)%	483	3,265	441	1,103	596
Implant 5	1,398	1,454	3,975	-	1,797		121%	1,797	82,557	3,578	13,594	7,243
Jadelle	1,400	1,500	7,400	-	6,500	9/09	14%	6,500	120,108	6,660	25,308	13,483
(b)PSI Implant 5 Distributed Inserted	(2)	(46)	(3,425)	-	(4,703)		-%	(4,703)	(37,551)	(3,083)	(11,713)	(6,241)
Implant 5 Insertion	704	1,208	14,604	12,496	8,090		81%	8,090	105,172	14,604	55,495	29,566
Non-PSI Implant 5 Inserted	702	1,162	11,179	12,496	3,387	1/14	230%	3,387	67,621	11,179	42,480	22,632
PSI Implant 5 Inserted	2	46	3,425	-	4,703		(27)%	4,703	37,551	3,425	13,015	6,934
Injectable 3-IM	-	(38)	(2,681)	-	13,588		(120)%	13,588	898,876	(603)	(603)	(239)
Depo-Provera	-	-	-	-	26,562	9/00	(100)%	26,562	724,283	-	-	-
Petogen	-	-	-	-	700	9/09	(100)%	700	230,835	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	(38)	(2,681)	-	(13,674)		-%	(13,674)	(56,242)	(603)	(603)	(239)
Injectable 3-IM Provided	2,531	2,923	45,849	52,468	41,625		10%	41,625	263,679	11,462	11,462	4,543
Non-PSI Injectable 3 IM Provided	2,531	2,885	43,168	52,468	27,951		54%	27,951	207,437	10,792	10,792	4,277
PSI Injectable 3 IM Provided	-	38	2,681	-	13,674		(80)%	13,674	56,242	670	670	266
IUD 10	(12)	(37)	(1,039)	-	(934)		0%	(934)	473	(935)	(4,301)	(2,198)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	(12)	(37)	(1,039)	-	(1,684)	3/16	-%	(1,684)	(10,268)	(935)	(4,301)	(2,198)
TCU 380A IUCD Copper T	-	-	-	-	750	4/12	(100)%	750	10,741	-	-	-
IUD 10 Insertion	80	184	2,721	1,776	1,855		47%	1,855	12,322	2,721	12,517	6,397
Non-PSI IUD 10 Inserted	68	147	1,682	1,776	171		884%	171	2,054	1,682	7,737	3,954
PSI IUD 10 Inserted	12	37	1,039	-	1,684	3/16	(38)%	1,684	10,268	1,039	4,779	2,443
IUD 5 Insertion	-	-	128	-	80		60%	80	208	128	422	229
Non-PSI IUD 5 Inserted	-	-	128	-	80		60%	80	208	128	422	229
IUS 5	(8)	(5)	(105)	(56)	126		(183)%	126	175	(95)	(312)	(169)
LNG-IUS	-	10	60	-	270		(78)%	270	655	54	178	97
(b)PSI IUS 5 Distributed Inserted	(8)	(15)	(165)	(56)	(144)		-%	(144)	(480)	(149)	(490)	(266)
IUS 5 Insertion	8	21	197	56	144		37%	144	529	197	650	352
Non-PSI IUS 5 Inserted	-	6	32	-	-		-%	-	49	32	106	57
PSI IUS 5 Inserted	8	15	165	56	144		15%	144	480	165	544	295
Lubricant	33,000	36,967	421,000	-	97,750		331%	97,750	973,300	-	-	-
Personal lubricants water based 4.5 g	33,000	36,967	421,000	-	97,750	2/17	331%	97,750	973,300	-	-	-
OCs	-	(110)	(10,150)	-	(36,058)		0%	(36,058)	(24,674)	(609)	(609)	(255)
(b)PSI OCs Distributed Provided	-	(110)	(10,150)	-	(43,258)		-%	(43,258)	(285,823)	(609)	(609)	(255)
Secure POP	-	-	-	-	7,200	4/12	(100)%	7,200	261,149	-	-	-
OCs Provided	12,062	13,206	167,743	187,344	102,704		63%	102,704	1,172,086	11,183	11,183	4,676
Non-PSI OCs Provided	12,062	13,096	157,593	187,344	59,446		165%	59,446	886,263	10,506	10,506	4,393
PSI OCs Provided	-	110	10,150	-	43,258		(77)%	43,258	285,823	677	677	283
PrEP	3,428	3,437	43,045	35,027	34,345		25%	34,345	80,506	3,587	-	1,403
PrEP	3,428	3,437	43,045	35,027	34,345		25%	34,345	80,506	3,587	-	1,403
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17		265%	17	479	62	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17	12/14	265%	17	479	62	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67		(100)%	67	67	-	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67		(100)%	67	67	-	-	-
Referral to Hypertension Management	13	28	335	-	564		(41)%	564	1,420	335	-	-
Referral to Hypertension Management	13	28	335	-	564		(41)%	564	1,420	335	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2		(100)%	2	992	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2	12/13	(100)%	2	992	-	-	-
Referral to Injectable 3	-	-	-	-	20		(100)%	20	770	-	-	-
Referral to Injectable 3	-	-	-	-	20		(100)%	20	770	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	5		(100)%	5	209	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	5	12/13	(100)%	5	209	-	-	-
Referral to Linkage to HIV Care	608	764	8,103	-	9,056		(11)%	9,056	25,335	8,103	-	4,485
Referral to Linkage to HIV Care	608	764	8,103	-	9,056		(11)%	9,056	25,335	8,103	-	4,485
Referral to OCs	-	-	-	-	17		(100)%	17	868	-	-	-
Referral to OCs	-	-	-	-	17	1/15	(100)%	17	868	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20		(85)%	20	253	3	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20		(85)%	20	253	3	-	-
Referral to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	93		(100)%	93	2,337	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	93	1/15	(100)%	93	2,337	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to TB DOTS (completion confirmed)	-	-	-	-	2		(100)%	2	19	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	2		(100)%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	74		(100)%	74	2,704	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	74	12/13	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referrals to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47		(100)%	47	116	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47	1/15	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3		(100)%	3	6	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3		(100)%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	2		(100)%	2	2	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	2		(100)%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	1		(100)%	1	28	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	1		(100)%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	53		(100)%	53	113	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	53		(100)%	53	113	-	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-		0%	-	9	1	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-	1/15	-%	-	9	1	-	-
Referral to Tubal Ligation	-	-	-	-	2		(100)%	2	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	2		(100)%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25		(96)%	25	73	1	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25		(96)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	10	-	48		(79)%	48	557	10	-	1
Referral to Tx for Urethral Discharge (Women)	-	-	10	-	48		(79)%	48	557	10	-	1
Referral to Voluntary Medical Male Circumcision	-	-	3	-	120		(98)%	120	10,818	3	-	10

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Voluntary Medical Male Circumcision	-	-	3	-	120	12/14	(98)%	120	10,818	3	-	10
Safe Water Solution	-	-	-	-	132,805		(100)%	132,805	780,659	-	-	-
WaterGuard Solution 150mL SI	-	-	-	-	132,805	4/14	(100)%	132,805	780,659	-	-	-
STI Screening	2,525	4,041	52,076	-	1,460		3467%	1,460	62,874	52,076	-	-
STI Screening	2,525	4,041	52,076	-	1,460		3,467%	1,460	62,874	52,076	-	-
TB Diagnosis	14	15	198	-	242		(18)%	242	1,589	198	-	-
TB Diagnosis	14	15	198	-	242		(18)%	242	1,589	198	-	-
TB DOTS	-	-	-	-	4		(100)%	4	54	-	-	-
TB DOTS	-	-	-	-	4	7/14	(100)%	4	54	-	-	-
TB Screening	11,346	13,360	155,468	-	134,977		15%	134,977	1,059,426	155,468	-	-
TB Screening	11,346	13,360	155,468	-	134,977		15%	134,977	1,059,426	155,468	-	-
Treatment for Cervicitis	10	11	159	-	73		118%	73	522	159	-	15
Treatment for Cervicitis	10	11	159	-	73		118%	73	522	159	-	15
Treatment for Genital Herpes	9	23	104	-	11		845%	11	140	104	-	3
Treatment for Genital Herpes	9	23	104	-	11		845%	11	140	104	-	3
Treatment for Inguinal Bubo	1	-	17	-	2		750%	2	29	17	-	-
Treatment for Inguinal Bubo	1	-	17	-	2		750%	2	29	17	-	-
Treatment for Lower Abdominal Pain	1	3	30	-	20		50%	20	67	30	-	-
Treatment for Lower Abdominal Pain	1	3	30	-	20		50%	20	67	30	-	-
Treatment for Nonherpetic Genital Ulcer	37	28	484	-	436		11%	436	1,320	484	-	173
Treatment for Nonherpetic Genital Ulcer	37	28	484	-	436		11%	436	1,320	484	-	173
Treatment for Urethral Discharge (Men)	38	36	331	-	92		260%	92	674	662	-	41
Treatment for Urethral Discharge (Men)	38	36	331	-	92		260%	92	674	662	-	41
Treatment for Urethral Discharge (Women)	78	75	903	-	493		83%	493	2,346	903	-	166
Treatment for Urethral Discharge (Women)	78	75	903	-	493		83%	493	2,346	903	-	166

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Vaginitis	-	-	8	-	10		(20)%	10	19	8	-	2
Treatment for Vaginitis	-	-	8	-	10		(20)%	10	19	8	-	2
Type 2 Diabetes Diagnosis	-	-	-	-	3		(100)%	3	8	-	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	3		(100)%	3	8	-	-	-
Type 2 Diabetes Screening	33	35	342	-	5,658		(94)%	5,658	12,076	342	-	-
Type 2 Diabetes Screening	33	35	342	-	5,658		(94)%	5,658	12,076	342	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	6		(100)%	6	12	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	6		(100)%	6	12	-	-	-
Voluntary Medical Male Circumcision	4,787	15,847	190,647	200,000	243,971		(22)%	243,971	653,312	190,647	-	1,291,803
Voluntary Medical Male Circumcision	4,787	15,847	190,647	200,000	243,971		(22)%	243,971	653,312	190,647	-	1,291,803

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.